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Summary 
Nanosized micelles self-assembled from amphiphilic block copolymers are 
compelling drug carriers for anticancer therapy. There are three key parameters in the 
design of micellar nanoparticles, i.e. particle size and size distribution, drug loading 
capacity and stability. Aliphatic polycarbonates-based amphiphilic block copolymers 
synthesized via organocatalytic living ring-opening polymerization (ROP) are 
excellent candidates for preparation of micelles due to their biocompatibility, well-
controlled molecular structure with narrow molecular weight distribution, and 
versatility to incorporate functionalities. The objective of this study was to design 
amphiphilic polycarbonate copolymers having functional groups to allow for non-
covalent interactions (e.g. ionic interaction, hydrogen bonding and hydrophobic 
interaction) between the core-forming hydrophobic blocks of the copolymers and 
between the micellar core and the encompassed drug molecules. It is postulated that 
the micelles made from the designed amphiphilic polycarbonates have desirable 
properties for anticancer drug delivery including nanosize, narrow size distribution, 
high drug loading capacity and excellent stability. To assess this hypothesis, my study 
was aimed to: 
(1): Systematically design block copolymers of poly(ethylene glycol) (PEG), 
ethyl-functionalized polycarbonate (PEC) and acid-functionalized polycarbonate 
(PAC). These polymers were used to load primary amine-containing anticancer drug 
doxorubicin (DOX) into micelles through ionic interaction formed between the acid 
group in the polymers and the amine group in DOX. The effects of polymer 
compositions and molecular configurations on drug loading capacity and particle size 
were investigated. The polymers with the optimal composition and molecular 
configuration achieved nanosized micelles and high drug loading capacity.  
 viii 
 (2): Enhance the kinetic stability of acid-functionalized polycarbonate 
micelles with the introduction of urea-functionalized polycarbonate (PUC) and PEG 
diblock copolymer to form unique and coherent mixed micelles via acid-urea 
hydrogen bonding interaction; and characterize the drug-loading capability and in 
vitro anticancer efficacy of the DOX-loaded mixed micelles. The mixed micelles 
exhibited superior kinetic stability compared to micelles derived from its constituent 
acid-functionalized copolymer while still maintaining nanosize and high drug loading 
level. The DOX-loaded mixed micelles with acid to urea content in 1:1 molar ratio in 
particular were able to demonstrate sustained drug release and in vitro cytotoxicity 
towards HepG2 cancer cell line, while the copolymers themselves exerted minimal 
cytoxicity.  
 (3): Simplify the fabrication of mixed micelles with the use of polycarbonates 
bearing both acid and urea groups in the same polymer chain. Block copolymers of 
PEG and polycarbonate appended with acid and urea groups were varied in the 
distribution and number of both functional groups to study their effects on particle 
size, drug loading, kinetic stability and stability in serum-containing medium. The 
random distribution of acid and urea groups in polycarbonate block was favoured, and 
an optimal number of acid and urea functional groups were obtained to yield micelles 
with desirable properties. 
 (4): Evaluate the use of mixed micelles for passively targeted in vivo drug 
delivery, and investigate the effects of kinetic stability of mixed micelles on 
biodistribution and anti-tumour efficacy in a 4T1 mouse breast cancer model. The 
kinetic stability of the mixed micelles was studied by varying the PEG length (5 kDa 
and 10 kDa) in the acid- and urea-functionalized polycarbonate diblock copolymers, 
while keeping the number of acid and urea functional groups constant. The mixed 
 ix 
micelles with 5000 g/mol PEG molecular weight exhibiting better kinetic stability, 
were shown to accumulate in tumours faster and to a greater degree, resulting in better 
antitumour effect in comparison to the mixed micelles with the longer PEG chain. 
(5): Compare liver tumour targeting abilities provided by the enhanced 
permeability and retention (EPR) effect against active targeting to galactose-
recognizing asialoglycoprotein receptors (ASGP-R) on the surface of hepatocytes. 
Polycarbonate copolymers bearing galactose and urea groups were used to 
encapsulate sorafenib, an anticancer drug for hepatocellular carcinoma (HCC), via 
drug-copolymer hydrophobic interactions and urea-urea hydrogen bonding and 
exhibited comparable antitumour efficacy to free sorafenib in an orthotopic HCC 
tumour rat model. The galactose-functionalized micelles were found to preferentially 
accumulate in the healthy liver tissue of the rats by targeting the ASGP-R on the 
surface of hepatocytes, while PEG-PUC micelles with no galactose moieties 
accumulated in the HCC tumour after 24 h via EPR effect.  
In conclusion, micelles assembled from functional polycarbonate-based 
copolymers provide a promising platform for drug delivery due to their effectiveness, 
targeting ability and non-toxicity. In addition, the EPR effect of micellar nanoparticles 
at leaky tumour tissues is important for passive targeting of anticancer drugs to the 
tumour tissues.  
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***p<0.001).  (C)  Tissue distribution of DiR-loaded micelles in the 
cross-sections of liver and tumour tissues to indicate penetration of 
micelles. 
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H NMR spectra of (A) PEG5K-(MTC-OBn)9 in CDCl3, (B) PEG5K-
PAC, and (C) PEG5K-PUC. 
 
Figure A4.1  
1
H NMR spectra of (A) 4-MBA-P(MTC-ipGal)-P(MTC-PEG)-
P(MTC-Urea) 5’b  and (B) its deprotected product 5b in DMSO-d6. 
 
Figure A5.1  Concentration of sorafenib (free base) in liver tumour compared to 
healthy liver at the end of the anti-tumour study. 
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Chapter 1 Introduction 
1.1 Cancer treatment 
Cancer is a class of disease whereby cells display uncontrolled growth and 
proliferation. The cells are self-sufficient in proliferating, unresponsive to anti-growth 
signals, have unlimited replication cycles while being able to escape from apoptosis 
and invade other tissues and metastasize [1]. Chemotherapy, surgery and radiation 
therapy are commonly employed to manage this disease. Chemotherapy 
conventionally involves the use of free drugs to kill rapidly dividing cells. However, 
there are challenges faced in the use of chemotherapy. Firstly, drugs used for 
chemotherapy are usually water insoluble, and thus not absorbed in the blood to 
provide sustained therapeutic efficacy. Secondly, anticancer drugs act non-specifically 
on other actively diving non-cancerous cells such as bone marrow cells, 
gastrointestinal tract cell linings or hair follicle cells, causing debilitating side-effects 
[2]. Finally, an effective dose has to be achieved to reach its therapeutic efficacy and 
thus repeated doses of anticancer drugs are needed. With these problems in hand, 
there is a pressing need to develop drug delivery carriers for effective transportation 
of anticancer drugs specifically to the tumour tissues. 
 
1.2 Developments on drug delivery systems  
Drug delivery is defined as the system to dispense a pharmaceutically active 
compound in the body to attain a therapeutic effect. In an extension of free drugs, 
drug delivery systems packaged these drugs in various forms, thus altering their 
properties when administered to the body. As drug discovery is a rapidly developing 
area of healthcare, research on drug delivery systems has similarly progressed to 
benefit the drug discovery industry (Figure 1.1) with the advent of lipid vesicles in the 
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1960s which were later known as liposomes [3]. From early on, nanotechnology has 
steered the way for research in drug delivery systems with the creation of 
supramolecular structures scaled to small form to carry drugs physically or chemically 
attached to them. Following the creation of liposomes, a variety of advanced materials 
were later developed to grant the first controlled-release drug delivery system 
spearheaded by Robert Langer in 1976, exhibiting slow release of soybean trypsin 
inhibitor from ethylene-vinyl acetate copolymer ‘sandwiches’ [4]. In the interest of 
controlled release systems, the biodegradability of drug delivery systems is also taken 
into account with the use of poly(esters) as drug delivery materials as early as the 
1970s [5]. In the 1980s, liposomes were further exploited by making them pH-
sensitive [6] and tagging antibodies on the vehicle surface for targeting purposes [7]. 
Focus then shifted to making the liposomes long-circulating in the late 1980s from the 
incorporation of surface sialic acid and achieving lipid bilayer stability [8]. 
Poly(ethylene glycol) (PEG) was then conjugated onto liposomes [9] and 
nanoparticles [10] alike in the 1990s. Dendrimers, highly branched macromolecules 
with multi-arms emanating from a core, were also used to attach drug molecules for 
drug delivery purposes in the last decade [11]. Multivarious drug delivery systems 
have seemingly evolved from the concept of nanotechnology and continue to do so 
today. The research on drug delivery systems was validated with the United States 
Food and Drug Administration (FDA) approval of Doxil (Alza Co.) which is a 
liposomal formulation of anticancer drug doxorubicin (DOX) that exhibits prolonged 
half-life [12] for the treatment of Kaposi's sarcoma in patients with acquired 
immunodeficiency syndrome or AIDS. The official approval and marketing of Doxil 
has shown that the clinical use of nanotechnology-based drug delivery systems is a 
distinct reality. Since then, more than 24 nanotechnology-derived therapeutic 
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formulations have been subsequently approved [13] which can only mean more 
opportunities for further innovation of drug delivery systems. 
 




The nanoscale feature of these drug delivery systems bestows several 
advantages over conventional free drugs. Firstly, the solubility of hydrophobic drugs 
is improved as they are encapsulated in the nanoparticle shield. This prolongs the drug 
half-life and prevents the drug from precipitating in the blood, enhancing their 
therapeutic efficacy. Secondly, the drug-loaded nanoparticles can passively 
accumulate in tumours through the enhanced permeability and retention (EPR) effect 
[14, 15]. With the drug encapsulated in nanosized particles, the particles are large 
enough to escape the premature elimination in the kidneys via glomerular filtration 
but small enough to participate in the EPR effect (Figure 1.2) to passively accumulate 
in tumour tissues [14, 16]. Blood vessels surrounding tumour tissues are leaky with 
the abnormal endothelial cells lining porous with fenestrations. Drug-loaded particles 
up to 200 nm can effectively traverse through the fenestrations to reach the tumour 
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tissues [17, 18]. Due to the characteristically poor lymphatic clearance in tumour 
tissues, the drug-loaded particles will tend to accumulate in the tumour tissues thereby 
exerting their therapeutic effect as the drug is being released [15]. Free drugs on the 
other hand will diffuse non-specifically to tissues. This passive targeting of drug-
loaded particles to tumour tissues will minimize undesirable side-effects of the drugs 
as normal cells will be less affected. Because the nanoparticles escape clearance and 
elimination, circulation time of the drug-loaded particles in the blood is longer than 
that of free drugs [19]. Moreover, encapsulating the drug within nanoparticles will 
protect against any in vivo drug degradation and reduce loss upon administration to 
the body [20, 21]. With these advantages provided by the nanotechnology-based drug 
delivery systems, debilitating side-effects of chemotherapeutic drugs and frequency of 
















Figure 1.2: Passive accumulation of drug-loaded copolymer micelles in tumour tissues via 
the EPR effect , (A) Block copolymer micelles effectively evade innate clearance mechanisms, 
resulting in prolonged blood circulation time; (B) nanosized micelle typically around 20-200 
nm diameter, efficiently extravasate through the leaky tumour vasculature, where the 
endothelial gap junctions vary between 400-600 nm; (C) impaired lymphatic drainage occur 
in tumour tissues; (D) a high interstitial concentration of drug-loaded micelles is thus retained 
in the tumour; (E) non-specific or (F) specific receptor-mediated internalization of drug-
loaded micelles is effected. Reproduced from [19] with permission. 
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In the following, the various types of colloidal drug delivery systems will be 
examined, with their advantages and limitations juxtaposed. Subsequently, the 
important factors to be taken into consideration in designing polymeric micelles as 
drug delivery carriers and the approaches undertaken to address limitations in using 
them will be discussed.  
 
1.3 Drug delivery systems 
1.3.1 Liposomes 
Liposomes are spherical nanostructures of bilayer membranes vesicles in the 
size range of 50 to 1000 nm; self-assembled from phospholipids in an aqueous 
environment. Since their discovery in the 1960s, liposomes have been used as a 
carrier for a multitude variety of compounds, be it hydrophilic (encapsulated in the 
aqueous core) or hydrophobic (embedded in the lipid bilayers). Liposome 
formulations encapsulated with antitumour and antifungal drugs have been 
commercialized since the 1990s [22], paving the first step in medical applications of 
liposomes. Conventional liposomes are assembled from egg phosphatidylglycerol/ 
egg phosphatidylcholine/cholesterol/dl-α tocopherol while hydrogenated soy 
phosphatidylcholine/cholesterol/or a lipid derivative of PEG, polyethylene glycol-
distearoylphosphatidylethanolamine (PEG-DSPE) lipids are commonly utilized now 
to form sterically stabilized, ‘stealth’ liposomes.     
As mentioned earlier, the FDA approval and commercialization of Doxil was 
the turning point in the research of nanotechnology-based drug delivery systems. 
Doxil is a liposomal formulation of a chemotherapeutic agent, DOX, which is 
administered intravenously for the treatment of AIDS-related Kaposi's sarcoma. This 
liposome formulation utilized ‘stealth’ concept to prolong blood circulation by the 
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addition of PEG-DSPE [23]. The surface modification of PEG-DSPE prevents the 
adsorption of plasma proteins onto the liposome surface to evade uptake from 
macrophages and prolong circulation time in the body. The inclusion of PEG-DSPE 
in the liposomal formulation was found to increase DOX levels in the plasma in 
rodents and dogs [24]. Long-circulating liposomes (half-life = 24 h) were also found 
to grant a reduction in phagocytic capacity of liver macrophages compared to short-
circulating liposomes that were rapidly cleared from the blood and largely 
internalized by macrophages in the liver [25].  
While the introduction of liposomes changed the face of soft drug delivery 
systems, there are problems inundated with the use of liposomal drug delivery 
systems. Firstly, the preparation of liposomes is a complex procedure. The preparation 
usually involves four steps: drying down of lipids from toxic organic solvents such as 
dichloromethane, dispersion of the lipids in aqueous media with or without 
ultrasonication, purification of the resultant liposomes and analysis of the final 
product [23].  Furthermore, residues of organic solvent present in the lipid and/or 
aqueous phases of the liposomes during their fabrication could result in undesired 
toxicity and side-effects. With that in mind, other methods of fabrication aimed to 
replace the use of organic solvents have been developed [23]. Secondly, liposomes 
encapsulate hydrophobic drugs within the lipid bilayer which could result in 
premature release of drugs during administration in the body [26]. The third concern 
with the use of liposomes is its structural fragility in the blood and limited stability 






Dendrimers are a relatively new class of polymers known for their distinctive 
three-dimensional and nanoscale tree-like branching architecture that condensed to 
spherical shapes in solution. The structure of dendrimers permits individual dendrons 
to diverge from a central core, with each layer of branching dendrons comprising a 
generation in the architecture [29]. Dendrimers are touted to be suitable drug delivery 
vehicles due to their water solubility, nanosize and monodisperse conformation 
stemming from their step-wise synthesis. Their structures also act as a reservoir of 
functional groups to be tethered to anticancer drugs or for physical encapsulation of 
said drugs. For example, DOX was conjugated to an amidoamine dendrimers with 
fringe-grafted oligo(ethylene glycol) and its cell cytotoxicity was tested on HeLa and 
MCF-7 cells [30]. Szoka’s group demonstrated the use of nanosized asymmetrical 
poly(ester) dendrimers with one hemisphere attached to DOX and another 
functionalized with PEG as an anticancer nanomedicine that had comparable 
antitumour efficacy as Doxil on a C-26 murine colon carcinoma mice model [31].  
While the myriad of functional groups on the periphery of dendrimers expand 
their applications as a drug delivery system, there are still critical elements involving 
the use of dendrimers. Firstly, dendrimers must be bigger than 5 nm to exploit the 
EPR effect and this requires multistep synthesis which results in low yields. Secondly, 
the cytotoxicity of dendrimers is enhanced with an increase in generation number and 
concentration of dendrimers [32]. Thus, a balance must be achieved for dendrimers to 
form large enough nanostructures with low cytotoxicity by controlling its generation 
number. Furthermore, the attachment of drugs on the fringe of dendrimers may result 
in aggregation due to the hydrophobicity of the drugs [33], which hinders their in vivo 
application. 
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1.3.3 Polymeric micelles 
Micellar structures consisting of a hydrophobic core and hydrophilic shell are 
self-assembled from amphiphilic copolymers in aqueous milieu and have been 
successfully used as drug delivery carries for water-insoluble drugs. The hydrophobic/ 
hydrophilic domains ratio in the copolymers ensures the formation of the micelles. 
The hydrophobic segments of the copolymers will aggregate together to reduce 
contact with the aqueous milieu and reduce the interfacial free energy of the 
copolymer-water system while the hydrophilic segments form the shell of the micelles 
as they are exposed to the aqueous environment. Another aspect of polymeric 
micelles design is the compartmentalization of drugs in the core of the micelles. The 
hydrophobic environment in the core of the micelles provides the space for 
encapsulation of water-insoluble drugs. Compatibility between the hydrophobic 
segment of the polymer and the drug has to exist for successful drug loading.  
The hydrophilic chain of the copolymer extends out to form the corona of the 
micelles, with direct contact with the aqueous media. The composition and 
configuration of the hydrophilic block of the copolymer can influence the micellar 
function in many ways. The hydrophilic block most commonly utilized in micellar 
systems is poly(ethylene glycol) (PEG). The process of exploiting PEG to form the 
micellar corona is described as PEGlyation. PEG itself is a FDA-approved polymer 
for clinical applications as it exerts low toxicity with no immunogenicity [34]. 
Supramolecular micelle structures consisting of block copolymers with PEG chains 
on the surface are well-documented. PEGlyation renders minimal nonspecific protein 
adsorption on the micellar surface due to its hydrophilic nature and steric repulsion 
effects and subsequently reduces opsonisation and liver uptake [35-41]. With the 
reduction in liver uptake by the liver macrophages (Kupffer cells), the blood residence 
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time of the micelles is enhanced, allowing for prolonged tumour accumulation [37]. 
For minimum protein adsorption, the molecular weight of PEG was reported to be in 
the vicinity of 2 to 5 kDa [37] with a compact PEG shielding preferred [42].  
It is noteworthy that micellar delivery systems possess attractive features such 
that they are preferred over other colloidal drug delivery systems. Foremost, the 
presence of the hydrophobic core in micellar structures serve as a reservoir to entrap 
and retain hydrophobic drugs that otherwise are impossible to solubilize without 
utilizing other potentially hazardous solvents such as Cremophor EL 
(polyoxyethylated castor oil) to solubilize paclitaxel. Hydrophobic drugs encapsulated 
in liposomes would be embedded in the bilayer rendering them prone to premature 
drug leakage in contrast to the sustained drug release exhibited by drug-loaded 
micelles [20]. Drug loading levels achieved within micellar structures could be 
enhanced compared to the use of liposomes due to the favourable interactions 
between core-forming hydrophobic block and drug of choice. Functional groups 
incorporated within the hydrophobic block help in forming specific interactions with 
the encapsulated drug. Secondly, the three-dimensional micellar structures are in 
nanoscale, allowing the nanoscopic micelles to yield high tumour uptake by virtue of 
EPR effect. Perhaps the most attractive feature of the polymeric micelles is that they 
are engineered from self-assembling synthetic block copolymers that can be 
accustomed for good compatibility with the hydrophobic drug of choice through non-
covalent interactions, installation of targeting signals that specifically recognize 
tumour tissues/cells and ideal physicochemical properties of cargo-loaded micellar 
structures for drug delivery.  
Besides the benefits conferred by using polymeric micelles as drug delivery 
carriers, there are disadvantages in utilizing such systems. Firstly, the polymeric 
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micelle structure is not maintained at all copolymer concentrations as there is a 
minimum concentration of copolymer needed for micelle self-assembly to proceed, 
called the critical micelle concentration (CMC).  When the drug-loaded polymeric 
micelles systems are diluted in the blood during administration, the concentration of 
the polymeric micelles may fall below its CMC value and micelle dissociation occurs. 
Secondly, a high level of competency and proficiency in polymer chemistry is needed 
to tailor-made the amphiphilic copolymers to be compatible with the drug of choice 
and for in vivo targeting to specific tissues. Block copolymers are usually more 
challenging to synthesize compared to random copolymers as control of monomer 
polymerization is needed to achieve discrete blocks in the copolymers. 
 
1.4 Polymeric micelles made from block copolymers 
Amphiphilic block copolymers containing hydrophilic block PEG and 
biodegradable hydrophobic blocks such as poly(propylene oxide) (Pluronics) [43, 44] 
poly(ester)s (poly(lactides)) [45, 46], poly(ε-caprolactone) [47], poly(lactide-co-
glycolide) (PLGA) [48]) and polypeptides (poly(histidines) [49, 50] and poly(aspartic 
acids) [51, 52]) have been employed to encapsulate DOX into micelles through 
hydrophobic interactions. By far, poly(ester)s and poly(L-amino acid)s copolymers 
are the most commonly reported core-forming blocks. 
 
1.4.1 PEG-poly(ester)s copolymers 
Micelles derived from PEG-b-poly(ester) have been commonly studied in the 
drug delivery field. They are especially attractive owing to their biodegradability 
manifested in its hydrolysis to non-toxic products [53].  However, they are less 
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versatile as it is difficult to incorporate functional groups into their molecules for 
better control of the interactions between carriers and drugs for example.   
Physical encapsulation of drugs by poly(ester)s micelles has been reported with 
an example being PEG-poly(ε-caprolactone) to encapsulate DOX to form nanoscopic 
drug-loaded micelles [47]. Yoo and Park on the other hand reported the conjugation 
of DOX to PEG-b-poly(D,L-lactic-co-glycolic acid) (PLGA) via the terminal hydroxyl 
group of PLGA, which had been pre-activated using p-nitrophenyl chloroformate [54]. 
The chemical conjugation of DOX to the copolymer permitted for a more sustained 
release profile than DOX physically encapsulated in PEG-b-PLGA micelles. Other 
examples include Burt et al. comparing different poly(ester) based copolymers to 
solubilize paclitaxel with the core-forming poly(D,L-lactide) block to be the best 
candidate as compared to copolymers with core-forming poly(D,L-lactide-co-
caprolactone) or poly(glycolide-co-caprolactone) blocks [55]. The in vivo 
biodistribution studies of radio-labeled paclitaxel-loaded PEG-poly(D,L-lactide)  
micelles suggested that paclitaxel was rapidly released from the micellar structures in 
the blood with more than 95% of the labeled copolymer eliminated within 15 h.   
 
1.4.2 PEG-poly(L-amino acid)s copolymers 
The versatility of block copolymers bearing poly(L-amino acids) block is 
appreciated due to the variety of amino acids available for polymerization, giving rise 
to copolymers with free amine or carboxylic acid functional groups that can be 
modified to solubilize the drug of choice or confer stability to resulting micelles. 
Another advantage of using poly(L-amino acids) as the core forming block is its 
inherent biodegradability into natural substances by enzymatic degradation. The 
major disadvantage of using poly(L-amino acid)s however is the low synthesis yield 
 12 
of the copolymers (~40%) [56], implying that this might not be a cost-effective class 
of biomaterials.     
One of the earliest polymeric micelles derived from poly(L-amino acids) is 
DOX-conjugated PEG-b-poly(aspartate) as reported by Kataoka’s group [51, 56-58]. 
Conjugation was achieved by the formation of amide bond between the carboxylic 
groups in poly(aspartate) block and the amine group in DOX. Conjugated DOX 
rendered the poly(aspartate) block to be more hydrophobic, resulting in the self-
assembly of the micelles with a stable core [58]. This polymer-drug conjugate micelle 
system exhibited in vitro cytotoxicity and in vivo anticancer activity against P 388 
mouse leukaemia cells and mouse model respectively [57]. Additional DOX was 
physically entrapped in this system due to the hydrophobic interactions and pi-pi 
stacking with the conjugated DOX in the micellar core [51]. While it was possible 
that physically entrapped DOX in the drug-conjugated micelle system may bestow its 
antitumour effects, conjugated DOX on the other hand had longer contact time in the 
tumour, killing tumour cells efficiently. Micelles derived from other amino acids 
include PEG-b-poly(L-histidine) which displays a pH-sensitive characteristic owing to 
the protonable imidazole side chain of histidine [59]. At lower pH, the imidazole 
groups were protonated, rendering the copolymer to be more hydrophilic and prone to 
micelle dissociation. This provides a mechanism by which drug release from the 
micelle system can be controlled by pH, applicable in the acidic tumour tissues and 
the acidic endolysosomal environment.   
 
1.4.3 PEG-poly(carbonates) copolymers 
Poly(carbonate)s are an emerging class of biomaterials in comparison to the 
widely used poly(amino acids) and poly(esters). Aliphatic poly(carbonate)s appears to 
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be suitable for use as a drug delivery platform in regards to their biodegradability and 
biocompatibility [60, 61]. Additionally, their degradation by-products (i.e. alcohol and 
carbon dioxide) are non-toxic in contrast to acidic degradation by-products of 
poly(ester)s [62, 63]. From the few studies reported so far, poly(carbonate)s are 
versatile materials whereby functional groups or bioactive moieties can be appended 
to poly(carbonate) chain which is extremely useful for drug delivery applications [64]. 
The synthesis yield of the aliphatic poly(carbonate)s is also high at more than 80% 
when compared to that of poly(L-amino acid) copolymers [65]. However, little 
attention has been paid to poly(carbonate)s as a class of materials for the drug 
delivery purpose. It is noteworthy that most poly(carbonate) copolymers reported in 
the literature were synthesized by ring-opening polymerization of trimethylene 
carbonate (TMC) using metal-based catalysts. Metal residues in the copolymers are a 
concern for downstream in vivo application.   
Feijen’s group described the self-assembly of PEG-b-poly(trimethylene 
carbonate) (PEG-PTMC) into micelles upon heating a film of the copolymer in water 
to 37 °C [66]. The micellar dispersions formed particles of 208 nm in diameter that 
decreased to 185 nm after a day of incubation. Upon loading of a model drug, 
dexamethasone, the cargo-loaded micelles were of 218 nm diameter with 11.2 wt% 
loading level. Drug release studies revealed an initial burst followed by sustained 
release over 20 days before no further release was detected. Triblock copolymers 
bearing poly(carbonate) block have also been reported [65]. PTMC-PEG-PTMC 
copolymers with varying PTMC length were utilized to encapsulate anticancer drug 
methotrexate. Drug-loaded micelles were of 50-160 nm in diameter with 1.8-6.3 wt% 
drug loading level. The drug release rate was found to increase with the molecular 
weight and PEG content of the copolymers. Xie et al. demonstrated the conjugation of 
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biotin moieties onto the polycarbonate block of PEG-b-poly(5-benzyloxy-
trimethylene carbonate-lactic acid) copolymer by first converting the ether groups in 
the carbonate repeating units to hydroxyl groups before reacting with biotin [64]. 
 
1.5 Factors in designing polymeric micelles 
 There are many critical features to be highlighted and optimized in designing 
polymeric micelles as drug delivery systems (Figure 1.3), which are discussed in the 
subsequent sub-sections.  

































Figure 1.3: Design features of polymeric micelles as safe and efficient drug delivery carriers: 
(A) Particle size of the micelles is desired to be in the 10-200 nm range to exploit the EPR 
effects fully and to ensure accumulation of micelles in tumours, (B) Micellar cores have to be 
rigid resulting from the various interactions within the core to improve on the kinetic stability 
of the micelles or to reduce the disperse rate of unimers, (C) High drug loading capacity of 
micelles is desired to minimize the amount of carrier into the body and it can be achieved by 








1.5.1 Particle size 
Particle size of micelles is vital to consider in view of physiological 
circumstances such as glomerular filtration, tissue extravasation or EPR effect. The 
fate of the drug-loaded micelles are determined by their particle size and surface 
charge and less influenced by the drug characteristics themselves as the drug would 
be embedded in the core of the nanostructures. Micelles exhibiting roughly 10 nm in 
size did not exhibit EPR effect [68] as they are easily cleared from the blood through 
excretion via glomerular filtration. It was reported that micelles smaller than 50 nm 
could penetrate poorly permeable pancreatic tumour while particle size had no effect 
for highly permeable tumours [69]. Nanoparticles of more than 200 nm in size were 
demonstrated to accumulate in liver, spleen and lungs instead [70], with lowered 
accumulation in tumours [42]. Therefore, the particle size of an effective 
nanomedicine micellar structure should be in the range of 10-200 nm. 
Modulating the particle size of drug-loaded polymeric micelles can be 
accomplished in several ways. The first approach lies in the structure of the 
copolymers. The relative length of the hydrophobic portion to the hydrophilic 
segment within a copolymer affected the particle size, and particle size increased with 
an increased length of the hydrophobic block [71]. Similarly, increasing the 
hydrophilic block length resulted in smaller nanoparticles due to the shielding of the 
micellar core by the longer shell [72]. Fabrication method of drug-loaded micelles is 
another aspect by which particle size can be controlled. The general method for 
preparing drug-loaded micelles is by dissolving both polymer and drug in a water-
miscible organic solvent (separately or in a mixture) followed by its introduction into 
water and subsequent removal of the organic solvent by dialysis or evaporation. The 
second method is a film casting procedure whereby a film of copolymer and drug is 
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produced followed by rehydration in water to form micelles. The former method is 
suitable for water-insoluble copolymers while the latter is for relatively water-soluble 
copolymers [73]. Using an unsuitable method of fabrication for a particular 
copolymer may result in aggregates or precipitations. The organic solvent chosen to 
dissolve the polymer and drug can affect the final particle size even after its removal 
[74, 75]. Additionally, there are physical methods to reduce particle size further either 
by extrusion or sonication [74].  
 
1.5.2 Drug loading capacity 
One elemental feature in the design of polymeric micelles is the ability to 
solubilize poorly water-soluble molecular drugs, manifested by its drug loading 
capacity. Drug delivery vehicles should favourably yield a high drug loading capacity 
to restrict the dose of carrier while accomplishing the same or better therapeutic effect 
as compared to the drugs alone. The easiest method to improve the loading levels of a 
drug within the carrier is by increasing the initial amount of drug to be loaded [46].  
Drug incorporation into the core of micelles can arise through physical encapsulation 
[48-52] or chemical conjugation [76, 77]. Hydrophobic drugs would physically 
compartmentalize in the core of the micelles due to its high affinity to the 
hydrophobic milieu in the core via hydrophobic interactions. Successful drug 
partitioning lies in the existing compatibility between the hydrophobic core-forming 
block of the copolymer and the drug [78, 79]. Reinforcing the interactions between 
drug and polymer by noncovalent interactions can increase the drug loading level [80].  
Functional groups such as amines and carboxylic acids were exploited and integrated 
in the core-forming block of copolymers to form specific interactions such as 
hydrogen bonding [47, 81, 82] or ionic interactions [83] between the micellar core 
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and the hydrophobic drug to further enhance the compatibility. DOX, an amine 
containing anticancer drug, could be protonated to form ionic interactions with the 
negatively charged aspartic acid residues in the core of micelles derived from 
poly(ethylene glycol)–poly(β-benzyl-L-aspartate) block copolymer, yielding 
enhanced drug loading levels of 15 to 20 wt% [52].  
Chemical conjugation of drugs involves being chemically tethered to the 
hydrophobic block of the copolymer to allow for higher drug loading capacity and to 
avert premature release of drugs by diffusion [84]. Spacers may be employed between 
small molecular drugs and the copolymer backbone to prevent steric hindrance [84]. 
Drugs conjugated to the copolymer become inert and regains its therapeutic activity 
after the specific linkages between drug and copolymer have cleaved via pH-sensitive 
hydrolysis [76] or enzymatic reactions [85]. Drug loading capacity of polymeric 
micelles can be controlled further by modifying other parameters such as increasing 
the core-forming segment of the copolymers [86], increasing the number of 
functionalities in the copolymer hydrophobic portion [87] along with altering the 
preparation method of drug-loaded micelles [88]. 
 
1.5.3 Micelle stability 
Micelle stability perhaps is the most confounding parameter to consider in the 
application of the drug delivery vehicles seeing that polymeric micelles are dynamic 
macromolecular structures. There are two aspects described in relation to the stability 
of polymeric micelles i.e. thermodynamic stability and kinetic stability. The 
thermodynamic stability of the polymeric micelle is defined in terms of the energetics 
of the polymer-water system which is believed to rely upon its polymer concentration 
[89]. The amphiphilic copolymer-water system at any point strives to achieve the 
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minimum Gibbs free energy which is the internal energy for the system that can be 
utilized for micellization. When an amphiphilic copolymer is dissolved in water above 
its CMC value, the water molecules surrounding individual unimers are trying to form 
the highest number of hydrogen bonds with each other. Because of the undesirable 
interactions between the hydrophobic block of the copolymer and water molecules, 
the hydrophobic blocks of the copolymers are forced together to reduce the total 
surface area that breaks up the water hydrogen bond matrix, giving the best energetic 
solution [90]. Polymer concentrations below the CMC result in freely existing 
individual unimers the energy to break the water hydrogen bond matrix is small 
enough to be offset by favourable interactions of hydrophilic block of copolymer with 
water. Therefore, CMC value of a copolymer is a thermodynamic parameter related to 
its self-assembly in water and it has become a standard to judge whether the micelle is 
stable thermodynamically i.e. the copolymer concentration is above or below CMC 
value to form micelle structures. Drug-loaded micelles will be subjected to infinite 
dilution in the blood stream upon systematic administration, which presents a 
challenge to polymeric micelle systems with high CMC values that can result in 
premature drug release. The CMC values of polymeric micelle systems are 
determined by the molecular size of copolymers in the micellar structure, the 
hydrophobicity of the core-forming block of the copolymers and the relative block 
length in the copolymers [89]. Intermolecular interactions within the micelle can also 
help in reducing the CMC [91]. 
While thermodynamic stability describes the micelle stability in terms of 
polymer concentration, kinetic stability refers to the micelle system’s ability to 
conserve its micelle assembly upon micelle-disrupting conditions such as the presence 
of charged proteins in the blood which is related to the movement of the individual 
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unimers in the polymeric micelle [92, 93]. In the micellization of copolymers, 
micelles are in a formation ↔ disassembly equilibration process exhibiting a change 
in micellar concentration [93, 94]. This exchange of chains between micelles is based 
on two mechanisms; (1) expulsion/insertion of unimers whereby a unimer is expelled 
from a micellar structure and recaptured by a different or original micelle and (2) 
fusion/splitting of micelles involving two different micelles being at close proximity 
such that a unimers is part of both micellar cores and later separating with the unimer 
becoming a part of one micelle [95]. Therefore, polymeric micelles systems that 
exhibit a higher tendency to resist the fusion/splitting of micelles are termed more 
‘kinetically stable’ in this thesis. The attributes of the core-forming block primarily 
influence the kinetic stability of polymeric micelles. Frozen or stiff micellar core-
forming blocks would disassemble slowly in micelle-disrupting conditions while a 
rubbery micellar core would render the micelles to disperse rapidly [96]. Multiple 
functionalities incorporated in the same or different polymer chains within a micelle 
can facilitate micelle assembly via intermolecular interactions such as electrostatic 
interactions [97], chemical cross-linking [98] and hydrogen bonding [81, 91] that can 
impart the micellar core less susceptible to dispersing during the blood circulation and 
improve its kinetic stability. 
 
1.5.4 Biodegradability 
Polymeric micelles for drug delivery applications are also engineered towards 
greater safety and biocompatibility of the copolymers. Non-biodegradable polymers 
would circulate in the body for prolonged periods of time which warrants further 
handling upon administration to the body [99].  Biodegradable polymer systems 
(bearing anhydride, ester and amide bonds) are preferred as they degrade via 
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hydrolysis or enzymatic cleavage producing water-soluble degradation products for 
excretion such as the case for poly(carbonate) polymers producing an alcohol and 
carbon dioxide [100]. Total elimination of the polymers by way of metabolism and 
excretion is coveted in these biodegradable polymer systems [99]. However, 
copolymers of non-biodegradable systems must be below 40 kDa in molecular weight 
to be excreted out through glomerular filtration [101].  Beyond the nature of the 
copolymers, biodistribution of these drug-loaded micelles is also critical in 
determining the cytotoxicity in using such therapeutics, especially if the particles 
accumulate in certain organ tissues non-specifically. The biodistribution profile of the 
particles is controlled by other parameters such as surface modification, particle size 
and surface charge. One of the challenges in the in vivo setting is that the drug-loaded 
polymeric micelles may be taken up by the mononuclear phagocytic system (MPS) in 
the liver and spleen due to its “foreign” nature in the body. By utilizing PEG in the 
corona of the micelles, this surface modification minimizes protein adsorption and 
recognition by the mononuclear phagocytic system, prolonging their circulation time 
[102]. PEGylation strategy for pharmaceuticals was initially developed to prolong 
blood circulation time of several polypeptide drugs that are prone to destruction by 
proteolytic enzymes, or rapid kidney clearance [103]. 
 
1.5.5 Surface modification of micelles 
While PEGlyation is an important surface design for many nanotechnology-
based drug delivery systems, other micellar surface modifications involve the 
incorporation of targeting ligands to concurrently improve micelle-cell interactions, 
enhance cellular uptake by cancer cells and reduce uptake by non-cancer cells. Such 
ligands are recognized by specific receptors on certain types of cancer cell surfaces, 
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inducing cellular uptake of ligand-decorated micelles through receptor-mediated 
endocytosis. Folic acid has been commonly employed as a targeting ligand as many 
types of human cancers have shown an over-expression of its receptor[54]. Yoo and 
Park demonstrated that folate-conjugated micelles were able to slow down tumour 
growth effectively, using a nude mouse model xenografted with folate receptor-
positive human epidermal carcinoma KB cells [104]. Polymeric micelles conceived 
with galactose moieties on the surface have also been reported in targeting the 
asialoglycoprotein receptors present on hepatocytes for the treatment of liver diseases 
[105, 106]. Other reported targeting ligands conjugated onto the micellar surface for 
anticancer drug delivery include monoclonal antibodies [107], biotin [108] and 
peptides [109, 110]. Another approach to active tumour targeting is the employment 
of stimuli-sensitive micelles. The structural integrity of these micelles are 
compromised to release their drug cargo in response to physical and/or environment 
signals, for instance the lower extracellular pH in tumour tissue [111], elevated 
temperatures [48] or ultrasound [112] at the target sites. Multi-stimuli sensitive 
micelles for anticancer drugs that respond to more than one stimulus for cargo release 
have also been reported [113, 114]. Surface charge of the micelles may change with 
ligand conjugation for active targeting. This should be kept in mind as neutral 
liposomes are preferred over charged ones as the former exhibited prolonged blood 
circulation and were cleared from the blood less rapidly [115]. Additionally, the 
technical incorporation of functionalities in a single copolymer may be a challenging 





1.5.6 Passive vs. active targeting 
Two strategies for targeting tumour tissues have been previously described. In 
the first strategy, the vast majority of nanomedicine formulations utilizing long-
circulating liposomes or polymeric micelles are geared towards passive targeting to 
tumours by virtue of the EPR effect [14, 15]. Another strategy to target tumour tissues 
is the utilization of targeting ligands that specifically bind to receptors that are over-
expressed at the target sites, as discussed above. This particular strategy termed active 
targeting, describes the specific ligand-receptor interaction for intracellular uptake 
after the nanocarriers reach the target site from blood circulation and extravasation. 
There are advantages and drawbacks for each of this strategy that will be discussed 
here. 
The exploitation of EPR effect as a strategy for these drug delivery carriers to 
accumulate in tumour tissues is convenient as it only relies on the physiological 
properties of the tumour tissues, i.e. leaky vasculature and slow lymphatic drainage. 
Therefore, nanoparticles are designed with desirable particle size and surface charge 
for prolonged circulation with EPR effect in mind as the gold standard for tumour-
targeting. However, as the EPR effect relies heavily on the leaky tumour vasculature, 
certain tumours do not exhibit the EPR effect due to heterogeneous vasculature and 
vessel permeability across different tumour types [116]. The second obstacle in 
passive tumour targeting is the high interstitial fluid pressure in the centre of solid 
tumours, decreasing vascular transport and uptake of drugs in tumours. This explains 
why larger and long-circulating nanomedicine accumulate longer in tumours rather 
than smaller molecules that can easily diffuse away due to mass fluid flow from the 
high interstitial fluid pressure in the tumour [117]. To overcome the fluid pressure, the 
administration of hypertension agents such as angiotensin-II was proposed to augment 
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the EPR effect. The increase in blood pressure would open the tumour vascular 
endothelial cell-cell junctions wider to allow for more extravasation of nanoparticles 
[118].  
Grafting a targeting ligand onto the surface of nanocarriers on the other hand 
grants enhanced cell uptake selectivity and efficacy as the chosen ligand binds to a 
receptor over-expressed by tumour cells or tumour vasculature but not by normal cells. 
It is also imperative that such nanocarriers would be internalized by the target cell 
after ligand-receptor binding via receptor-mediated endocytosis for example. By 
targeting tumour cells, direct cell killing is achieved whereby cells near to vasculature 
bringing the nanocarriers to the tumour will internalize such nanomedicine 
formulations [119]. On the flipside, targeting tumour endothelium will result in killing 
the tumour cells by preventing new blood vessels recruitment [119]. Active targeting 
of nanocarriers has resulted in an enhancement in therapeutic effect due to the 
increased tumour cell uptake [120] but that does not necessarily translate to elevated 
tumour accumulation after intravenous administration [117, 120]. To truly achieve 
targeted drug delivery, the choice of ligand-receptor pair has to be judicious as 
receptors over-expressed on tumour cells still exist on normal cell surface. As other 
organs like blood, liver, lungs and spleen have greater access to the carriers than 
tumour tissues, care has to be undertaken that the nanocarriers do not target other 
healthy tissues due to receptor expression on these other organs [121].  
 
1.6 Mixed micelles 
 Polymeric micelles derived from single copolymers are often inadequate in 
one or more aspects essentially due to restrictions in the number of building blocks. 
On the contrary, the mixture of two or more heterogeneous block copolymers (e.g. 
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AB + CB [122] or AB + AC [123] or AB + CD [124]) to conceive mixed micelles is a 
pragmatic and adept method to address the limitations without utilizing complicated 
synthetic routes. A model for the co-micellization of AB + CB variety of diblock 
copolymers in solution has been suggested, which was found to be dependent on the 
relative concentrations of the two species of diblock copolymers [125]. Furthermore, 
the resulting CMC of a mixed micelles system can be mathematically calculated from 
the CMC values and molar fractions of its constituents [126]. Advantages bestowed 
from the use of mixed micelles include enhancing the thermodynamic (through 
lowering CMC) and kinetic (by elevating the hydrophobic interactions, 
stereocomplexation, H-bonding, ionic interaction or chemical cross-linking between 
the core-forming blocks) stability [122], improving drug loading levels [127], 
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Figure 1.4: Schematic presentation of the formation of mixed micelles through various core 
interactions. (A) Hydrogen bonding, stereocomplexation or ionic interaction; (B) 
Hydrophobic interactions; and (C) Chemical cross-linking (e.g. disulfide bond). Reproduced 




Mixed micelles self-assembled from dissimilar block copolymers interacting 
through weak van der Waal interactions or commonly known as hydrophobic 
interactions in drug delivery related literature, and non-covalent interactions via 
molecular recognition (stereocomplexation, H-bonding and ionic interactions) as well 
as chemical cross-linking in the core or shell as illustrated in Figure 1.4 are expected 
to behave differently. We will discuss mixed micelles assembled via the 
abovementioned interactions and provide an insight on how the interactions can be 
characterized in the following sections. 
 
1.6.1 Hydrophobic interactions (van der Waals interactions) 
In the drug delivery related literature, the interactions between the hydrophobic 
core-forming blocks of amphiphilic copolymers in polymeric micelles are often 
termed ‘hydrophobic interactions’ due their similarity in hydrophobicity and their 
‘water-fearing’ properties. Studies have shown that the hydrophobic interactions 
between the core-forming block thought to induce the self-assembly of micelles are 
essentially van der Waals interactions [129]. In this thesis, to be congruous with the 
literature based on drug delivery systems, the term hydrophobic interactions is used to 
describe the van der Waals interactions between different hydrophobic core-forming 
blocks in mixed micellar systems as the most commonly examined class of 
noncovalent interactions. Table 1.1 provides an overview of mixed micellar drug 
delivery systems that are derived from hydrophobic interactions.  
 
Table 1.1: Overview of mixed micelles made from synthetic amphiphilic block copolymers 







Drug  Significance  Ref. 





Docetaxel To enhance 
bioavailability and 
intracellular uptake of 
[130] 
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docetaxel relative to 
mPEG-b-poly(lactide) 
micelles 
 Pluronic L61 Pluronic 
F127 
DOX To stabilize Pluronic 
L61 micelles by 
preventing aggregation 
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critical solution 
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Pluronic block copolymers consisting of hydrophilic poly(ethylene oxide) and 
hydrophobic poly(propylene oxide) blocks are the most widely used to assemble 
mixed micelles systems for drug delivery [127, 130, 131, 140] in the literature in 
consideration of their availability and biocompatibility [141]. However, Pluronic 
micelles are limited by their low loading capacity and high CMC values leading to 
dissociation when diluted post-administration [44]. Blending Pluronic polymers with 
another copolymer to form mixed micelles can alleviate the low stability of existing 
micelles and improve bioavailability of the encapsulated drugs [130, 131]. Similarly, 
when the relatively more hydrophobic Pluronic L61 was mixed with Pluronic F127 
with the longer hydrophilic block, aggregation of Pluronic L61 was prevented in 
aqueous solution [128]. Blending of Pluronic L101 with Pluronic 105 also expanded 
the micellar core of the latter so that more paclitaxel molecules were encapsulated 
[127]. 
 The mixed micelle approach accommodates for easy modulation of the surface 
density of the ligands by varying the ratio of constituents of the mixed micelles. 
Folate, bearing that its receptor is over-expressed on the surface of many types of 
cancer cells, has been introduced onto the surface of mixed micelles to target cancer 
cells [77, 127]. Park’s team reported mixed micelles made from doxorubicin-block-
poly(D,L-lactic-co-glycolic acid)-block-PEG (DOX-b-PLGA-b-PEG) and PLGA-b-
PEG-Folate, and used them to encapsulate DOX [77]. The cytotoxicity of DOX-
loaded mixed micelles with folate was greater than that of DOX-b-PLGA-b-PEG 
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micelles without folate. In addition, the content of DOX was higher in KB xenograft 
tumours when administered with the folate-functionalized mixed micelles formulation. 
Other than folate, peptides [134, 136] and chemical functional groups such as sulfate 
[131] were conjugated to mixed micelles systems for targeting. 
 To verify the formation of uniform mixed micelles, a number of methods have 
been reported. For example, in the mixed micelles made from Pluronic F127 and 
PPS20-b-PEO44 micelles, analytical ultracentrifugation (AUC) analysis was used in 
conjuction with 
1
H-NMR analysis to prove the formation of the mixed micelles [131]. 
A single peak in the size exclusion chromatograph (SEC) would indicate that coherent 
mixed micelles were formed if the individual polymers form micelles with different 
sizes. Likewise, one dynamic light scattering (DLS) peak signifies the formation of a 
single population of mixed micelles, exhibiting narrow diameter distribution [127, 
130, 142]. Two-dimensional proton nuclear Overhauser effect or 2D NOE plots of 
mixed micelles and its individual constituents can convey the formation of mixed 
micelles from the cross peaks present in the spectrum due to physically close protons 
from chemically different polymers [123, 143]. Transmission electron microscopy 
(TEM) is a practical technique to visualize the morphology of micelles. Mixed 
micelles were observed to be spherical in shape, just like their one-component 
counterparts [123, 133, 134].  
 
1.6.2 Stereocomplexation 
Studies on stereocomplexation between enantiomers bearing different 
stereochemistry however are less pervasive in contrast to the study on mixed micelles 
driven by hydrophobic interactions. Poly(lactide) (PLA) is widely used in 
stereochemistry studies owing to its biodegradability and biocompatibility and most 
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importantly, its existence in four enantiomeric forms (L-lactide, D-lactide, meso-
lactide and racemic-lactide). It is commonly known that when poly(L-lactide) (PLLA) 
and poly(D-lactide) (PDLA) are blended in 1:1 ratio, a composite is formed that 
displays a melting point higher than that of the individual enantiomers [144]. This 
composite displays characteristically enhanced physical and chemical stability [145] 
which could be exploited for drug delivery purposes. The stereocomplexation 
between the enantiomeric PLAs emerges from H-bonding from specific CH3O=C 
and CHO=C interactions between both stereoisomers of poly(lactide) [146]. 
Leroux’s group demonstrated the enhanced kinetic stability of stereocomplex micelles 
between PDLA and PLLA blocks [147]. The stereocomplex micelles and their 
individual copolymer micelles were subjected to a destabilizing agent, sodium 
dodecyl sulfate (SDS) with the fraction of dissociated micelles monitored by dynamic 
light scattering studies. Stereocomplex micelles exhibited superior kinetic stability 
with minimal drop in scattered light intensity indicating a smaller degree of micelle 
dissociation as compared to the drastic reduction of signal displayed by the individual 
copolymer micelles. Increasing the hydrophobic PLA lengths were shown to increase 
the kinetic stability as well, revealing the dependence of the kinetic stability on the 
stereocomplexation interactions within the micellar core. Redispersing lyophilized 
stereocomplex micelles were also stable while aggregations were seen for the 
individual PDLA or PLLA micelles [147]. 
The stereocomplexation of individual block copolymers composing of PDLA and 
PLLA with PEG hydrophilic segment were additionally utilized in several studies for 
the formation of therapeutic nanoparticles. Chen et al. demonstrated that the 
stereocomplexation composite of PEG-PDLA and PEG-PLLA exhibited lower CMC 
values and smaller particle size than PDLA or PLLA micelles. The stereocomplex 
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micelles also yielded higher drug loading level and encapsulation efficiency for 
rifampin than that displayed by the individual components micelles [148]. 
Stereocomplex micelles exhibiting higher drug encapsulation efficiency were also 
observed by Yang et al. for paclitaxel drug [82]. While these studies described the 
stereocomplexation of AB + AC types of block copolymers, our group has opted for 
the stereocomplexation of more than two dissimilar blocks, i.e. PEG-PDLA and 
thermo-responsive poly(N-isopropylacrylamide) (PNIPAAm-PLLA) [149]. The 
repulsion from the PEG and PNIPAAm blocks were recompensed by the 
stereocomplexation of PDLA and PLLA blocks. The mixed micelles exhibited lower 
critical solution temperature (LCST) of about 20 °C which could be exploited for 
injection to surface tumour when it is loaded with an anticancer drug. Different 
molecular architectures exploiting stereocomplexation has also been reported by our 
group such as Y-shaped miktoarm PEG-PDLA-PDLA stereocomplexed with PEG-
PLLA-PLLA [150] or block copolymers containing PEG and pendent PLA groups 
branched from hydrophobic polycarbonate block [151]. 
  
1.6.3 Hydrogen Bonding 
Hydrogen bonds are short-range interactions that only form if the two interacting 
groups (i.e. hydrogen bonding donor and receptor) are in close proximity to each 
other not unlike stereocomplexation. It is postulated that two dissimilar amphiphilic 
copolymers self-assemble into micelles due to unfavourable interactions of the 
hydrophobic blocks with water before hydrogen bonds form between copolymer 
unimers to stabilize the hydrophobic core. Although hydrogen bonding has the 
potential to drive the formation of mixed micelles, studies on hydrogen bonding 
mixed micelles is relatively less prevalent than other types of mixed micelles. Current 
 31 
studies reported involves the micellization of block copolymers in solvents other than 
pure aqueous medium [152, 153]. This thesis will bridge the gap in knowledge of 
mixed micelles driven by hydrogen bonding, and study the role of hydrogen bonding 
within the core of mixed micelles in kinetic stability and in vivo biodistribution.  
The characterization of H-bonding between copolymers and/or homopolymers 
discussed henceforth occurred in non-aqueous solvents. Competitive H-bonding is an 
approach that can be used to confirm H-bonding as the interactions formed between 
two different copolymers can be broken with the introduction of a competitive 
compound that can form stronger interactions with either of the polymers. Gohy et al. 
added urea in poly(methacrylic acid)-block-poly(ethylene oxide) (PMAA21-b-PEO177) 
micelles, whereby its self-assembly was hypothesized to be driven by the 
intramolecular H-bonding of PMMA to PEO due to the much longer length of PEO 
block [154]. Intramolecular complexes formed the core of micelles, surrounded by the 
shell of uncomplexed PEO segments. PMAA21-b-PEO177 micelles were dissembled 
upon addition of urea as the copolymer formed hydrogen bonds with urea instead, 
verifying the essential role of H-bonding in the self-assembly of the copolymer. The 
mixed micelle systems were commonly studied in apolar solvents such as toluene 
[124] or aprotic organic solvents such as THF and DMF in the first place [155, 156] 
to prevent competitive H-bonding effect. It remains to be seen how mixed micelles 
with H-bonding between the different copolymers act in aqueous medium.  
Mixed micelles derived from hydrogen bonds can be adjusted rationally by 
changing several factors to modulate the H-bonding. Elevated temperatures can break 
hydrogen bonds, dissociating mixed micelles systems. The hydrodynamic radius, Rh, 
of the micelles derived from poly(styrene)-block-poly(4-vinylpyridine) (PS-b-P4VP) 
and poly(acrylic acid) (PAA) in DMF remained consistent until temperatures reached 
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55 °C whereby the Rh started to decrease [157]. Changing the pH of the milieu by 
adding acidic and basic water to organic solvents can also disrupt the hydrogen bonds 
in mixed micelles due to ionization of hydrogen bonding acceptors or donors. The 
disruption of the hydrogen bonds between P4VP and PAA, and the addition of water, 
reversed the core/shell structure of the micelle into a PS core and a P4VP shell. 
Finally, the solvent used in dissolving the different copolymers governs the formation 
of H-bonding between them. Polar solvents may participate in H-bonding with the 
copolymers, breaking the H-bonding complexation of the mixed micelles. Having the 
mixed micelles systems in different solvents will additionally yield different results 
when temperature and pH are varied due to the distinction in the extent of solvents’ 
polarities and consequent competition for hydrogen bonds as shown by Lefèvre et al.  
[157].  
 
1.6.4 Ionic interactions 
Long-range ionic interactions or charge transfer were also employed to form 
mixed micelles in addition to short-range interactions. This type of mixed micelles is 
known as polyion complex (PIC) micelles. Oppositely charged blocks from the pair of 
block copolymers come together to from aggregates through long-range electrostatic 
interaction upon dissolving in water, driving the formation of mixed micelles. PIC 
micelles have the extra advantage of encapsulating ionic compounds such as folic acid 
[158], coenzyme A [159] or plasmid DNA [160] in the core of the micelles.  
The formation of PIC micelles is additionally influenced by hydrophobic 
interactions to a certain degree under certain pH conditions. This co-action between 
the hydrophobic interactions and electrostatic interactions was demonstrated by 
Cohen Stuart and Schlaad’s team with the structural changes of positively charged 
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poly(4-(2-amino hydrochloride-ethylthio) butylene)-block-poly(ethylene oxide) 
(PAETB49-b-PEO212) and negatively charged poly(4-(2-sodium carboxylate-ethylthio) 
butylene)-block-poly(ethylene oxide) (PCETB47-b-PEO212) PIC micelles [97]. At 
intermediate pH values, the two block copolymers were fully ionized, forming mixed 
micelles with PEO shell and having a swollen core with gel-like properties as the 
copolymers interacted through electrostatic attraction. These ionic interactions were 
thought to encourage the exchange of different unimer chains from different micelles 
as the interactions are long-range. The swollen cores of the individual and mixed 
micelles aided in the free exchange of unimer chains. With an increase or decrease in 
pH as one copolymer became less ionized, the micellar core became more compact 
with water being expelled out. Hydrophobic interactions then became the dominant 
driving force in the micellization of the PIC micelles, rendering the polymer chains in 
the mixed micelles immobile and indifferent to environmental stimuli. The mobility 
of polymer chains are tellingly influenced by how compact the core is, determined by 
the dominant interactions holding the different unimers.  
The ionic interactions within PIC micelles can be altered by several factors such 
as pH, salt concentration and chain length of the charged block. Upon pH changes in 
the PIC micelles system, the increasing neutralization of one block copolymer will 
produce a decrease in the electrostatic attraction between the different block 
copolymers and hydrophobic interactions become dominant in the micellization. In 
the system of PAETB49-b-PEO212 and PCETB47-b-PEO212 mixed micelles [97], 
hydrodynamic radius of the PIC micelles was studied with pH change. Aggregates of 
these mixed micelles which were present at near physiological pH condensed to a 
smaller size as pH was increased or decreased. The micelles shrinkage was attributed 
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to the purging of water from micellar cores due to the increasing hydrophobic 
interactions holding the mixed micelles at extreme pH values.  
Electrostatic attraction between the oppositely charged block copolymers in PIC 
micelles can compete with additional salts. Stability of PIC micelles is susceptible to a 
critical salt concentration, above which dissociation of PIC micelles occurs due to the 
interactions formed between block copolymers and the salt ions instead. The 
dissociation of poly(2-vinylpyridine)-block-poly(ethylene oxide) (P2VP41-b-PEO204) 
and poly(methacrylic acid)-block-poly-(ethylene oxide) (PMAA21-b-PEO177) PIC 
micelles was monitored from the decrease in fluorescence intensity of pyrene at 363 
nm with an increase in NaCl concentration in the aqueous system, indicating polar 
environment due to the freely existing charged block copolymers unimers in solution  
[154].  
The degree of polymerization of block copolymers is another influential factor in 
the paradigm of PIC micelles self-assembly. Harada and Kataoka blended 
poly(ethylene glycol)-block-poly(L-lysine) and poly(ethylene glycol)-block-poly(,β-
aspartic acid) copolymers with the same molar ratio of L-lysine and aspartic acid units, 
forming PIC micelles of 15 nm diameter and very low polydispersity [161]. When 
blending two sets of these copolymers with different degree of polymerization of the 
poly(amino acid) blocks (18 and 78 repeating units) in aqueous solution, it was found 
that PIC micelles were only formed when the pair of oppositely charged polymers 
matched in their block length [162]. Unmatched pairs of block copolymers would 
interact to neutralize the charges without forming micellar structures. The main 
motivation for a pair of block copolymers with the same poly(amino acid) chain 
length to recognize each other is to have equal number of poly(amino acid) residues to 
neutralize the charges for stable PIC micelles [154].  
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1.6.5 Chemical cross-linking 
While the previous interactions described to drive the micellization of mixed 
micelles are purely physical, chemical interactions within mixed micelles bestow 
stability to copolymers otherwise unable to form stable micelles [98, 163] as well as 
halting the disassembly of PIC micelles [164]. The dynamic nature of micelles also 
renders them unstable at various stimuli such as high temperature, low concentrations 
and solvent substitution. Cross-linking within the mixed micelles can form at various 
potential locations: in the shell of the mixed micelles, in the core of the mixed 
micelles or entrapping the micelles in another polymer cross-linking network. Cross-
linking is mostly exploited as more of an additional approach to stabilize mixed 
micelles rather than the driving force in micellization. Self-assembly of micelles 
precedes the initiation of cross-linking to retain the micellar structure over long 
periods of time or against other stimuli. 
As mentioned in Section 1.6.1, the mixed micelles approach allows for the 
modulation of the surface density of the ligands decorated on the micellar surface by 
varying the relative amount of individual copolymers forming the mixed micelles. 
Wooley’s group demonstrated the micellization of mannose-functionalized shell 
cross-linked mixed micelles assembled from poly(acrylic acid-b-methyl acrylate) 
(PAA-b-PMA) and mannosylated PAA-b-PMA. To ‘freeze’ the micellar 
configuration, a condensation-based cross-linking was accomplished between the 
acrylic acid groups present in the polymer shell via 2,2′-
(ethylenedioxy)bis(ethylamine) [165].  
Chemical cross-linking can also be employed to stabilize the micellar core to 
ensure that even incompatible copolymers can form stable aggregates [98]. Hui et al. 
demonstrated the assembly of mixed-shell micelles from polystyrene-block-poly(2-
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vinylpyridine) (PS-b-P2VP) and poly(ethylene oxide)-block-poly(2-vinylpyridine) 
(PEO-b-P2VP) in DMF with the addition of 1,4-dibromobutane as a cross-linker for 
P2VP although PEO and PS chains are highly incompatible [98]. With the core of the 
mixed micelles cross-linked in a network, the PEO and PS blocks were fully mixed as 
they were restrained to the micellar core. The mixed-shell micelles in DMF did not 
induce any aggregation or precipitations when dialyzed against water despite shell-
forming PS block being insoluble in water. Kataoka’s group exploited the use of PIC 
micelles assembled from PEG-P(Lys) and homopolymer poly(α,β-aspartic acid) 
before cross-linking the PIC micellar core via oxidation of thiols present in lysine 
repeating units [164]. This PIC micelle was customized for drug delivery as the 
disulfide bonds are cleavable inside the cells upon uptake due to the relatively high 
intracellular reducing milieu compared to extracellular fluid.  
Other than chemical cross-linking of copolymers in the shell or core of the mixed 
micelles, stabilization of polymeric micelles can be achieved in mixed micelles 
entrapped in a network formed from a third homopolymer [163]. Mixed micelles 
containing a mixed PEO/poly(2-hydroxyethyl methacrylate) (PHEMA) shell with a 
poly(propylene oxide) (PPO) core were physically entrapped within 
poly(pentaerythritol tetraacrylate) network induced by UV free radical polymerization 
to provide stabilization to the micelles. The morphology of the micelles was 
maintained under several conditions such as varying polymer concentrations, being 
subjected to ultrasonic irradiation and addition of methanol solvent due to the external 
network where the micelles were embedded. 
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1.7 Summary  
In summary, polymeric micelles proved to be ideal colloidal drug delivery 
carriers. Designing our own copolymers affords us to be in control of tuneable 
properties such drug-copolymer compatibility by appending functional groups, 
enhancement of kinetic stability due to formation of interactions within micellar 
structures, modulation of particle size upon drug loading and sustained drug release 
profile. The use of mixed micelles introduced dissimilar copolymer blocks either in 
the resulting micellar core or shell that could be exploited to increase drug loading 
level or kinetic stability of the micelles. While several long-standing classes of block 
copolymers are utilized, there is a need to explore new ones that are easily 
functionalizable and yet do not compromise on synthetic yield and toxicity in the 
body systems. Advances in synthetic routes of copolymers such as the use of 
organocatalytic ring-opening polymerization is a promising tool to engineer 
copolymers designed to overcome limitations of drug delivery without the use of 
metal catalysts and having control over molecular weight distributions. With some 
formulations of polymeric micelles encapsulating anticancer agents moving forward 
to clinical trials [166] and combined with efforts to surpass the barriers of drug 
delivery, clinical chemotherapy using polymeric micelle formulations may be an 
actuality in the future. 
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Chapter 2 Hypothesis and Aims 
 
Amongst the colloidal drug delivery systems being researched on, nanoscopic 
polymeric micelles are touted to be more beneficial due to several reasons: 1) their 
distinct core-shell structure accommodates the encapsulation of hydrophobic drugs in 
the core while the hydrophilic shell commonly consisting of PEG aids in 
solubilization of supramolecular structures and reduction in uptake by MPS to 
prolong blood circulation; 2) self-assembling synthetic copolymers can be appended 
with different functional groups to improve compatibility with drugs or to induce 
interactions within micellar structures; 3) nanoscopic micelles are able to accumulate 
passively in tumours by virtue of the EPR effect. Common classes of block 
copolymers such as polyesters and poly(amino acid)s utilized to form micelles are 
limited in low synthetic yields or incorporation of functional groups. Aliphatic 
polycarbonates on the other hand are an emerging class of biomaterials that have the 
potential to address these barriers. Thus, the ultimate objective of this thesis is to 
design amphiphilic polycarbonate copolymers having functional groups to allow for 
non-covalent interactions (e.g. ionic interaction, hydrogen bonding and hydrophobic 
interaction) between the hydrophobic blocks of the copolymers and between the core 
of the self-assembled micellar nanoparticles and the encapsulated drug molecules. 
My hypothesis is that amphiphilic polycarbonates with well-controlled molecular 
weights and low polydispersities granted by organocatalytic ring-opening 
polymerization (ROP) of functionalized carbonate monomers are non-toxic and 
competent in delivering anti-cancer drugs. The basis of our hypothesis stems from our 
work in collaboration with Dr James Hedrick’s group (IBM, U.S.A.) in creating 
functionalized aliphatic polycarbonate copolymers. Polycarbonate synthesis usually 
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proceeds in two directions; chain copolymerization of diols or ROP of cyclic 
carbonate monomers. The latter route utilizes a variety of catalysts, granting low 
control over molecular weights, high polydispersity (more than 1.2) and low end-
group fidelity of resulting copolymers [167]. The use of salen ligands in the metal-
based catalysts is also a concern for biological toxicity. Hedrick’s group had 
developed a method of ROP of trimethylene carbonate (TMC) using organocatalysts 
screened from N-heterocyclic carbenes, guanidine and amidine bases, and the 
bifunctional thiourea-tertiary amine system [167]. With this toolbox at our disposal, 
we could synthesize functionalized aliphatic polycarbonate-based copolymers simply 
through ROP of carbonate monomers that are modified with various functional groups. 
Doxorubicin, DOX, was chosen as a model anticancer drug for proof-of-concept 
studies. The presence of a protonable amine group in DOX could be exploited for its 
encapsulation in micelles through ionic interactions. By appending acid groups onto 
the polycarbonate chain of copolymers, it is postulated that DOX encapsulation by 
acid-functionalized polycarbonate copolymers would yield high drug loading levels. 
Another anticancer drug, sorafenib, was used in this study for investigations in using 
the polycarbonates as drug carriers for the treatment of liver cancer. To assess my 
hypothesis, this study was aimed to: 
1. Systematically design acid-functionalized polycarbonates for loading of amine-
containing DOX into micelles through ionic interactions, and exploring the 
possibility of using these micelles as drug delivery carriers of amine-containing 
anticancer drugs. 
2. Enhance the kinetic stability of acid-functionalized polycarbonate micelles with 
the introduction of urea-functionalized polycarbonate copolymer to form 
coherent mixed micelles through hydrogen bonding; and evaluate the drug-
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loading capabilities and in vitro anticancer efficacy of the DOX-loaded mixed 
micelles. 
3. Simplify the fabrication of mixed micelles by evaluating the use of 
polycarbonate copolymers bearing both acid and urea groups to fabricate 
micelles; and investigate the effects of distribution and number of both 
functional groups within the polycarbonate block on particle size and size 
distribution, drug loading capacity, in vitro drug release and cytotoxicity of 
DOX-loaded micelles. 
4. Compare mixed micelles formed from acid- and urea-functionalized 
polycarbonate copolymers and those made from copolymers bearing both acid 
and urea groups on the polycarbonate block; and investigate the effects of 
kinetic stability of mixed micelles on biodistribution and anti-tumour efficacy 
in a 4T1 mouse breast cancer model. 
5. Evaluate the efficacy and practicality in using galactose-functionalized 
polycarbonates for active targeting in an orthotopic liver cancer rat model.  
 
Studies addressing each specific aim are in the following framework: In Chapter 
3, several PEG-polycarbonate block copolymers with varying acid group placement 
and content were designed for the encapsulation of DOX (Aim 1). The acid-
functionalized polycarbonate copolymers were then blended with urea-functionalized 
polycarbonate copolymers to boost the kinetic stability of the DOX-loaded micelles, 
providing proof-of-concept for the delivery of amine-containing anticancer drugs 
(Aim 2). In Chapter 4, block copolymers of PEG and polycarbonate bearing both acid 
and urea groups were designed in order to simplify the fabrication of DOX-loaded 
mixed micelles with the distribution and number of both functional groups studied in 
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relation to the physicochemical properties and drug loading capacity of the micelles 
(Aim 3). In Chapter 5, a comparison between the two polycarbonate systems (i.e. 
mixed micelles formed from the block copolymers of PEG and urea- or acid-
functionalized polycarbonate and micelles self-assembled from block copolymers of 
PEG and polycarbonate bearing both acid and urea groups) was done for DOX 
delivery. The micelle system with more desirable drug delivery properties was 
utilized to study the effects of kinetic stability on its in vivo application (Aim 4). In 
Chapter 6, two micelle systems exploiting the EPR effect (micelles formed from 
block copolymers of PEG and urea-functionalized polycarbonate through hydrogen 
bonding interactions) and active targeting (the micelles formed from galactose-
functionalized polycarbonate block copolymers) were compared for the delivery of 
sorafenib (an anticancer drug) to hepatocellular carcinoma (HCC) in an orthotopic 
liver cancer rat model (Aim 5). A conclusion and future outlooks are imparted in 
Chapter 7 to complete this thesis. 
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Chapter 3 Design of biodegradable polymeric micelles self-assembled 
from polycarbonate copolymers containing acid or urea groups 




As communicated in Chapter 1, attention has recently shifted to the emerging 
field of nanomedicine for chemotherapy instead of using free drugs, made relevant 
with the FDA’s approval of a few nano-formulations such as Doxil. The use of 
nanotechnology affords the capabilities of forming nanostructures with controlled 
properties to envelop clinically used chemotherapy drugs that usually are water 
insoluble and exhibit a short half-life in the blood stream with a high overall clearance 
rate. The research of nanoscale drug carriers have recently shifted to the era of using 
biodegradable amphiphilic block copolymers to self-assemble into core-shell 
structured micelles. Compared to liposomes, these polymeric micellar structures are 
superior in several ways i.e. having highly controllable functionalities and molecular 
architectures to be compatible with the drug of choice, possessing high drug loading 
capacity and exhibiting sustained drug release [20].  
The most common issues in using micellar drug carriers that still need to be 
addressed include: 1) lack of control of size and size distribution, 2) low kinetic 
stability (when exposed to infinite dilution after their administration), and 3) low drug 
loading capacity. Particle size can be modulated by increasing the hydrophilic block 
and decreasing the hydrophobic block to increase hydrophilicity of the copolymers 
[71, 72] or by subjecting the micelles to physical sonication [74]. Additionally, 
cohesive interactions in the micellar core may render the micelle assemblies compact, 
decreasing particle size. Kinetic stability can be improved by introducing covalent 
cross-linking to the core or shell of premixed micelles [164, 168, 169] or noncovalent 
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interactions such as ionic interactions [97, 154] or stereocomplexation [147] within 
the micellar structure to increase the rigidity of the micellar assemblies and slow 
down unimer exchange, making the micelles less susceptible to dispersing upon 
infinite dilution in the blood [96, 170]. Drug loading levels can be improved by 
increasing the size of the hydrophobic block [86] although that is complicated by the 
increase in size of the overall micelle cargo complex. Alternatively, loading levels can 
be improved by reinforcing polymer-drug interactions by utilizing noncovalent 
interactions through molecular recognition [80, 171]. Roovers’s group reported that 
star-shaped core polyamidoamine-poly(ε-caprolactone)-poly(ethylene glycol)  
micelles were able to encapsulate acidic drug, indomethacin, at high drug loading 
levels as compared to basic DOX, due to the acid-base ionic interactions between 
indomethacin and tertiary amine-containing core of the micelles [171].  
In this chapter, amphiphilic block copolymers with controlled architectures 
were synthesized to improve on the current model of polymeric micelles for drug 
delivery by employing a combination of reversible noncovalent interactions. Our 
micelle system is aimed to (1) address kinetic stability of micelles in ultra-dilute 
conditions, and (2) enhance loading capacity of micelles for amphiphilic drugs. 
Pendent molecular recognition functionalities in our polymeric micelle system is 
elemental for the formation of both polymer-polymer and polymer-cargo interactions. 
While there are various examples of polymeric micelle systems designed to resolve 
the two above-mentioned issues such as poly (L-amino acids) [172], 
poly(methacrylates) [80], poly(propylene oxide) [141] and poly(ε-caprolactone) [173] 
micelles, they do come with synthetic problems such as wide polydispersities, 
difficulty in incorporating functionalities, low end-product yield and expensive 
starting materials in the case of amino acids. Polymers synthesized with narrow 
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molecular weight dispersity is especially important for making micelles with narrow 
size distribution that is critical for in vivo applications as size distribution affects the 
biodistribution of micelles as mentioned in Chapter 1. Polycarbonates are an attractive 
class of biomaterials due to the ease of incorporating various functionalities. 
Polycarbonates can be synthesized by inorganic catalysts [174-177] or organic 
catalysts. The synthetic methods employing inorganic catalysts are impractical due to 
toxic metal residues, multiple synthetic steps and high polydispersities. With the 
advancement in the use of organocatalysts for the ring-opening polymerization (ROP) 
of cyclic carbonates, copolymers with controllable molecular weight, narrow 
polydispersities and various functionalities can be generated as shown by Hedrick’s 


























































































































































Scheme 3.1: (A) PEG-b-Poly(acid carbonate) (PAC) were postulated to sequester DOX via  
acid-base interactions between the protonable amine group in the DOX (site indicated by the 
blue circle) and the acid groups in the copolymer. (B) PEG-b-PAC and PEG-b-Poly(urea 
carbonate) (PUC) copolymers were blended to form mixed micelles self-assembled via acid-
urea hydrogen bonding while DOX formed ionic interactions with the acid groups and 
hydrogen bonding (sites indicated by the yellow circle) with urea groups in the micellar core.    
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A number of anticancer drugs contain amine groups in their molecular 
structures such as doxorubicin (DOX), daunorubicin, sunitinib, imatinib etc. 
Amphiphilic polycarbonates containing acid-functional groups are postulated to be 
able to sequester amine-containing drugs due to the formation of drug-copolymer 
ionic interactions (Scheme 3.1). A balance between the hydrophilic pendent acid 
groups and the hydrophobicity of the copolymers must be achieved however to not 
compromise on the critical micelle concentration (CMC), which is an important factor 
that determines thermodynamic stability of the resulting micelles. Therefore, in this 
chapter, block copolymers of PEG and acid-functionalized polycarbonate were used 
to form micelles for the delivery of DOX while exploring several polymer structural 
designs with varying placement and distribution of the carboxylic acid functionalities 
within the polycarbonate block. The effect of acid groups on drug loading level and 
micelle stability was investigated by comparing micelles self-assembled from triblock 
copolymers whereby the acid-containing block was at the end (PEG-b-poly(ethyl 
carbonate)-b-poly(acid-carbonate)) micelles derived from triblock copolymers with 
the acid block in the middle (PEG-b-poly(acid-carbonate)-b-poly(ethyl carbonate)) or 
diblock copolymers with a random distribution of the carboxylic acid functionalities 
in the polycarbonate block (PEG-b-poly(ethyl carbonate-r-acid carbonate). To further 
improve the kinetic stability of said micelles, a PEG-polycarbonate diblock 
copolymer with urea functional groups capable of self-assembling as well as 
recognizing interactions with carboxylates [179, 180], was also synthesized and 
blended with the acid-functional copolymers to prepare mixed micelles based on 
hydrogen bonding interactions between the urea group and the acid group (Scheme 
3.1). The effect of urea group number in the urea-functionalized copolymers was 
studied. The influence of the relative acid to urea molar content in the mixed micelles 
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was also explored on the drug release rate and in vitro cytotoxicity of HepG2 human 
hepatocellular carcinoma cell line. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Phosphate-buffered saline (PBS) buffer was purchased from 1
st
 Base 
(Singapore) and diluted 10 times as per recommended. DOX was acquired from 
Boryung Pharmaceutical Co. Ltd. (South Korea) and 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma-Aldrich and used 
as received. HepG2 human liver carcinoma cell line was acquired from ATCC 
(U.S.A.). Dulbecco's modified eagle medium (DMEM) and fetal bovine serum (FBS) 
were purchased from Invitrogen Corporation. 
 
3.2.2 Synthesis and characterization of acid- or urea-functionalized polycarbonates 
Polycarbonate copolymers in this study and the functionalized 
methylcarboxytrimethylene carbonate (MTC) monomers were synthesized by Dr 
Chuan Yang (Institute of Bioengineering and Nanotechnology, A*STAR). 
Polymerization proceeds via metal-free organocatalytic ROP of cyclic functionalized 
carbonates in the presence of 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) amine 
catalyst, using mPEG as an initiator. Details in the synthesis of acid- and urea-
functionalized monomers and their subsequent polymerization and molecular 





3.2.3 Determination of critical micellization concentration (CMC) 
The CMC of the block copolymers in DI water at room temperature were 
determined by fluorescence spectroscopy (LS50B luminescence spectrometer, Perkin 
Elmer, USA) using pyrene as a probe. Following the addition of aliquots of pyrene 
solutions in acetone (6.16 × 10
-5
 M, 10 µL) to glass vials, the acetone was allowed to 
evaporate. Subsequently, polymer solutions with various concentrations ranging from 
0.01 to 2000 mg/L (1 mL) were added to the glass vials, giving the final pyrene 
concentration to be 6.16 × 10
-7
 M. The solutions were kept overnight at room 
temperature. The excitation spectra of the solutions were scanned from 300 to 360 nm 
with an emission wavelength of 395 nm. Both excitation and emission bandwidths 
were set at 2.5 nm. The intensity ratios of I337/I334 obtained from the excitation spectra 
were plotted as a function of polymer concentration. The intersection of the tangent to 
the curve at the inflection and the tangent of the points at low polymer concentrations 
gave the CMC value. 
 
3.2.4 Preparation and characterization of DOX-loaded micelles 
DOX was encapsulated into the block copolymer micelles by way of a 
sonication/membrane dialysis method. Briefly, 5 mg of DOX was solubilized in 1.5 
mL of dimethylacetamide (DMAc) and neutralized with three moles excess of 
triethylamine. Polymer (10 mg) was dissolved in 0.5 mL of DMAc and mixed with 
the DOX solution by vortexing, followed by the dropwise addition of the DOX and 
polymer solution to 10 mL of DI water while being sonicated at 130 W for 2 min by a 
probe-based sonicator (Vibra Cell VCX 130). The resulting solution in a dialysis bag 
was dialyzed against 1000 mL of DI water for 48 hours with molecular weight cut-off 
(MWCO) of 1000 Da (Spectra/Por 7, Spectrum Laboratories Inc.), with the water 
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changed at 3 h, 6 h and 24 h. The solution inside the dialysis bag was collected at 48 h, 
and lyophilized. Each experiment was performed in triplicates. The loading level of 
DOX was measured by dissolving a known amount of lyophilized DOX-loaded 
micelles in 1 mL of DMSO and measuring its absorbance using a UV-Vis 
spectrophotometer (UV 2501PC Shimadzu, Japan) at 480 nm. A standard line was 
constructed to determine DOX concentration in the range of 1 to 100 mg/L, and the r
2
 
value of the absorbance at 480 nm plotted linearly against DOX concentration in 
DMSO was at least 0.99. DOX loading level was calculated using the following 
formula: 
%100
micelles loaded-DOX of mass
micellesin   loaded DOX of mass
%)wt(level loading Actual 
 
 
3.2.5 Dynamic light scattering (DLS) measurement 
Particle size was acquired from freshly prepared drug-loaded micelles (~ 0.6 
mg/mL) and blank micelles solutions (1 mg/mL) using dynamic light scattering (DLS, 
scattering angle: 90°) using Zetasizer 3000 HAS (Malvern Instrument Ltd., Malvern, 
UK), which is equipped with a He-Ne laser beam at 658 nm. Large aggregates were 
removed by centrifugation at 4000 rpm for 10 min. For zeta potential analysis, 
polymers and freeze-dried DOX-loaded micelles were dispersed in phosphate-
buffered saline (PBS, pH 7.4) at a concentration of 1 mg/mL and measured using the 
same machine. Each sample was measured 3 times and an average particle size and 
zeta potential was obtained. As the samples might contain individual micelles and 
aggregates (multimodal distribution or giving more than one DLS size peak), the 
particle size was obtained based upon a results analysis method chosen in the 
Zetasizer software (‘Multiple Narrow Modes’) to take account of the different DLS 
signals when different particles size populations are in Brownian motion.  
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3.2.6 Micelles kinetic stability study 
Kinetic stability of the DOX-loaded micelles in DI water was studied 
employing sodium dodecyl sulfate (SDS) as a destabilizing agent. The change in 
scattered light intensity was recorded by DLS using Zetasizer 3000 HAS (Malvern 
Instrument Ltd., Malvern, UK) over 48 h. Briefly, the scattered light intensity of the 
sample was measured prior to the addition of SDS at time 0. SDS aqueous solution 
was added to blank or DOX-loaded micelles (1 mg/mL) in a final concentration of 
2.23 mg/mL and mixed by pipetting. The scattered light intensity of the micelle-SDS 
sample was then measured at 0.5, 1, 2, 4, 8, 24 and 48 h post-addition of SDS. 
Bubbles from pipetting in the solution would disperse naturally after a very short 
period of time. 
 
3.2.7 In vitro release of DOX 
The lyophilized DOX-loaded micelles were dissolved in PBS buffer (pH 7.4) at 
a concentration of 1 mg/mL and placed into a dialysis bag with MWCO of 1000 Da 
(Spectra/Por 7, Spectrum Laboratories Inc.). The bag was immersed in 30 mL of PBS 
buffer (pH 7.4) inside a 37 °C water bath (Polyscience, Spectra-Teknik (S) Pte Ltd.) 
while being shaken at 100 rev/min. At selected time points, 1 mL of the release 
medium was removed for analysis and replaced with 1 mL of fresh PBS buffer. The 
absorbance of DOX in the solution was determined using the UV-Vis 
spectrophotometer (UV 2501PC Shimadzu, Japan) at 480 nm, and DOX content was 





3.2.8 In vitro cytotoxicity study 
Cytotoxicity of free DOX, blank mixed micelles and DOX-loaded mixed 
micelles was investigated by MTT assay. HepG2 were cultured in DMEM, 
supplemented with 10% FBS, 5% penicillin-streptomycin, 2 mM L-glutamine, D-
glucose (4.5 g/L) and 110 mg/L sodium pyruvate, and incubated at 37 °C, 5% CO2. 
The HepG2 cells were seeded at a density of 10
4
 cells per well on 96-well plates and 
kept overnight. Free DOX, blank mixed micelles, and DOX-loaded mixed micelles 
were dissolved in the corresponding cell culture medium at various concentrations, 
and the prepared sample solution (100 µL) used to replace the medium in each well. 
Each sample was tested in eight replicates for each concentration. The plates were 
incubated at 37 °C, 5% CO2 for 48 h. Consequently, the sample-containing medium 
was replaced with a mixture of fresh growth medium (100 µL) and MTT solution (20 
µL, 5 mg/mL), and the plates equilibrated at 37 °C, 5% CO2 for 4 h. To dissolve the 
purple formazan crystals internalized by live cells, the medium was removed and 
DMSO (150 µL) was added. The absorbance of formazan crystals in each well was 
calculated as that at 550 nm deducted by that at 690 nm. Cell viability was formulated 
as a percentage of formazan absorbance of the control non-treated control cells. 
 
3.3 Results and Discussion 
3.3.1 Synthesis of acid-functionalized polycarbonates 
Amphiphilic polycarbonate copolymers functionalized with acid groups were 
synthesized through organocatalytic ROP of MTC monomers containing 
benzyloxycarbonyl groups (MTC-OBn) and/or ethyloxycarbonyl groups (MTC-OEt), 
derivatives of 2,2-bis(methylol)propionic acid with mPEG (2400 g/mol) as the 
macroinitiator (Scheme 3.2). Copolymers bearing the benzyl protecting groups 
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obtained were of narrow molecular weight distribution (PDI: 1.14-1.2, Table 3.1) with 
their compositions and molecular weights estimated from 
1
H NMR spectroscopy and 
corroborated with GPC (Table 3.1). The benzyl protecting groups were later removed 
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3.3.2 Effect of distribution of acid groups in the polycarbonate block 








































































































































(0.250.01) 58.5 -47.83.8   
a
 Determined from 
1
H NMR spectra; 
b
 Obtained from GPC, 
c 
Measured in DI water,                  
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Figure 3.1: Effects of acid location and content on particle size and DOX loading. (A) 
Particle size and DOX loading of micelles formed from PEG-PEC-PAC2 (end), PEG-PAC-
PEC (middle) and PEG-PEAC (random); (B) Particle size and DOX loading of micelles made 
from copolymers with different acid contents (%) ; i.e. PEG-PEC (0%), PEG-PEC-PAC1 
(23%), PEG-PEC-PAC2 (45%), PEG-PEC-PAC3 (70%) and PEG-PAC (100%). 
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A series of acid-containing polycarbonates with similar acid content (~50%) 
were produced with the placement of acid groups varied throughout the hydrophobic 
polycarbonate block i.e. i.e. PEG-b-poly(ethyl carbonate-r-acid carbonate) (PEG-
PEAC), PEG-b-poly(ethyl carbonate)-b-poly(acid carbonate) (PEG-PEC-PAC2) and 
PEG-b-poly(acid carbonate)-b-poly(ethyl carbonate) (PEG-PAC-PEC) (Scheme 3.2). 
These copolymers consisted of two different domains in the hydrophobic portion, one 
with ethyl-containing carbonate and the other with acid-functionalized carbonate in 
various orientations; terminal end, middle or random. Another copolymer, PEG-PEC, 
serves as a control with no acid functionalities in the hydrophobic backbone. This 
particular series of polycarbonates were synthesized to understand how the placement 
and addition of acid groups within the polycarbonate block would affect self-
assembly and cargo loading. The addition of acid groups increased the copolymers’ 
water solubility which aided its ability to form cargo-loaded micelles with particle 
size control. The acid groups also acted as a reservoir for the ionic interactions with 
doxorubicin, DOX, an anticancer drug containing a protonable amine, -NH2. The 
acid-containing copolymers were encapsulated with DOX through a sonication and 
membrane dialysis method. 
It is apparent that the placement of the acid groups in the copolymer affected 
the self-assembly of the micelle and micelle packing to give varying particle sizes 
while still effectively encapsulating DOX (~35–36 wt%) as compared to PEG-PEC 
(24 wt%) (Figure 3.1). The placement of acid block at the end (PEG-PEC-PAC2) 
seemed to be the ideal position as it yielded the lowest particle size before and after 
DOX loading (69 and 107 nm respectively) while giving low CMC value (5.2 mg/L, 
Table 3.1). The particle sizes of DOX-loaded PEG-PAC-PEC, PEG-PEAC and PEG-
PEC were all above 200 nm (294, 455 and 568 nm respectively, Figure 3.1) and were 
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ineffective for EPR effect and unsuitable for DOX-loading for drug delivery purposes. 
While the addition of acid groups on the polycarbonate backbone increased its CMC 
values (5.2, 14.3 and 58.5 mg/L vs. 0.52mg/L, Table 3.1), the placement of acid 
groups at the end block of the copolymer gave the lowest CMC value (5.2 mg/L). 
Interestingly, the CMC of PEG-PEC-PAC2 was found to be slightly lower than that of 
PEG-PAC-PEC in the thesis (5.2 vs. 14.3 mg/L). The micellization of copolymers 
proceed by aggregating the hydrophobic core-forming blocks together to reduce the 
total surface area that disrupts the hydrogen bonding matrix in aqueous solvent. PEG 
block forms favourable hydrogen bonds with water molecules [181]. The acid groups 
in the PAC block in the copolymers would be ionized in the water and the ionized 
acid groups could form ion-dipole bonds with water molecules which are as strong as 
hydrogen bonds while the polycarbonate backbone forms unfavourable interactions 
with water. The proximity of PAC block to PEG block in PEG-PAC-PEC copolymer 
allowed the hydrogen water matrix not to be disrupted extensively as both PAC and 
PEG form interactions with water, allowing more of the PEG-PAC-PEC unimers to 
exist freely in the solution before micellization occurs. However, as the concentration 
of the PEG-PAC-PEC unimers increase in solution, micellization occurs as the 
disruption of the water hydrogen bonding matrix from the unfavourable interactions 
of polycarbonate backbones become more dominant than the interactions of acid 
groups with water  and the polycarbonate blocks were aggregated together. As for 
PEG-PEC-PAC2, the presence of more hydrophobic PEC block adjacent to the 
hydrophilic PEG block caused a distinct change in interactions with water as PEC 
block will disrupt the water hydrogen bonding matrix and so they aggregate at a lower 
concentration to expel water molecules from the micelle core.  
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The elevated drug loading levels can be attributed to enhanced polymer-drug 
interactions via acid-base ionic bonds between the protonated amine group in DOX 
and the acid groups in the copolymer at the neutral pH of micelle fabrication milieu as 
the pKa values of the PEG-PEC-PAC2 and DOX were determined to be 6.4 and 8.2 
respectively. With such high DOX loading levels (above 30 wt%), the presence of 
acid groups on the polycarbonate backbone is appreciated compared to other 
copolymers loaded with DOX such as PEG-b-poly(β-benzyl L-aspartate) [52] and 
folate-PEG-b-poly(L-histidine) mixed with or without folate-PEG-b-PLLA [138] 
which gave to about 17-20 wt% loading level. Polycarbonates having the ability to be 
readily functionalized unlike polyesters can enhance polymer-drug interactions to 
give desirably higher drug loading levels. 
 
3.3.3 Effect of number of acid groups in the polycarbonate block 
After demonstrating that the location of acid groups at the end of the copolymer 
produced the ideal micelle size, we next study the effect of acid content in the 
copolymer with respect to ethyl substitution within the hydrophobic domain while 
keeping the acid groups at the end block of the copolymer. Copolymers with different 
contents of acid groups were studied (PEG-PEC, PEG-PEC-PAC1, PEG-PEC-PAC2, 
PEG-PEC-PAC3 and PEG-PAC with 0%, 23%, 45%, 70% and 100% acid content 
respectively, Scheme 3.1 and Table 3.1). CMC values of the PEG-PEC-PAC 
copolymers increased with increasing acid content due to the elevated hydrophilicity 
of the copolymers (Table 3.1). The particle sizes of the copolymer micelles were 
below 200 nm with PEG-PEC-PAC2 micelles giving the lowest particle size (Table 
3.1). Figure 3.1B shows that the drug loading level of the copolymers increased with 
acid content from the heightened copolymer-drug ionic interactions. However, the 
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copolymers with the superlative 0% and 100% acid content gave large aggregates 
during DOX-loading. This can be attributed to the extreme hydrophobic/hydrophilic 
balance in the polymers thereby preventing compact micelle packing. Notably, 
copolymers with intermediate acid content of 23%, 45% and 70% self-assembled into 
DOX-loaded micelles of particle size below 200 nm (84-120 nm) while yielding high 
drug loading levels (31-37 wt%). PEG-PEC-PAC2 with 45% acid content formulated 
higher DOX loading level than PEG-PEC-PAC1 (35 vs. 31 wt%) and DOX-loaded 
PEG-PEC-PAC2 micelles were able to re-disperse in aqueous solution after 
lyophilisation, unlike DOX-loaded PEG-PEC-PAC3 micelles. These findings 
collectively suggest that PEG-PEC-PAC2 with 45% acid content is a better candidate 
as DOX delivery vehicle.   
The surface charge of the micelles in PBS indicates whether the acid-
functional block is exposed in the corona during the self-assembly process (Table 3.1). 
PEG-PEC blank micelles produced less negative zeta-potential due to the lack of acid 
groups. PEG-PEC-PAC2, PEG-PAC-PEC and PEG-PEAC gave rise to blank micelles 
with less negative zeta-potential compared to PEG-PAC due to their lower acid 
content. The placement of the acid groups within the hydrophobic block has no 
impact on the zeta potential however (-34.6mV vs. -38.1mV, Table 3.1). The 
comparable zeta potentials of the PEG-PEC-PAC2 and PEG-PAC-PEC micelles 
suggested that the micellar structure for both micelles were the same, with the 
micellar core being one homogenous polycarbonate block with no phase separation 
between the different PEC and PAC blocks. Upon loading with DOX, the zeta 
potentials of PEG-PEC-PAC2 and PEG-PAC micelles were reduced, signifying 
sequestration of the acid groups due to their acid-base interactions with DOX in the 
hydrophobic micellar core. This is advantageous as more negatively charged particles 
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are cleared from the blood at a faster rate due to favourable uptake by phagocytic cells 
of the mononuclear phagocyte system (MPS) [115, 182].  
 





























Figure 3.2: Scattered light intensity measured at 90º of DOX-loaded PEG-PAC and PEG-
PEC-PAC2 micelles, and PEG-PAC/PEG-PUC1 as well as PEG-PAC/PEG-PUC2 mixed 
micelles against time after the addition of SDS. Relative intensity (%) is represented as the 
percentage of the scattered light intensity at time x with relative to the scattered light intensity 
at time 0. 
 
As discussed previously, acid groups at the terminal end of polycarbonate 
block aided in the micellization of PEG-polycarbonate copolymers with DOX 
yielding ideal particle size and high drug loading levels. As low kinetic stability of 
micelles is one of the problems associated with drug delivery systems, the kinetic 
stabilities of DOX-loaded PEG-PAC and PEG-PEC-PAC2 were studied by DLS 
(Figure 3.2) in the presence of a micellar destabilizing agent and anionic surfactant i.e. 
sodium dodecyl sulphate (SDS) [147, 183, 184] due to the interactions of the block 
copolymers and SDS that commences at SDS concentrations below its CMC value 
and continues even when SDS forms micellar structures at higher concentrations  
[185-187]. SDS is thought to increase the solubility of the block copolymer by 
adsorbing onto the copolymer micelles structures and forming interactions with the 
PEG chains of the copolymers (possibly through ion-dipole and attractive van der 
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Waals dipole-dipole interactions) and the hydrophobic core-forming blocks in the 
micelles through van der Waals dispersion interactions to solubilize them. As SDS is 
of much smaller molecular weight than that of individual copolymer unimers, SDS 
molecules can spatially form these interactions between micelle unimers to induce 
micelle dissociation. However, if the copolymer unimers within the micelles were 
made frozen from intermolecular forces holding them in place, the micelles can resist 
the inclusion of small SDS molecules and its subsequent micellar disassembly. Here, 
we challenge the energetically favourable or thermodynamically stable PEG-b-
polycarbonate micelles at a concentration (1000 mg/L) well above their CMC values 
to the destabilizing nature of SDS, whereby SDS can mimic proteins with anionic 
surface charge in the blood. As concentrations of the copolymers were ensured to be 
much higher than their CMC values, any micelle stability issues should not be due to 
their different CMC values or energetically favourable state of disassembly but due to 
their propensity to disassemble upon micelle-disrupting conditions. The SDS 
concentration utilized was 2.23 mg/L as similarly used by others in literature [183, 
184] and above the CMC value of SDS (at approximately 1.8 mg/L) [185]. 
DLS was utilized to measure the scattered light intensity of the polycarbonate 
micelle structures over time relative of the intensity at time 0. The drop in intensity of 
the scattered light indicates the extent of micelle dissociation (Figure 3.2). After the 
addition of SDS, the scattered light intensity of DOX-loaded PEG-PAC micelles 
plummeted promptly, signaling that almost all of the micelles were dispersed. DOX-
loaded PEG-PEC-PAC2 fared better with about 10% of remaining scattering light 
intensity observed, suggesting that the ethyl substitution within the polycarbonate 
domain in the copolymers ameliorated the kinetic stability of the micelles slightly. 
Although PEG-PAC micelles were above their CMC values and in micellar structures 
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in this study, the acid groups in the micellar core may form repulsive forces against 
one another. Thus, in the presence of micelle-disrupting conditions conferred by the 
addition of SDS, almost all of PEG-PAC micelles dissociated as the intermolecular 
interactions within the micellar core were against keeping the core-forming blocks 
together. 


























































PEG-PUC1 (n = 113; z = 6)
PEG-PUC2 (n = 113; z = 15)
PEG-PUC3 (n = 113; z = 24)
 
Scheme 3.3: Synthesis of urea-functionalized polycarbonates for mixed micelles assembly. 
  
 
Table 3.2: Properties of urea-functionalized polycarbonate block copolymers and mixed 



















(1.08) 16.6 1369  46 0.37  0.01 4.8  1.6 
PEG-PUC2 9850 10.0 1057  103 0.54  0.01 25.4  3.0 
PEG-PUC3 12640 6.31 191  40 0.19  0.07 12.5  1.9 
PEG-PAC/PEG-
PUC1 (1:1)  
 
























11.2 147  16 0.20  0.01 31.9  0.3 
a
 Determined from 
1
H NMR spectra; 
b
 Obtained from GPC, 
c
 DOX-loaded micelles 
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To improve on the kinetic stabilities of the acid-functionalized polycarbonates, 
diblock copolymers of PEG and urea-functionalized polycarbonate with varying 
length of polycarbonate block were synthesized and employed to blend with acid-
functionalized polycarbonate copolymers to form coherent mixed micelles. The urea 
groups in the polycarbonates were thought to interact with themselves, the acid 
groups and DOX cargo through hydrogen bonding interactions, which can stabilize 
the micelles and enhance the kinetic stability of the micelles. Urea-functionalized 
copolymers with narrow molecular weight distributions were synthesized similarly 
via organocatalytic ROP of urea-carbonate monomer using mPEG (5000 g/mol) as the 
initiator (Scheme 3.3). A higher molecular weight of mPEG was needed to improve 
on the water solubility of urea-functionalized copolymers. PEG-b-poly(urea 
carbonate) (PEG-PUC) copolymers were blended with PEG-PAC in 1:1 molar ratio 
before dissolving in water to self-assemble as mixed micelles. The self-assembly of 
PEG-PAC/PEG-PUC2 mixed micelles lowered the CMC of PEG-PAC from 152.8 
mg/L to 15.8 mg/L (Table 3.1, Table 3.2). When DOX was encapsulated into the 
mixed micellar core, the particle size yielded was much smaller (177 nm) compared to 
that of the DOX-loaded individual copolymers, PEG-PAC and PEG-PUC2 (595 and 
1057 nm respectively, Table 3.1, Table 3.2). Polydispersity (PDI) of the mixed 
micelles was also perceived to be low (0.16). Coherent mixed micelles were 
postulated to be formed due to the existence of a single CMC value and low PDI of 
cargo-loaded micelles. Drug loading level of PEG-PAC/PEG-PUC2 mixed micelles 
was 40% and remained unaffected by the presence of PEG-PUC2 copolymer (Table 
3.2). Due to the acid-urea hydrogen bonds, the mixed micelles were able to sequester 
DOX more effectively and yield nanostructures without precipitates as compared to 
acid-functionalized polycarbonate copolymers. 
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DOX-loaded PEG-PAC/PEG-PUC2 mixed micelles were also similarly 
challenged with SDS which acts as a micellar destabilizing agent as a means to 
compare its kinetic stability against PEG-PAC described previously. The extent of 
intensity drop for PEG-PAC/PEG-PUC2 mixed micelles was less than that of PEG-
PAC and PEG-PEC-PAC2 micelles, indicating that the mixed micelles systems 
exhibited higher kinetic stability than both acid-functionalized micelles (Figure 3.2). 
The micelle systems utilized in the SDS study were at a concentration of 1000 mg/L, 
which is well above their CMC values and thus micelle assemblies were expected to 
be maintained due to energetics of the system. However, dissociation of the micelles 
was still observed to varying degrees for different micelle systems. This was 
attributed to their tendency to resist disassembly in micelle-disrupting conditions and 
resist forming interactions with SDS by keeping the micellar core frozen with 
noncovalent acid-urea intermolecular interactions. Mixed micelles stabilized via acid-
urea hydrogen bonding in the micellar core were able to exhibit enhanced kinetic 
stability than PEG-PEC-PAC2 micelles purely self-assembled from weaker 
hydrophobic interactions (van der Waals interactions). The stronger hydrogen 
bonding within mixed micelles conferred micelle rigidity, slowing the movement of 
unimers in the mixed micelles to resist to a larger extent to the micelle-disrupting 
unimer interactions with SDS. This signifies that introduction of noncovalent 
interactions within micelle structures is influential in enhancing the micellar kinetic 
stability.  
 
3.3.5 Effect of number of urea groups in mixed micelles 
The effect of number of urea groups on the mixed micelles self-assembly and 
kinetic stability was next investigated. Urea functionalized copolymers with varying 
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urea units, PEG-PUC1, PEG-PUC2 and PEG-PUC3 (Scheme 3.3), were blended with 
PEG-PAC in 1:1 molar ratio during encapsulation of DOX (Table 3.2). All DOX-
loaded mixed micelles exhibited nanoscale size with narrow size distribution (PDI 
values ranging from 0.15 - 0.24) and high DOX loading levels as shown in Table 3.2. 
Varying the length of the urea-functionalized polycarbonates did not affect the drug 
loading level of resulting mixed micelles drastically (Table 3.2). DOX-loaded PEG-
PAC/PEG-PUC3 mixed micelles exhibited the smallest particle size at 139 nm while 
DOX-loaded PEG-PAC/PEG-PUC1 and PEG-PAC/PEG-PUC2 mixed micelles 
similarly formed particles below 200 nm. The higher number of urea units in PEG-
PUC3 probably intensified the urea-acid hydrogen bonding, making the micelles more 
compact. 
In the presence of SDS, the degree of micelle dissociation decreased with 
increasing urea length in the mixed micelles as DOX-loaded PEG-PAC/PEG-PUC1 
mixed micelles retained 40% of its initial scattered light intensity compared to that of 
70% exhibited by DOX-loaded PEG-PAC/PEG-PUC2 mixed micelles (Figure 3.2). 
This could be attributed to the higher degree of hydrogen bonding stabilizing the 
micelle with increased urea units. However, a longer length of urea-functionalized 
carbonate units would result in more hydrophobic mixed micelles, leading to easier 
aggregation in water over time. PEG-PAC/PEG-PUC2 mixed micelles exhibited the 
highest drug loading at 40% with relatively high kinetic stability, showing its 
potential as a good drug delivery carrier. The zeta potential of blank PEG-PAC/PEG-
PUC2 mixed micelles were approximately neutral as compared to that of PEG-PAC 
micelles (-0.9 vs. -54.4 mV). It was postulated that the acid-urea interactions 
sequestered the acid groups into the core of the micelles, decreasing the possibility of 
the acid groups in the corona of the micelles.  
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3.3.6 Effect of acid to urea ratio in mixed micelles 
While previous studies were done using mixed micelles in 1:1 molar ratio of 
acid to urea groups, the various relative mixed micellar molar ratios of both acid and 
urea groups were further investigated using PEG-PAC/PEG-PUC2 mixed micelles. 
Increasing the acid content in the mixed micelles would increase the CMC values 
(15.8mg/L, 20.0mg/L and 35.5mg/L for 1:1, 2:1 and 3:1 molar ratio respectively, 
Table 3.2) by virtue of the enhanced hydrophilicity of acid groups. Upon 
encapsulation of DOX, DOX-loaded mixed micelles with molar ratios 1:1 and 2:1 
exhibited similar particle sizes, while particle size of the mixed micelles increased at 
molar ratio 3:1. As DOX-loaded PEG-PAC micelles formed particles of 595 nm, 
higher acid content would increase resulting mixed micelles particle size. DOX 
loading levels however remained relatively unchanged with increasing acid content 
(Table 3.2) probably due to saturation of DOX encapsulation. The drug-encapsulated 
mixed micelles exhibited more negative zeta potentials with increasing acid groups (-
6.6, -11.8 and -12.7 mV for 1:1, 2:1 and 3:1 molar ratio respectively).  
On the flipside, CMC values of the mixed micelles decreased with increasing 
urea content (15.8, 12.0 and 11.2 mg/L for 1:1, 1:2 and 1:3 molar ratio respectively, 
Table 3.2) due to the increased hydrophobicity of higher urea content. The particle 
size and DOX loading level of PEG-PAC/PEG-PUC2 system decreased along with 
the molar ratio of acid to urea from 1:1 to 1:3 (177 to 147 nm and 40 to 32 wt% 
respectively, Table 3.2). The decrease in particle size with increasing urea content 
could be attributed to the increased hydrophobicity of the micelles, making them 
compact to shield from the aqueous environment. Increasing urea content would 
decrease the degree of ionic interactions between the acid groups in the micellar core 
and DOX, resulting in lower drug loading levels. The zeta potential of DOX-loaded 
 64 
mixed micelles increased to near-neutral with increasing urea content relative to acid 
groups i.e. -5.3 mV and -4.8 mV for molar ratio 1:2 and 1:3 respectively.  
 

































































































































Figure 3.3: (A) Release profiles of DOX-loaded mixed micelles formed from PEG-PAC and 
PEG-PUCS1 at various acid to urea molar ratios in PBS (pH 7.4), 37 °C; viability of HepG2 
cells after incubation with (B) free DOX and the DOX-loaded mixed micelles and (C) PEG-
PUC2, PEG-PAC and mixture of PEG-PAC/PEG-PUC2 (1:1 molar ratio) block polymers for 
48 h 
 
In vitro drug release profiles and cytotoxicity against HepG2 cancer cells of 
the drug-loaded mixed micelles systems were next investigated to evaluate its 
application as a drug delivery carrier. As shown in Figure 3.3A, sustained release of 
DOX from the mixed micelles was observed over a period of 6 h at 37 °C and pH 7.4 
without an initial burst, following which DOX release was too insignificant to be 
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detected under the simulated in vitro environment. It could be perceived that release 
rates of DOX from the mixed micelles were markedly influenced by the relative acid 
to urea molar ratio (Figure 3.3A). DOX release was slower from mixed micelles with 
increased acid to urea ratios (2:1 and 3:1) in comparison to the mixed micelles formed 
at the acid to urea molar ratio of 1:1, on account of heightened acid-base interactions 
between DOX and the micellar core. On the other hand, precipitations of DOX-loaded 
micelles with acid to urea ratios of 1:2 and 1:3 occurred during the in vitro release 
study due to the increased hydrophobicity of mixed micelles, resulting in even slower 
DOX release as compared to the mixed micelles formed at the other molar ratios of 
acid to urea. More than 50% of DOX was released in less than 24 h for mixed 
micelles formed at the acid to urea molar ratio of 1:1 which was similarly observed 
for other reported micelle carriers of DOX [188, 189]. To maximize the therapeutic 
efficiency of these drug-loaded nanocarriers, drug release from the mixed micelles has 
to be retarded during blood circulation to prevent premature loss of drug and release 
of drug has to be accelerated once it reaches the tumour site. Firstly, the main 
mechanism of in vitro drug release is the diffusion of drug from micellar core while 
the amount of drug released is proportional to the concentration gradient of drug 
between the surrounding PBS solvent and the PBS solvent inside the dialysis bag [26]. 
Amphipathic drugs such as DOX may reside in the core-corona interface of the 
micelle [190], making the in vitro release faster especially with a drug concentration 
gradient present. This was similarly observed with another amphipathic drug whereby 
80% of indomethacin was released from PEO-b- poly[2-(diisopropylamino)ethyl 
methacrylate] polymeric micelles in 8 h in which indomethacin was encapsulated via 
acid-base interactions in the micellar core [80]. During in vivo application, the 
micelles would have been diluted in the blood instead and concentration gradient 
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between the blood and micellar core may not be significant. The tendency of the 
micelles to be intact in the blood has more influence on the drug release during blood 
circulation [79]. Secondly, DOX release may accelerate in the tumour cells during in 
vivo application due to the degradation of the polymers in the presence of enzymes 
such as lipase. 
Cytotoxicity of the DOX-loaded micelles and free DOX on HepG2 cells were 
assessed by MTT assay shown in Figure 3.3B. The DOX-loaded mixed micelles 
particularly at acid to urea molar ratios of 1:1, 2:1 and 3:1 readily suppressed 
proliferation of HepG2 human liver carcinoma cells. The IC50 values of DOX, a 
concentration at which 50% cells are killed, were similar at 0.20, 0.23, 0.20 and 0.18 
mg/L for DOX-loaded micelles at acid to urea ratios of 1:1, 2:1, 3:1 and free DOX 
respectively. As for the mixed micelles at acid to urea molar ratios of 1:2 and 1:3, IC50 
values of DOX (0.32 and 0.40 mg/L respectively) were slightly higher than that of 
DOX in other mixed micelles formulations owing to the probable slower release of 
DOX (Figure 3.3A). Higher IC50 values for encapsulated DOX formulations 
compared to free DOX implies that the DOX release from micelles might be a slow 
process, as observed by others using other nanoparticle formulations [47, 191]. 
Notably, these functional polycarbonates copolymers did not induce cytotoxicity 
against HepG2 cells even at high concentrations (Figure 3.3C), indicating that any 
cytotoxicity of DOX-loaded micelles towards the HepG2 cells were solely due to the 
effect of DOX. 
  
3.4 Conclusion 
In this study, novel functional aliphatic polycarbonate copolymers were 
designed to self-assemble into nanosized micelles based on reversible non-covalent 
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interactions for the delivery of amine-containing DOX. The copolymers were 
synthesized via organocatalytic ring opening polymerization, yielding copolymers 
with well-controlled molecular weight, low polydispersities and end-group fidelity. 
Two different approaches were described for developing amphiphilic polycarbonate-
based block copolymers with hydrophilic PEG domain and various functionalities for 
hydrophobic drug delivery. The first approach involves the use of triblock copolymers 
of PEG, poly(ethyl carbonate) and acid-functionalized polycarbonates to sequester 
DOX effectively via acid - base ionic interaction resulting in high drug loading levels 
while still forming micellar nanostructures with low polydispersity. The introduction 
of the ethyl carbonate in the hydrophobic domain improved its kinetic stability. In the 
second approach, novel mixed micelles were self-assembled from acid- and urea-
functionalized polycarbonates and stabilized by acid-urea hydrogen bonding 
interactions to further improve kinetic stability. The hydrogen bonding within mixed 
micelles catered to their enhanced kinetic stability with the micellar structures being 
nanosize with narrow size distribution and high cargo loading capacity. DOX was 
released from the mixed micelles effectively and IC50 values of drug-loaded mixed 
micelles were similar to that of free DOX against HepG2 cells. The polycarbonate 
copolymers showed no cytotoxicity to HepG2 cells. With these features, the mixed 
micelles are a promising delivery carrier for the delivery of anticancer drugs with 
amine functional groups.   
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Chapter 4 Micelles formed from block copolymers of PEG and 
polycarbonate bearing both acid and urea groups for the delivery 
of amine-containing DOX 
 
4.1 Background 
In the previous chapter, controlled/living ring-opening polymerization (ROP) 
was introduced as a worthwhile synthetic tool box for the development of functional 
polycarbonate copolymers due to its ability to control molecular weight, molecular 
weight distribution, composition and functionalities with end-group fidelity. With this 
tool box, acid- and urea-functionalized poly(carbonate) and poly(ethylene glycol) 
(PEG) block copolymers were synthesized. The incorporation of acid groups were 
influential in yielding high DOX loading capacity owing to the acid-base ionic 
interactions between acid groups and the amine group in DOX. Kinetic stability of the 
acid-functionalized micelles were improved with the introduction of urea-
functionalized polycarbonates copolymers to form coherent mixed micelles via 
hydrogen bonding interactions between urea and acid groups.  
Further development of well-defined polycarbonate copolymers containing 
acid and urea groups is explored in this chapter. To simplify polymer synthesis and 
fabrication process of above-mentioned mixed micelles, we designed and synthesized 
block copolymers of PEG and polycarbonate containing both pendent urea and acid 
functional groups to self-assemble into dual-functional micelles with postulated high 
drug loading capacity and stability. Different molecular architectures of the dual-
functional block copolymers were synthesized via organocatalytic ROP of urea- and 
acid-functional cyclic carbonate monomers with methoxy PEG as the macroinitiator. 
The number of acid units and urea units were kept similar in each polycarbonate block. 
The resulting supramolecular nanostructures possessing heterogeneous functional 
groups are ideal for studying the effects of non-covalent interactions governing the 
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drug loading and kinetic stability of micelles. In particular, we examined the influence 
of the distribution of the acid/urea groups in the copolymer (in a block or random 
form) and the number of the functional groups on the self-assembly behaviours of the 
polymers using DOX as a model drug. Other aspects crucial to the accomplishment of 
drug delivery such as in vitro release profile, cellular uptake and cytotoxicity against 
HepG2 human liver carcinoma cell line of the DOX-loaded dual-functional micelles 
were also investigated. Preliminary studies investigating the biodistribution of DOX-
loaded micelles were also performed in mice via intravenous (i.v.) administration. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Similar materials were used as described in Chapter 3. HEK293 human 
embryonic kidney cell lines were acquired from ATCC (U.S.A.).  
 
4.2.2 Synthesis and characterization of urea-functionalized copolymers with benzyl 
protecting carboxylic acid group  
Polycarbonate copolymers bearing both acid and urea groups studied in this 
chapter were synthesized by Dr Chuan Yang (Institute of Bioengineering and 
Nanotechnology, A*STAR). Polymerization proceeds via metal-free organocatalytic 
ring-opening polymerization (ROP) of cyclic functionalized carbonates in the 
presence of N-(3,5-trifluoromethyl)phenyl-N’-cyclohexylthiourea (TU) thio urea 
catalyst, using mPEG as an initiator. Details of the synthesis of acid- and urea-
functionalized monomers and their polymerization and molecular characterization are 
given in Appendix B. The CMC values of the acid- and urea-functional block 
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copolymers were measured in de-ionized (DI) water using pyrene as a probe as 
previously described in Section 3.2.3.  
 
4.2.3 Preparation of DOX-loaded micelles and characterization of DOX-loaded 
micelles  
DOX encapsulation into the various polymeric micelles was carried out 
through a sonication/membrane dialysis method and the loading levels of DOX-
loaded micelles were measured as described previously in Section 3.2.4. The sizes 
and zeta potentials of micelles were analyzed using Zetasizer 3000 HAS (Malvern 
Instrument Ltd., Malvern, UK), as stated in Section 3.2.5. Kinetic stability of the 
DOX-loaded micelles and blank micelles (1 mg/mL) were monitored by DLS using a 
final SDS concentration of 2.23 mg/mL as previously stated in Section 3.2.6. DOX 
release study for DOX-loaded micelles (1 mg/mL) was conducted in PBS buffer (pH 
7.4) with further details found in Section 3.2.7. Cytotoxicity of free DOX, blank 
micelles and DOX-loaded micelles against HepG2 and/or HEK293 cells were 
investigated by MTT assay as described previously in Section 3.2.8. HepG2 and 
HEK293 cells were both cultured in DMEM supplemented with 10% FBS, 5% 
penicillin-streptomycin, 2 mM L-glutamine, 4.5 g/L D-glucose and 110 mg/L sodium 
pyruvate, and incubated at 37 °C, 5% CO2.  
 
4.2.4 Stability studies of micelles in serum-containing medium 
Particle size of blank or DOX-loaded micelles solution (~ 1 mg/mL) 
containing 10% fetal bovine serum (FBS) was monitored by DLS using Zetasizer 
3000 HAS (Malvern Instrument Ltd., Malvern, UK) over 48 h. 
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4.2.5 Transmission electron microscopy (TEM) 
A few drops of the micelle solution containing 0.2% (w/v) of phosphotungstic 
acid were added on a 200 mesh carbon-coated copper grid that was plasma-treated for 
2 seconds, and the sample dried at room temperature. The morphology of the blank 
and DOX-loaded micelles was observed using a FEI Tecnai G
2
F20 electron 
microscope with an acceleration voltage of 200 keV.  
 
4.2.6 Cellular uptake-qualitative analysis by confocal laser scanning microscopy 
(CLSM) 
The cellular uptake of DOX using free DOX or functional micelle formulation 
was studied qualitatively in HepG2 cells by CLSM. Cells were seeded onto a 4 well-
cover slip borosilicate glass chamber (NUNC) at a density of 40,000 cells/well and 
incubated overnight in DMEM enriched with 10% FBS, 2 mM L-glutamine, 50 
units/mL penicillin and 50 μg/mL streptomycin at 37 °C, 5% CO2. The cells were 
administered with free DOX (1 µg/mL) and DOX-loaded micelles (1 µg/mL 
equivalent DOX concentration) the next day for 4 h, followed by incubation with 
Hoechst staining (5 μg/mL) for 30 min. The cells were then washed with PBS for 3 
times. The images were taken with excitation and emission wavelengths of 532 and 
595 nm respectively. 
 
4.2.7 Cellular uptake-quantitative analysis by flow cytometry 
Quantitatively, the cellular uptake of free DOX and DOX-loaded micelles was 
further evaluated in HepG2 cells via flow cytometry. The cells were seeded onto 12-
well plate at a density of 10
6
 cells per well, and maintained for 24 h at 37 °C, 5% CO2. 
The cells were then treated with free DOX (1 µg/mL) and DOX-loaded micelles (1 
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µg/mL equivalent DOX concentration) for 4 h. The cells were then washed 
comprehensively with PBS, trypsinized and collected by centrifugation at 1500 rpm 
for 10 min. The cell pellet was resuspended in PBS and assessed for fluorescent 
intensity per cell and percentage of cells that internalized DOX. Percentage of the 
cells that internalized DOX was obtained from the ratio of events with DOX 
expression over the number of gated events. The total number of events was recorded 
as 10,000. Auto-fluorescence produced by the cells was taken into account by 
referencing the fluorescent intensity measurement of the treated cell sample to that 
given by HepG2 cells without any treatment. The measurements were done with 
excitation and emission wavelengths of 532 and 595 nm respectively.  
 
4.2.8 Biodistribution of DOX-loaded 1b micelles 
The animal protocols were approved by the Institutional Animal Care and Use 
Committee, Biological Resource Centre, Agency for Science, Technology and 
Research, Singapore. Biodistribution of DOX was evaluated for DOX-loaded 1b 
micelles and free DOX formulations in male BALB/c mice (25 – 30 g) via tail vein 
intravenous injection at an equivalent dose of 5mg/kg DOX. Six mice were sacrificed 
at 5 min, 30 min, 2, 4, 8 and 24 h after administration of each formulation. Organs 
were harvested (heart, liver, spleen, lungs and kidneys) and stored in -80ºC. The 
amount of DOX in the organs was quantified by high performance liquid 
chromatography (HPLC) assay. The organs were weighed and homogenized in the 
mobile phase solution of 75% 3M KH2PO4 and 25% H2O. DOX extraction solvent 
consisting of 50% acetonitrile, 30% methanol and 10% H2O was added to the 
homogenized samples and vortexed for 2 min. The samples were then centrifuged at 
14 000 rpm at 4ºC for 15 min before the supernatant collected for HPLC analysis 
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(Waters 2690 Separations Module with Waters 2475 Multi-λ Fluorescence Detector) 
using the abovementioned mobile phase. The DOX peak was identified at an 
excitation wavelength of 480 nm and an emission wavelength of 580 nm. 
 
4.3 Results and Discussion 
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Scheme 4.1: Synthesis procedures and structures of acid- and urea-functionalized 
polycarbonates. 
 
Amphiphilic acid/urea-functionalized polycarbonates with varying 
hydrophobic lengths and molecular architectures were synthesized via ROP of two 
monomers derived from 2,2-bis(methylol)propionic acid bearing pendent functional 
benzyloxycarbonyl group (MTC-OBn) or pendent urea group (MTC-OU) using 
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methoxy PEG (MW 5,000 g/mol) as a macroinitiator (Scheme 4.1). The distribution 
of the acid/urea groups in the polycarbonate hydrophobic block resulted from the 
order in which the different functionalized carbonate monomers were reacted. 
Sparteine and TU were used as catalysts instead of superbasic amidine 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) as per the protocol in the previous study in 
Chapter 3, as DBU caused precipitation of the MTC-urea monomer during 
polymerization. Functionalized copolymers bearing the benzyl protecting group were 
obtained in nearly quantitative yields with narrow molecular weight distribution (PDI 
< 1.2, Table 4.1). The molecular structures together with the molecular weights of the 
block copolymers before deprotection were estimated from 
1
H NMR spectroscopy 
(Table 4.1), with the results consistent with those obtained from GPC (relative to 
polystyrene standards). The carboxylic acid groups in the copolymers were exposed 
via hydrogenolysis (H2/Pd-C) of the benzyl protecting groups, which was affirmed by 
1
H NMR analysis (Figure A2.1). Organocatalytic ROP has proven itself again to be a 
sensible approach to prepare polycarbonate copolymers as it provided exquisite 
control over the number of acid/urea groups while producing polymers with narrow 
molecular weight distribution. 
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(0.19 ± 
0.01) 





















































50 ± 1 
(0.19 ± 
0.03) 

























43 ± 4 
130 ± 6 
(0.34 ± 
0.01) 
























36 ± 2 
136 ± 10 
(0.32 ± 
0.03) 







 Determined from 
1
H NMR spectra; 
b
 Obtained from gel permeation chromatography (GPC) 
measurement; 
c
 Measured in PBS, pH 7.4; 
d
 Measured in DI water 
 
 
4.3.2 Effect of acid/urea distribution 
Three types of block copolymers with comparable molecular weights and 
number of acid/urea groups were synthesized with acid and urea groups distributed in 
two different block forms (i.e. 2 and 3) and random form (i.e. 1c) (Table 4.1) to 
comprehend as to how the allocation of acid/urea functional groups govern self-
assembly and drug loading. CMC values of 1c, 2 and 3 micelles were comparable 
(Table 4.1), signifying that the polymers with varying distributions of acid and urea 
groups resulted in similar hydrophilicity in aqueous solution. Both 2 and 3 micelles 
yielded distinctly two size populations (Table 4.1): i.e. one at approximately 40 nm 
and the other at about 130 nm, resulting in a polydispersed distribution (PDI: 0.32-
0.34). 1c micelles contrarily displayed narrow size distribution (PDI: 0.18). The 
placement of the acid/urea groups tellingly modulated the self-assembly behavior of 
the copolymers. Copolymers with urea and acid groups in block form were postulated 
to likely fold upon themselves due to intra-molecular hydrogen bonding formed 
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between the acid block and the adjacent urea block, resulting in aggregation of 
primary micelles (i.e. the population with sizes of 130 nm). Self-assembly of 
primary micelles with the population size of 40 nm was possibly driven by inter-
molecular hydrogen bonding interactions between the acid block and the urea block 
on different polymer unimers. The presence of two different size populations of the 
micelles could be visualized by TEM (Figure 4.1A, B). As both acid and urea 
functionalities were distributed randomly throughout the hydrophobic block in 1c, 
self-assembly by intra-molecular hydrogen bonding was prevented, leading to 










Figure 4.1: TEM images of blank (A) 2 and (B) 3 micelles in DI water; (C) blank and (D) 
DOX-loaded 1b micelles. 
 
 
From zeta potential analyses in PBS buffer (pH 7.4), the micelles surfaces 
were found to be negatively charged with comparable zeta potentials (Table 4.1). In 
contrast to another block copolymer of PEG and 9 units of acid-functional carbonates 
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without urea functionality, the degree of negative charges of the acid/urea-functional 
micelles was significantly reduced (-26.7 vs. -8.5 and -11.6 mV). This is probably due 
to the sequestration of the acid groups into the micelle core from the urea-acid 
hydrogen bonding interaction, thus increasing the zeta potential.  
Upon encapsulation of DOX, 1c, 2 and 3 copolymers imparted high drug 
loading levels largely because of strong ionic interactions between acid groups in the 
micellar core and the amine group in DOX, while the distribution of urea/acid groups 
did not influence DOX loading capacity significantly (Table 4.1). Drug encapsulation 
also yielded a lower degree of negative charges on the micellar surface due to 
neutralization of the acid groups by the amine group in DOX (e.g. zeta potentials of 
1c micelles with and without DOX: -2.8 and -10.9 mV respectively, Table 4.1). It is 
desirable to have less negatively charged surface to prevent uptake by phagocytic 
cells, resulting in faster clearance from the blood [115, 182]. Similar to their blank 
micelles counterpart, DOX-loaded 2 and 3 micelles exhibited a much wider size 
























































































Figure 4.2: Scattered light intensity measured at 90º of (A) blank and (B) DOX-loaded 1a, 1b, 
1c, 2 and 3 micelles against time after being challenged with SDS. Relative intensity (%) is 




The effect of the distribution of functional groups on the kinetic stabilities of 
the blank and DOX-loaded micelles was examined in the presence of sodium dodecyl 
sulfate (SDS) acting as a destabilizing agent. Within 30 min after the addition of SDS 
to the micelles, the scattered light intensity of the blank and DOX-loaded micelles 
declined significantly and maintained relatively constant up to 48 h, indicating micelle 
dissociation (Figure 4.2). Notably, both 2 and 3 micelles with or without DOX 
loading were less stable than 1c micelles even though they had a comparable number 
of acid/urea functionalities, with 3 micelles being more kinetically stable than 2 
micelles. This indicated that the inter/intra-molecular hydrogen bonding modulated 
the micelle stability. While inter-molecular hydrogen bonding within the core retained 
the assembly of the micelles, SDS might easily dissociate the weak aggregations of 
primary micelles assembled via intra-molecular hydrogen bonding interactions. DOX-
loaded 1c micelles exhibited a slight decrease in kinetic stability, whereas the stability 
of DOX-loaded 2 and 3 micelles dropped significantly as compared to their blank 
micelles (Figure 4.2). These findings collectively showed that the random placement 
of urea and acid groups was more favourable. 
 
4.3.3 Effect of the number of acid/urea groups in the polycarbonate block 
The number of urea and acid groups (in random form) was varied from 5 to 8, 
13 and 19 (denoted as 1a, 1b, 1c and 1d, Scheme 4.1, Table 4.1) to study its effect on 
self-assembly and drug loading. From Table 4.1, the CMC values of the copolymers 
decreased with increasing number of acid and urea groups despite the enhanced 
hydrophilicity of the polycarbonate block with increasing number of acid groups. The 
decreasing CMC trend entailed that the urea-acid and urea-urea interactions were 
significant in determining the CMC. It was also observed that micelle size increased 
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with increasing number of acid/urea groups due to the longer hydrophobic block 
(Table 4.1). However, when the number of the acid/urea units was increased from 13 
to 19, the particle size decreased accordingly from 77 to 50 nm. Longer polycarbonate 
block lengths with an increased number of urea/acid groups provided stronger inter-
molecular interactions in the core of micelles, hence leading to the formation of a 
more compact core and smaller micellar particle size. Importantly, all the micelles 
exhibited narrow size distribution, which was attributed to the narrow molecular 
weight distribution of the polymers. The degree of negative charges of blank micelles 
increased slightly with an increased number of urea/acid groups. Regardless of that, 
the acid groups of 1b micelles were efficiently incorporated into the micellar core via 
urea-acid interactions, leading to higher zeta potentials compared to micelles derived 
from purely acid-functionalized polycarbonates (-9.5 vs. -26.7 mV). 
Particle size increased marginally due to the encapsulation of drugs, but 
remained below 200 nm for all formulations (Table 4.1). The DOX-loaded micelles 
exhibited PDI values of 0.14 - 0.23, signifying narrow size distribution. The particle 
size of DOX-loaded micelles decreased with an increased number of acid/urea groups 
(184, 87, 84 and 70 nm for 1a, 1b, 1c and 1d respectively). As DOX contains a 
primary amine group and a few carbonyl and hydroxyl groups, the acid-base ionic 
interaction drives the drug encapsulation together with additional hydrogen bonding 
and DOX-DOX/DOX-polycarbonate hydrophobic interactions. Increasing the number 
of acid/urea groups enhanced the inter-molecular interactions between the 
polycarbonate blocks via urea-urea and/or urea-acid hydrogen bonding interactions, 
and strengthened micellar core-DOX interactions. These interactions drive the 
assembly of a more stabilized and compact micellar core, yielding smaller particle 
size. 1a, 1b, 1c and 1d also exhibited comparable drug loading capacity. Additionally, 
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negative charges of micellar surface were reduced after DOX loading, e.g. zeta 
potentials of 1b micelles with and without DOX were -1.2 and -9.5 mV, respectively 
(Table 4.1). DOX-loaded 1a and 1b micelles were able to re-disperse in aqueous 
solution after lyophilisation for long-term storage, but re-dispersion of DOX-loaded 
1c and 1d micelles was unattainable. The particle size of reconstituted DOX-loaded 





























Figure 4.3: Size of DOX-loaded 1b and 1c micelles in DI water containing 10% fetal bovine 
serum monitored as function of time. 
 
The stability of DOX-loaded 1b and 1c micelles in a serum-containing 
medium was also studied (Figure 4.3). The particle size of DOX-loaded 1b micelles 
did not change significantly over 48 h, whereas DOX-loaded 1c micelles aggregated 
after a few hours. It is undesirable for micelles to aggregate in serum-containing 
media, implicating protein adsorption on the surface, which may lead to fast clearance 
by the mononuclear phagocyte system (MPS) [34]. The kinetic stabilities of blank and 
DOX-loaded 1a, 1b and 1c micelles were also examined. As shown in Figure 4.2, the 
kinetic stability of the blank and DOX-loaded micelles increased with the number of 
acid/urea groups due to enhanced hydrogen bonding (urea-urea, acid-urea and urea-
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DOX), ionic (acid-DOX) and hydrophobic (polycarbonate-DOX and DOX-DOX) 
interactions in the micellar core.  
Briefly, 1b is the best candidate amongst the dual-functional copolymers 
presented in this study for the preparation of micellar drug delivery vehicles. 1b 
micelles provided relatively high DOX loading capacity as that of the mixed micelles 
system described in Chapter 3 with nanosize and narrow size distribution. In addition, 
DOX-loaded 1b micelles were also able to re-disperse after freeze-drying making 
their storage convenient. As shown in Figure 4.1C and D, both blank and DOX-
loaded 1b micelles were spherical and of narrow size distribution. 
 



























Figure 4.4: In vitro release profile of DOX-loaded 1b micelles in PBS (pH 7.4) at 37 ºC. 
 
Sustained drug release from micelles without any initial burst release 
represents another important criterion for a micellar drug delivery system to be 
applicable in vivo. As shown in Figure 4.4, DOX-loaded 1b micelles were able to 
release 45% of the encapsulated DOX in a sustained manner during the first 7 hours 
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without obvious initial burst release, following which DOX release was too slow to be 
detected. However, DOX release may be accelerated during in vivo application or 
inside the cells as the polymer may be readily degraded in the presence of enzymes. 
As previously discussed in Chapter 3, in vitro drug release may be accelerated due to 
the existing drug concentration gradient inside and outside of the dialysis bag which 
will not correlate to the in vivo drug release as kinetic stability of the nanostructures is 
more influential in the premature drug release during blood circulation. 
 




























































































































































Figure 4.5: Cellular uptake of DOX. Confocal images of HepG2 cells after incubation with 
(A, B) free DOX and (C, D) DOX-loaded 1b micelles for 4h (DOX: 1 mg/L); (E) fluorescent 
intensity of HepG2 cells and (F) percentage of HepG2 cells internalized with DOX after 
incubation with free DOX and DOX-loaded 1b micelles for 4h (DOX: 1 mg/L). 
 
The fluorescent property of DOX molecules allows them to be examined via 
confocal microscopy and flow cytometry. The cellular uptake and intracellular 
distribution of DOX-loaded 1b micelles were investigated in contrast to free DOX. In 
Figure 4.5A-D, the red regions represent DOX molecules while the blue regions 
 83 
indicate Hoechst-stained nuclei. Free DOX passively diffused into the cells, whereas 
1b micelles were internalized most probably by non-specific endocytosis [192, 193]. 
The free DOX molecules mostly entered the nucleus, perceived from the co-
localization of Hoechst and DOX after 4 h incubation (Figure 4.5A, B), while DOX 
molecules were localized in both the cytosol and the nucleus when delivered by the 
micelles due to sustained release of DOX (Figure 4.4 and Figure 4.5C, D). The flow 
cytometry analysis showed that a comparable percentage of cells internalized DOX 
for both formulations (Figure 4.5F) although the extent of DOX internalization at 4 h 
was higher when delivered by the free DOX formulation (Figure 4.5E). A similar 
phenomenon was also reported by others [48, 194]. 
 






































































Figure 4.6: (A) Viability of HepG2 and HEK293 cells after incubation with blank 1b 
micelles; (B) Viability of HepG2 cells after incubation with free DOX and DOX-loaded 1b 
micelles for 48h at 37 °C. 
 
As shown in Figure 4.6A, 1b itself did not exert any cytotoxicity against 
HepG2 or HEK293 cell lines up to 400 mg/L. DOX-loaded 1b micelles effectively 
suppressed proliferation of HepG2 cells with its IC50 value comparable to that of free 
DOX (0.26 mg/L and 0.20 mg/L respectively, Figure 4.6B), suggesting that DOX was 
effectively released from 1b micelles. The cell viability was noticeably correlated 
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with DOX dosage. Although only 45% of the encapsulated DOX was released in the 
simulated in vitro milieu (Figure 4.4), the comparable IC50 values for free DOX and 
DOX-loaded 1b micelles implied that the polymer degraded faster inside the cells, 
resulting in a more rapid and higher extent DOX release. 
 









































































































Figure 4.7: Biodistribution of (A) DOX-loaded 1b micelles and (B) free DOX after 
administration of 5mg/kg DOX equivalent. 
 
Preliminary biodistribution studies of DOX-loaded 1b micelles were 
investigated in comparison with free DOX formulation in male BALB/c mice. Free 
DOX or DOX-loaded 1b micelle (equivalent DOX dose of 5 mg/kg) were injected via 
tail-vein into the mice. The DOX level in the heart tissues of mice treated with both 
DOX formulations were of particular interest as cardiotoxcity is one of the common 
side-effects of DOX in the clinical setting [195]. The biodistribution pattern of DOX 
in Figure 4.7 demonstrated that 5 min post-injection, the DOX concentration in the 
heart of mice treated with free DOX was about twice as that of mice treated with 
DOX-loaded 1b micelles (7.34 vs. 3.59 μg DOX/g heart). This implied that the 
cardiotoxicity risk of DOX-loaded 1b micelles formulation is lower. DOX 
concentrations in other tissues (except liver) were lower for mice treated with DOX-
loaded 1b micelles compared to that of free DOX. The higher DOX concentration in 
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the liver tissue was probably due to uptake of a small percentage of micelles by the 
macrophages in the liver. This phenomenon was similarly reported by others [196]. 
1b is a worthy candidate for micellar drug delivery formulations due to its desirable 
physicochemical properties and biological activities. The polymer systems described 
in Chapter 3 and 4 contain different numbers of acid/urea functionalities with 
different polycarbonate block lengths and thus the systems cannot be compared 
directly. A comparison of performance between copolymer 1b and acid and urea 
mixed micelles system consisting of comparable number of acid and urea functional 
groups as 1b will be further discussed in the next chapter. 
 
4.4 Conclusion 
In this chapter, we have discussed the design and synthesis of a family of block 
copolymers of PEG and polycarbonate bearing both acid and urea functional groups 
via metal-free organocatalytic ROP approach, and demonstrated that these 
copolymers can self-assemble into micelles with high capacity for loading amine 
containing DOX. The number and placement of acid/urea groups affected self-
assembly behaviour and micelle packing upon DOX loading. When acid and urea 
groups were arranged in block configuration, resulting micelles displayed wider size 
distribution and lower stability compared to the micelles derived from copolymers 
with acid and urea functionalities randomly distributed. Meanwhile, increasing the 
number of randomly pendent acid/urea functionalities additionally improved the 
kinetic stability of micelles. Notably, micelles with a large number of acid/urea 
groups were not stable in a serum-containing medium, and were difficult to re-
disperse in water after lyophilizing. With these factors in mind, an optimized number 
of acid/urea groups are obtained. Micelles derived from 1b with the optimized 
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number and distribution of acid/urea groups exhibited high DOX loading level, 
desirable nanosize and narrow size distribution as well as kinetic stability. It was not 
cytotoxic against HepG2 and HEK293 cells. DOX-loaded 1b micelles exhibited 
comparable killing efficiency with free DOX against HepG2 cells. The present study 
proves the feasibility of appending acid and urea functionalities in the same 
copolymer chain to achieve low particle size and high drug loading upon DOX 
loading as an alternative to the mixed micelles structures introduced in Chapter 3 in 
the design of micellar drug delivery carriers. 
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Chapter 5 Effect of kinetic stability of polycarbonate micelles on 
biodistribution and antitumour efficacy 
 
5.1 Background 
Two different platforms on which pendent acid and urea functionalities could 
be attached to were previously introduced. In Chapter 3, individual block copolymers 
of PEG and acid or urea-functionalized polycarbonate block were utilized to self-
assemble into coherent mixed micelles, yielding nanosized structures and high 
loading capacity for amine-containing DOX. In Chapter 4, with the aim to simplify 
copolymer synthesis and mixed micelle fabrication, diblock copolymers of PEG and 
polycarbonate bearing both acid and urea groups were designed and synthesized for 
DOX loading. In these two studies, the mere presence of acid/urea functional groups, 
varying the number of acid/urea groups and the distribution of the functional groups 
were found to affect the kinetic stability of the micelles. As to how kinetic stability of 
micelles translates to in vivo application is a less researched area. In this chapter, the 
two previously described polycarbonate systems studied in Chapters 3 and 4 will be 
assessed as to which system would be a better drug delivery vehicle especially in the 
context of kinetic stability. 
The stability of copolymer-derived micelles is essential to its practicality as a 
drug delivery carrier and is driven by thermodynamic and kinetic laws as previously 
mentioned in Chapter 1[16, 79, 89, 197]. Micelles may still be stable in the blood 
stream for a certain period of time even at polymer concentrations below its CMC. 
For instance, PEG-poly(caprolactone) block copolymer exhibited longer circulation 
half-life and slower elimination at a concentration above its CMC [198]. Nevertheless, 
the micellar structure remained intact even at a concentration 2-fold below its CMC 
due to its high kinetic stability [198]. Interactions within individual micellar structures 
 88 
contribute to enhancing the inherent kinetic stability of the micelles be it noncovalent 
interactions such as stereocomplexation [151], electrostatic interaction [97] or 
hydrogen bonding as described in our particular acid/urea polycarbonate micelle 
system in Chapters 3 and 4 as well as chemical cross-linking [163].  
In this chapter, the effect of kinetic stability on biodistribution and antitumour 
efficacy of DOX-loaded mixed micelles was studied. Block copolymers of acid- or 
urea-functionalized polycarbonate and PEG with different molecular weights (i.e. 
5,000 and 10,000 g/mol), i.e. 5K PEG-PAC, 10K PEG-PAC, 5K PEG-PUC and 10K 
PEG-PUC, were synthesized via organocatalytic ROP of acid- or urea-functionalized 
cyclic carbonate using monomethoxy PEG as a macroinitiator. The number of acid- or 
urea-functionalized carbonate units in the copolymer was kept at 9 to compare against 
copolymer 1b from Chapter 4. Mixed micelles were self-assembled from PEG-PAC 
and PEG-PUC containing different PEG lengths, and characterized for CMC, particle 
size and size distribution, DOX loading capacity, kinetic and serum stability, and drug 
release profiles. Cytotoxicities of blank and DOX-loaded mixed micelles were 
investigated in comparison with free DOX against HepG2 human liver carcinoma and 
4T1 mouse mammary carcinoma cell lines. Mixed micelles were loaded with a near 
infra-red dye, 1,1’-dioctadecyltetramethyl indotricarbocyanine iodide (DiR) to study 
its biodistribution in a 4T1 tumour-bearing mouse model through live in vivo imaging 
upon administration via tail vein. The antitumour efficacy of free DOX and DOX-
loaded micelles with different PEG lengths was also investigated in the murine breast 
tumour model by observing tumour size and body weight, and histological analysis. 
 
5.2 Materials and Methods 
5.2.1 Materials 
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XenoLight DiR dye was obtained from Caliper Life Sciences Inc. (U.S.A.). 
4T1 mouse mammary carcinoma cell line was acquired from ATCC (U.S.A.). Fetal 
bovine serum, DMEM and Roswell Park Memorial Institute medium (RPMI)-1640 
media were obtained from PAA, Austria.  
 
5.2.2 Synthesis and characterization of urea-functionalized (PEG-PUC) and benzyl-
protected acid-functionalized (PEG-P(MTC-OBn)) copolymers  
Aliphatic polycarbonate copolymers bearing acid or urea groups and their 
carbonate (MTC) monomers described in this chapter were synthesized by Dr Chuan 
Yang (Institute of Bioengineering and Nanotechnology, A*STAR). Polymerization 
proceeds via metal-free organocatalytic ring-opening polymerization (ROP) of cyclic 
functionalized carbonates in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) and N-(3,5-trifluoromethyl)phenyl-N’-cyclohexylthiourea (TU) thio urea 
catalysts for PEG-P(MTC-OBn) and PEG-PUC copolymers respectively, using 
different molecular weights of mPEG (Mn 5000 and 10,000 g/mol) as an initiator. 
Synthesis details of acid- and urea-functionalized monomers and their subsequent 
polymerization and molecular characterization are given in Appendix C. The CMC 
values of all block copolymers were determined in DI water with pyrene as a probe as 
detailed in the previous chapters.  
 
5.2.3 Preparation of DOX-loaded micelles and characterization of DOX-loaded 
micelles 
DOX encapsulation into various polymeric micelles was carried out through a 
sonication/membrane dialysis method as described in the previous chapters. DOX 
loading level was acquired using a UV-Vis spectrophotometer as stated in the 
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previous chapters. Particle size of freshly prepared DOX-loaded micelles (~ 0.6 
mg/mL) and blank micelles solutions (1 mg/mL) were acquired from DLS as 
described in the previous chapters. Visualization of the DOX-loaded micelles was 
accomplished by TEM and the stability of the DOX-loaded micelles (~ 1 mg/mL) in 
serum-containing medium was assessed as described in Chapter 4. Kinetic stability of 
the DOX-loaded micelles (1 mg/mL) was measured by DLS at a final SDS 
concentration of 2.23 mg/mL. Lyophilized DOX-loaded micelles were dissolved in 
PBS buffer (pH 7.4) at a concentration of 1 mg/mL for in vitro release studies that 
was described in detail in the previous chapters. Cytotoxicity of free DOX, blank 
mixed micelles and DOX-loaded mixed micelles was investigated by MTT assay as 
described previously in Chapters 3 and 4. HepG2 and 4T1 cells were cultured in 
DMEM and RPMI-1640 respectively, supplemented with 10% FBS, 5% penicillin-
streptomycin, 2 mM L-glutamine and 110 mg/L sodium pyruvate, and incubated at 
37 °C, 5% CO2. D-glucose (4.5 g/L) was additionally supplemented in DMEM.  
 
5.2.4 Biodistribution of mixed micelles 
Biodistribution of mixed micelles was investigated in 4T1 mouse model 
through non-invasive bioimaging. A near-infrared fluorophore, DiR, was loaded into 
the mixed micelles according to the protocol described in Section 3.2.4. Briefly, 
polymer (10 mg) and DiR (0.3 mg) were dissolved in DMSO (2 mL) and the mixture 
pipetted drop-by-drop into 10 ml of DI water with sonication for 10 min. The 
resulting solution was dialyzed against DI water for 48 h, and the water changed at 3, 
6 and 24 h. The loading level of DiR was determined by a method similar to that of 
DOX (Section 3.2.4), i.e. dissolving a known amount of lyophilized DiR-loaded 
mixed micelles in DMSO and measuring its absorbance at wavelength 759 nm.  
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The animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC), Biological Resource Centre, Agency for Science, Technology 
and Research (A*STAR), Singapore. Female Balb/c mice were injected 
subcutaneously with 0.5  106 4T1 cells each. Two weeks post-injection, when the 
tumour reached about 5-7 mm in diameter, the mice were treated with 8 mg/kg DiR-
loaded mixed micelles via tail-vein injection. Whole-body fluorescence images were 
taken using Xenogen IVIS 100 (Caliper Life Sciences, U.S.A.) with the ICG filter 
(excitation at 710-760 nm, emission at 810-875 nm) at time points ranging from 30 
min to 96 h post-administration. Anesthetized animals (n = 3 for each micelle 
formulation and n = 2 for free DiR dye) were placed in one lateral position on the 
heated plate (37 ºC) for image-taking. The exposure time was set to 3 s. The tumours 
and organs were removed from sacrificed mice at 96 h post-administration, and 
subsequently imaged.  
 
5.2.5 In vivo therapeutic efficacy and histological analysis 
4T1 cells were inoculated subcutaneously at the right flank of 6-8 weeks old 
BALB/c mice at a dose of 10
6
 cells per animal. The mice were randomly divided into 
6 groups of ten mice each: PBS control, free DOX, 5K PEG and 10K PEG mixed 
micelles and their corresponding blank micelles formulations. Ten days post-
inoculation, the animals were injected intravenously via tail vein at a dose of 5 mg/kg 
(DOX equivalent) four times at a 4-day interval (Days 0, 4, 8 and 12) with free DOX, 
DOX-loaded 5K PEG and 10K PEG mixed micelles, the equivalent blank mixed 
micelles and PBS solution. Tumour volume and body weight were monitored to 
assess tumour inhibition activity and overall toxicity of each formulation, respectively. 
The tumour dimensions were measured with a vernier caliper, and the tumour volume 
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was calculated using the formula: Tumour volume = (width)
2
  length  ½. At the 
end of the in vivo study, the hearts and tumours were excised from sacrificed mice and 
fixed in 10% formalin solution followed by paraffin embedding and terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. 
Apoptotic bodies in the tumour and heart sections were quantified by counting the 
number of TUNEL-positive nuclei in ten fields of magnification 400 with the 
highest number of apoptotic bodies and obtaining the mean of the ten fields for each 
sample. Embedding and staining were done by the Histopathology Unit of Biopolis 
Shared Facilities, Singapore. Images were acquired and analyzed in the SBIC-Nikon 
Imaging Centre at Biopolis, Singapore using a Nikon AZ 100 microscope.  
 
5.2.6 Statistical analysis 
All data are presented as mean ± SD. The differences in body weight and 
tumour volume were evaluated using unpaired Student’s t-test and were considered 
significant if p<0.05. 
 
5.3 Results and Discussion 
5.3.1 Synthesis of acid/urea-functionalized polycarbonate and PEG diblock 
copolymers 
 Copolymers synthesized from organocatalytic ring opening polymerization 
(ROP) are attractive as no toxic metals are utilized and molecular architecture of 
resulting polymers can be well controlled [199, 200]. The diblock copolymers of PEG 
and benzyl-protected acid- or urea-functionalized polycarbonate were synthesized 
through organocatalytic ROP using monomethoxy PEG with different molecular 
weights as macroinitiators (Scheme 5.1). The monomer MTC-OBn and MTC-OU 
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were derived from ring closure of 2,2-bis(methylol)propionic acid (Appendix A). The 
number of MTC-OBn and MTC-Urea repeat units was chosen to be 9 for a fair 
comparison with polymer 1b from Chapter 4. From their 
1
H-NMR spectra (Figure 
A3.1), fidelity of MTC-OBn and MTC-Urea repeat units were met at 9 units each. 
The molecular weights of the copolymers estimated from the 
1
H NMR spectra 
corresponded with those obtained from GPC analysis (relative to polystyrene 
standards). The polydispersity indices of molecular weights were 1.08, 1.13, 1.10 and 
1.11 for 5K PEG-PAC, 10K PEG-PAC, 5K PEG-PUC and 10K PEG-PUC 
respectively (Table 5.1). Hydrogenolysis (H2/Pd-C) removed the benzyl protecting 
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5.3.2 Mixed micelles formed from PEG-PAC and PEG-PUC 
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Figure 5.1: DLS size distribution of (A) blank and (B) DOX-loaded PEG5K-PAC, PEG5K-
PUC and PEG5K-PAC/PEG5K-PUC mixed micelles, and (C) blank as well as (D) DOX-
loaded PEG10K-PAC, PEG10K-PUC and PEG10K-PAC/PEG10K-PUC mixed micelles. 
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The assembly of coherent mixed micelles from PEG-PAC and PEG-PUC was 
affirmed by the presence of a single critical micelle concentration (CMC) and a lone 
peak in the DLS size distribution whereas their individual copolymers displayed 
multiple peaks (Figure 5.1A, C). Formation of mixed micelles were facilitated by 
urea-acid hydrogen bonding interactions, generating significantly lower CMC values 
as compared to their respective acid-functionalized copolymers PEG5K-PAC and  
PEG10K-PAC (17.8 vs. 63.1 and 22.4 vs. 595.6 mg/L, Table 5.1). The CMC values of 
these mixed micelles copolymers were significantly lower than other established 
block copolymer classes such as Pluronics, reportedly exhibiting CMC values from 
100 to 10 000 mg/L for Pluronic copolymers of various molecular weights of 
polyethylene oxide (PEO) and polypropylene oxide (PPO) blocks [128].  The particle 
sizes of PEG5K -PAC and PEG10K-PAC micelles were 231 and 126 nm with PDI of 
0.35 and 0.29, respectively (Table 5.1). Contrarily, the urea-functionalized PEG5K-
PUC and PEG10K-PUC copolymers self-assembled into micelles of 41 and 29 nm 
with relatively lower PDI values (0.19 and 0.18 respectively). Combining PEG-PAC 
and PEG-PUC prior to self-assembly in water resulted in micelles with sizes below 
100 nm and narrow size distribution. When individual solutions of acid- and urea-
functionalized copolymers were simply mixed however, the resulting solutions 
exhibited wide size distribution (PDI: 0.38, 0.52 for 5K PEG and 10K PEG micelles 
respectively). These findings further imply that blending acid- and urea-functionalized 
copolymers before adding water produced mixed micelles with nanosize and narrow 
size distribution.   
Comparing 5K PEG mixed micelles with 1b micelles (both containing the 
same number of acid and urea groups) studied in Chapter 4, their corresponding blank 
micelles exhibited comparable particle size of ~60 nm with narrow size dispersity. 
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Notably, CMC value of 1b is higher at 55.5 mg/L in contrast to that of 5K PEG mixed 
micelles at 16.8 mg/L (Table 4.1 and Table 5.1). Here, it is postulated that the spatial 
arrangement of the acid and urea functional groups governs the thermodynamic 
stability of the micelles, with discrete placement of the functional groups on separate 
chains resulting in lower CMC value. Perhaps appending the acid groups on the same 
polycarbonate backbone with urea groups increases the relative hydrophilicity as 
compared to polymers containing both functional groups on different individual 
polymer chains.  
 
Figure 5.2: TEM image of DOX-loaded 5K PEG-PAC/5K PEG-PUC mixed micelles in DI 
water. 
 
Doxorubicin (DOX) was encapsulated by the micelles via a membrane dialysis 
method. DOX-loaded PEG-PAC or PEG-PUC micelles had sizes close to or above 
200 nm with polydisperse distribution (PDI: 0.44-0.78) (Table 5.1). In contrast, drug-
loaded mixed micelles derived from PEG5K-PAC and PEG5K-PUC or PEG10K-
PAC and PEG10K-PUC exhibited particle size below 100 nm with monodisperse 
distribution (66 and 87 nm with PDI of 0.14 for 5K PEG and 10K PEG mixed 
micelles, respectively) and yielding a single peak in the DLS spectra (Figure 5.1B, D). 
DOX-loaded 1b micelles exhibited similar particle size as drug-loaded PEG5K-
PAC/PEG5K-PUC mixed micelles (87 nm, Table 4.1). The particle sizes of PEG5K-
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PUC and PEG10K-PUC changed dramatically after dug loading (~20 and 7 times 
respectively) while the other copolymer or mixed micelle systems showed less 
dramatic particle size increase (~1.2 - 2 times). It is expected for the particle size of 
polymeric micelles to increase after drug loading to allow for cargo encapsulation. On 
the other hand, the particle sizes and PDI of PEG5K-PUC and PEG10K-PUC changed 
drastically after drug loading because of the precipitates formed upon preparation of 
the respective DOX-loaded micelles. Aggregates formation was attributed to the 
inherent hydrophobicity of the urea groups in the two copolymers. The zeta potentials 
of DOX-loaded 5K PEG (-0.8 ± 0.3 mV) and 10K PEG (-0.1 ± 0.2 mV) mixed 
micelles were slightly more positive than that of DOX-loaded 1b micelles (-1.2 ± 0.2 
mV), making them unlikely to be captured by macrophages [115, 182]. The DOX-
loaded 5K PEG mixed micelles were spherical in shape with relatively uniform size 
distribution as observed under TEM, similar to that of 1b micelles (Figure 5.2). 
Biodistribution of nanoparticles is generally governed by its particle size [201]. 
Nanoparticles of approximately 10 nm are readily cleared from the blood and excreted 
via glomerular filtration, rendering them unable to accumulate in the tumour 
effectively [68]. Nanoparticles of more than 200 nm size on the other hand are known 
to accumulate in the liver and spleen [70] with lower accumulation in the tumour [42]. 
The mixed micelles reported in this study have sizes of 66 and 87 nm and are thus 
expected to accumulate in the tumour based on the EPR effect.  
The work described in Chapter 3 proved that the presence of the acid groups in 
the micellar core increased loading capacity of amine group-containing drugs due to 
ionic interactions between the acid group in the micelle and amine group in DOX. 5K 
PEG and 10K PEG mixed micelles achieved 28.9 and 22.8% of DOX loading, 
respectively, which were close to those yielded by the acid-functionalized micelles, 
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but significantly higher than those produced by the urea-functionalized micelles 
(Table 5.1). Due to its lower relative hydrophobicity as compared to PEG5K-PUC, 
PEG10K-PUC micelle formation may be slower and thus more DOX could leak out 
from the dialysis bag, lowering its drug loading level. Notably, the 5K PEG mixed 
micelles conceived from polymers with shorter PEG length exhibited higher drug 
loading efficiency, which resulted in slightly bigger particle size (87 vs. 66 nm). 
DOX-loaded 1b micelles gave the highest drug loading level at 33.5 wt% (Table 4.1). 
These results demonstrated that PEG length exerted an impact on drug loading 
capacity and particle size while spatial distribution of the acid and urea groups 
influenced drug loading level slightly.  
Long-term storage of drug-encapsulated nanoparticles in dry form is favoured 
to prevent prematurely released drug from nanoparticles dissolved in aqueous solution. 
Redispersion of lyophilized nanoparticles is usually facilitated with the use of 
cryoprotectants such as sugars to avoid aggregation and precipitation of nanoparticles. 
The lyophilized DOX-loaded mixed micelles were able to reconstitute in water easily 
without the use of cryoprotectants, yielding particle sizes close to that measured 
before lyophilisation (86 ± 2 and 74 ± 1 nm for 5K PEG and 10K PEG mixed micelles 
respectively).  
 




















































































Figure 5.3: Micelle stability. (A) Size of DOX-loaded mixed micelles made from the diblock 
copolymers with different PEG lengths in DI water containing 10% fetal bovine serum 
changes as a function of time. (B) Scattered light intensity measured at 90º of DOX-loaded 
mixed micelles against time after being challenged with 2.23 mg/L SDS. Relative intensity 
(%) is represented as the percentage of the scattered light intensity at time x in relative to the 
scattered light intensity at time 0. 
 
It is crucial for the micelles to be stable in the presence of serum for in vivo 
application. The particle size of DOX-loaded 5K PEG and 10K PEG mixed micelles 
did not change considerably after 48 h incubation with 10% serum with no 
precipitation or aggregation observed, similar to DOX-loaded 1b micelles (Figure 
5.3A). These mixed micelles had the potential for in vivo applications. The kinetic 
stabilities of the DOX-loaded mixed micelles were then examined by challenging the 
micelle solutions with a destabilizing agent, SDS, and then recording scattered light 
intensity of the solutions with DLS (Figure 5.3B). The drop in the scattered light 
intensity represents the extent of micelle dissociation. Interestingly, the 5K PEG 
mixed micelles fared better in the presence of SDS compared to 1b micelles. The 
scattering light intensity of DOX-loaded 1b dropped to about 50% from its initial 
intensity (comparable to 10K PEG mixed micelles) while DOX-loaded 5K PEG 
mixed micelles retained 80% of its initial intensity (Figure 4.2B, Figure 5.3B). It is 
postulated that the acid and urea groups being pended on different polymer chains for 
mixed micelle assembly resulted in ordered inter-polymer hydrogen bonding which 
could be more intense than random hydrogen bonding interactions conceived from the 
functional groups randomly distributed along the polymer chain of 1b. The kinetic 
stability of the mixed micelles would be better due to the more intense hydrogen 
bonding interactions, showing more resistance to dissociate in the presence of SDS. 
Weighing these evidence, the mixed micelles system assembled from individual 
copolymers of PEG and polycarbonate block appended with either acid or urea groups 
is the better candidate for drug delivery owing to their enhanced kinetic stability, 
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nanosize, narrow size distribution and high drug loading. This particular system 
would be utilized for further in vivo studies in this chapter. 
5K PEG mixed micelles were also significantly more stable than 10K PEG 
mixed micelles (Figure 5.3B). The length of the hydrophobic block of the diblock 
copolymers was kept constant in the two mixed micelle systems. Thus, the increase in 
PEG length enhanced the overall hydrophilicity of the diblock copolymers and tuned 
the hydrophilicity/hydrophobicity balance, giving lower kinetic stability. Likewise, 
Creutz et al. demonstrated that by increasing the hydrophobicity of 
poly((dimethylamino)alkyl methacrylate-block-sodium methacrylate) copolymers, the 
rate of micelle dissociation was lowered, providing better stability [202]. Moreover, 
the lower cargo loading capacity of 10K PEG mixed micelles resulted in less pi-pi 
stacking of DOX molecules in the micellar core to maintain the micellar structure. 
Due to its greater kinetic stability, DOX-loaded 5K PEG mixed micelles are 
postulated to be more favourable for in vivo application in comparison to the 10K 
PEG mixed micelles.  
 



































Figure 5.4: In vitro release profiles of DOX-loaded 5K PEG and 10K PEG mixed micelles in 
PBS (pH 7.4) at 37 ºC. 
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 Another important criterion for in vivo application of a drug delivery system is 
sustained drug release from nanoparticles. The in vitro release profiles of DOX from 
the PEG-PAC/PEG-PUC mixed micelles with different PEG lengths are shown in 
Figure 5.4. The release profiles exhibited no significant initial burst while 38.6% and 
48.6% of the encapsulated DOX were released in a sustained manner over 8 h for the 
5K PEG and 10K PEG mixed micelles respectively. After 8 h, the release of DOX 
was too slow to be detected. Nevertheless, DOX release rate inside cells may be 
elevated due to the degradation of the copolymers in the presence of enzymes. DOX 
release from the 5K PEG mixed micelles was slower than 10K PEG mixed micelles 
possibly because DOX took a longer distance to diffuse from the bigger 5K PEG 
mixed micelles to the medium. Furthermore, as more DOX molecules are 
encapsulated in the core of 5K PEG mixed micelles (Table 5.1), the stronger pi-pi 















































































































































Figure 5.5: Viability of (A) HepG2 and (B) 4T1 cells after incubation with free DOX, DOX-
loaded 5K PEG and 10K PEG mixed micelles. Viability of HepG2, 4T1 and HEK293 cells 
after incubation with blank (C) 5K PEG-PAC/5K PEG-PUC and (D) 10K PEG-PAC/10K 
PEG-PUC mixed micelles for 48 h at 37 ºC. 
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The cytotoxicity of DOX-loaded mixed micelles was tested against HepG2 
and 4T1 cell lines in comparison with free DOX and blank mixed micelles. Free DOX 
and the DOX-loaded mixed micelles of different PEG lengths were able to inhibit 
cancer cell proliferation efficiently in a concentration-dependent manner (Figure 5.5A, 
B). DOX-loaded mixed micelles exhibited relatively higher cell-based IC50 values 
than free DOX (HepG2: 0.2 mg/L for free DOX and 0.5 mg/L for 5K PEG and 10K 
PEG mixed micelles; 4T1: 0.7, 1.7 and 2.0 mg/L for free DOX, 5K PEG and 10K 
PEG mixed micelles respectively) probably due to sustained DOX release from the 
mixed micelles. DOX-loaded 5K PEG and 10K PEG mixed micelles in particular had 
comparable IC50 values despite faster in vitro DOX release from 10K PEG mixed 
micelles over 48 h (Figure 5.4). DOX release from the mixed micelles was most likely 
due to DOX diffusion as enzyme-free degradation of polycarbonates is extremely 
slow [61]. On the other hand, the presence of enzymes inside the cells accelerated 
polycarbonate degradation. The degradation rates of both 5K PEG and 10K PEG 
block copolymers might be comparable due to their similar polycarbonate block 
length, yielding similar DOX release rate inside the cells and thus exhibiting similar 
cytotoxicity. Blank mixed micelles remarkably did not exert any cytotoxicity against 
either of the cancer cell lines or embryonic kidney cell line (Figure 5.5C, D), 
suggesting that the cell cytotoxicity of DOX-loaded micelles was solely due to DOX. 
 
5.3.5 Biodistribution of mixed micelles in tumour-bearing mice 
Tumour-targeting performance of the mixed micelles owing to EPR effect was 
appraised in BALB/c mice bearing subcutaneous 4T1 tumours. Mixed micelles 
incorporated with a near infra-red fluorescent (NIRF) dye, DiR, were injected 
intravenously via tail vein, and the fate of the micelles visualized through non-
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invasive NIRF imaging over 96 h. DiR is a lipophilic dialkylcarbocyanine dye that 
fluoresces in the NIR band, which prevents any light absorption by tissues, auto-
fluorescence and scattering usually associated with the use of visible light dyes [203]. 
Therefore, DOX-loaded micelles were not utilized for in vivo imaging because the 
emission spectrum of DOX lies in the visible light range which is readily absorbed by 
the tissues, giving undesirable images with scattered fluorescent signals. Whole-body 
imaging showed no DiR signals in all mice at 30 min post-administration of the DiR-
loaded mixed micelles, suggesting that the micelles had not accumulated in tissues 
(Figure 5.6A, B).  However, DiR signals could be discerned at 2.5 h post-
administration of the 5K PEG mixed micelles, covering over a larger area as 
compared to 10K PEG mixed micelles. The onset contrast of DiR signal in the tumour 
as compared to the rest of the animal was apparent at 5 h post-administration of the 
5K PEG mixed micelles, implying that the micelles started accumulating in the 
tumour at 5 h (Figure 5.6A). However, the contrast between the subcutaneous tumour 
and the rest of the animal tissues was distinct only at 24 h onwards for the 10K PEG 
mixed micelles, with the intensity of DiR signal weaker in the tumours at each time 
point as compared to the 5K PEG mixed micelles (Figure 5.6A, C). As a control, free 
DiR dye was also injected at an equivalent dose as that in the mixed micelle 
formulations. For the free dye formulation, non-specific biodistribution of fluorescent 
signals was observed with no DiR signal detected in the tumours at any of the time 
points (Figure 5.6E). DiR signal was the strongest in the liver and spleen in contrast to 
the other organs (Figure 5.6F), indicating that free DiR could be partly internalized by 
the mononuclear phagocytic system. The dye (molecular weight = 1013.39 g/mol) did 
not accumulate in the kidneys as renal elimination is expected for compounds with 
molecular weight below 40,000 g/mol [101]. These results established the passive 
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tumour-targeting ability of the mixed micelles, and that 5K PEG mixed micelles 
exhibiting greater kinetic stability accumulated faster and at a higher extent in the 
tumours contrarily to 10K PEG mixed micelles. 
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Figure 5.6: Whole-body imaging of subcutaneous 4T1 tumour-bearing mice after tail veil 
injection of (A) 5K PEG, (C) 10K PEG mixed micelles (E) free DiR dye and tissue 
distribution of DiR-encapsulated (B) 5K PEG, (D) 10K PEG mixed micelles and (F) free DiR 
dye at 96 h post-injection. 
 
The tissue distribution of the DiR-loaded mixed micelles was investigated at 
96 h post-administration (Figure 5.6B, D). The intensity of the DiR signal varied in 
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the tissues with palpable contrast seen in the tumours compared to the negligible 
fluorescence in the heart for both micelle formulations, which is particularly crucial as 
DOX can cause cardiotoxicity [195]. Furthermore, the DiR signal was more 
pronounced in the tumours for the 5K PEG mixed micelles, while the signal was 
especially more intense in the liver for the 10K PEG mixed micelles (Figure 5.6B, D). 
This insinuates that the 10K PEG mixed micelles dispersed more easily in the blood 
upon injection due to its lower kinetic stability, hence releasing more DiR molecules 
which would then distribute to the liver, giving rise to pronounced DiR signal in the 
organ. This phenomenon agreed with what was seen in the control mice injected with 
free DiR (Figure 5.6F). The micelles that remained intact would then accumulate in 
the tumour. As the 5K PEG mixed micelles were more kinetically stable (Figure 
5.3B), the micelles accumulated more effectively in the tumour, and are expected to 
display higher antitumour efficacy.  
 
5.3.6 In vivo antitumour efficacy  
Antitumour efficacy of DOX-loaded mixed micelles was studied against 4T1 
tumour-bearing BALB/c mice via tail-vein injection with tumour volume monitored 
with time. Assuming that both DOX-loaded mixed micellar formulations 
administrated were completely diluted in the blood volume of mice (1.75 mL) [204], 
the final concentration of the 5K PEG mixed micelles and the 10K PEG mixed 
micelles copolymers in the blood would be 139 mg/L and 191 mg/L respectively, 
about 8-fold above their respective copolymer CMC values (Table 5.1). This 
indicated that the mixed micelles nanostructures would not disassemble due to 
thermodynamic factors upon dilution in the blood. Furthermore, as demonstrated by 
Allen’s group [198], thermodynamically unstable micelles (copolymers below CMC 
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value) may still retain their micellar structure due to the strong kinetic stability of the 
micelles, conferring enhanced in vivo stability. Therefore, both CMC values and 
kinetic stability are indicators of in vivo stability of micelle nanostructures.  
The tumour growth rate was the highest in the negative control groups of mice 
injected with PBS, blank 5K PEG and 10K PEG mixed micelles, suggesting that the 
mixed micelles themselves had no antitumour effect, whereas any effect on tumour 
growth would be solely due to DOX (Figure 5.7A). The mice treated with free DOX, 
DOX-loaded 5K PEG and 10K PEG mixed micelles exhibited a slower progression of 
tumour growth in varying extent. DOX-loaded 5K PEG mixed micelles suppressed 
tumour growth more effectively than free DOX and DOX-loaded 10K PEG mixed 
micelles especially at Days 22 and 26. This was due to the accumulation of 5K PEG 
mixed micelles in the tumour at a higher extent by virtue of its greater kinetic stability 
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Figure 5.7: Evolution of (A) tumour volume and (B) body weight over 26 days for mice 
bearing 4T1 tumours administered with PBS (control), free DOX, DOX-loaded 5K PEG and 
10K PEG mixed micelles and their respective blank micelles. Percentage of tumour volume or 
body weight was calculated by dividing the tumour volume or weight at a given time point 
over the respective values at day 0 and being multiplied by 100%. Mice were administered 
with 5 mg/kg of DOX for free DOX and DOX-loaded mixed micelles and the equivalent 
weight of blank mixed micelles at days 0, 4, 8 and 12. The symbols * and + indicate 
significant difference in (A) tumour volume or (B) body weight between DOX-loaded 5K 
PEG mixed micelles-treated (●) and free DOX-treated (▲) mice and  between DOX-loaded 
5K PEG mixed micelles-treated (●) and 10K PEG mixed micelles-treated (○) mice 


































Figure 5.8: Body weight of 8-9 weeks old healthy BALB/c mice (at day 0) over a period of 
26 days, n = 5. 
 
 
 The body weights of mice in the control and treated groups were also 
monitored as it reflects general toxicity of different delivery formulations. The body 
weights of untreated mice increased over time (Figure 5.7B), showing 15% increase at 
day 26. The body weights of healthy mice without tumour increased only up to 3% 
from their initial weight (Figure 5.8), signifying that any increase in the body weight 
of tumour-bearing mice without treatment might be solely attributed to tumour growth. 
The body weights of the free DOX-treated mice decreased by approximately 10% at 
Day 26 despite the tumours of mice treated with free DOX growing the fastest among 
DOX-treated groups, implying general DOX toxicity. Furthermore, there was no 
significant difference in body weights between the free DOX-treated and DOX-loaded 
10K PEG mixed micelles-treated groups. In contrast, the body weights of the mice 
treated with 5K PEG mixed micelles remained unchanged. These findings established 
that 5K PEG mixed micelles with greater kinetic stability delivered DOX to the 
tumour more effectively than free DOX and 10K PEG mixed micelle formulations, 
consequently reducing toxicity elicited by non-specificity of DOX.  
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The histological analysis of tumours and hearts of mice treated with DOX-
loaded 5K PEG mixed micelles was studied since DOX-loaded 5K PEG mixed 
micelles were more effective than DOX-loaded 10K PEG mixed micelles (Figure 5.9). 
TUNEL-stained histological sections of tumours and hearts of the mice used in 
antitumour efficacy study are shown in Figure 5.9A-G. The presence of apoptotic cells 
in tissues can be visualized by TUNEL staining represented as the brown regions. The 
number of apoptotic bodies in the tumours of untreated control mice and mice 
injected with blank 5K PEG mixed micelles was low (Figure 5.9A, D and K, 4 ± 1 per 
field), which is in agreement with the observation of no therapeutic effect of the blank 
micelles (Figure 5.7A). More apoptotic bodies were seen in the tumour sections of 
mice treated with free DOX or DOX-loaded 5K PEG mixed micelles. In particular, 
DOX-loaded mixed micelles induced a higher number of apoptotic cells than free 
DOX (Figure 5.9B, C and K, 6 ± 1 and 10 ± 2 for free DOX and DOX-loaded 5K 
PEG mixed micelles respectively). These results collectively validated that DOX-
loaded 5K PEG mixed micelles had a higher antitumour activity than free DOX, and 
the antitumour mechanism of DOX-loaded mixed micelles is based on DOX-induced 
apoptosis. 
It is established that DOX causes cardiotoxicity in clinical use [195]. As 
shown in Figure 5.9L, the heart sections of mice treated with PBS (Figure 5.9E) and 
DOX-loaded 5K PEG mixed micelles (Figure 5.9G) seemed normal with a low 
number of apoptotic bodies present (2 ± 1), while a significantly greater number of 
apoptotic bodies were seen in heart sections of mice treated with free DOX (13 ± 6, 
Figure 5.9F). Hematoxylin and eosin (H&E) staining of hearts in mice treated with 
free DOX also exhibited cardiotoxicity signs such as cytoplasmic vacuolation (white 
arrows, Figure 5.9I) and loss of myofibrils whereas hearts of mice treated with 5K 
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PEG mixed micelles appeared normal and similar to that of untreated control mice 
(Figure 5.9H-J). This implies that DOX-loaded 5K PEG mixed micelles could 
suppress tumour growth effectively without inducing cardiotoxicity. This corroborates 
the idea of colloidal drug delivery system that grants the drug to amass in the tumour 
site with minimal exposure to other organs, reducing or eliminating adverse side-
effects caused by non-specificity of the drug.  
From Figure 5.6, it can be insinuated that passive targeting of the 5K PEG 
mixed micelles commenced between 2.5 h and 5h post-administration. In this time 
frame, about 30- 35 % of DOX was released during the in vitro drug release study 
(Figure 5.4). Therefore, there was a concern of pre-mature leakage of DOX before 
substantial accumulation of mixed micelles in the tumour occurred. As discussed in 
Chapter 3, in vitro drug release may not correlate with the drug release profile in the 
blood as the micelles would be diluted in the blood and the drug concentration 
gradient across the micellar core and blood can differ with those in the in vitro release 
study. Furthermore, the structural stability of the micelles due to the thermodynamic 
and kinetic factors is of more importance in the blood as not to compromise on 
premature drug release. We have determined that the dose of DOX-loaded 5K PEG 
mixed micelles in the blood was higher than the CMC values of the copolymers 
indicating that the micelles are thermodynamically stable. As shown in Figure 5.7B, 
the body weights of the mice treated with 5K PEG mixed micelles did not show 
significant drop throughout the anti-tumour study. The lack of general toxicity of the 
DOX-loaded 5K PEG mixed micelles formulation coupled with its better anti-tumour 
efficiency suggest that the 5K PEG mixed micelles were able to retain DOX to a 
substantial degree during blood circulation so as not to cause body weight loss and 
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Figure 5.9: TUNEL (A-G) and H&E staining (H-J) of 4T1 tumour and/or heart tissues at the 
end of antitumour study from a representative mouse in each treatment group. Tumour or 
heart sections from a mouse injected with PBS (A, E, H); tumour sections from a mouse 
treated with four doses of 5 mg/kg free DOX (B, F, I) at days 0, 4, 8 and 12; tumour sections 
from a mouse treated with four doses of 5 mg/kg DOX-loaded 5K PEG mixed micelles (C, G, 
J) and tumour sections from a mouse treated with four equivalent doses of blank 5K PEG 
mixed micelles (D) at days 0, 4, 8 and 12. White arrows indicate representative vacuolization. 
Quantification of mean apoptotic bodies per field (×400) in tumour (K) and heart (L) sections 
for the ten highest densities of apoptotic bodies was identified. 
 
5.4 Conclusion 
Diblock copolymers with the same length of acid- or urea-functionalized 
hydrophobic polycarbonate block and different molecular weights of hydrophilic PEG 
block were successfully synthesized and mixed micelles were self-assembled via 
urea-acid hydrogen bonding. DOX-loaded mixed micelles formed particles with sizes 
below 100 nm and narrow size distribution as well as high drug loading level due to 
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ionic interactions between the acid in the micelles and amine in DOX. Specifically, 
the DOX-loaded mixed micelles made from diblock copolymers with 5K PEG were 
more kinetically stable than DOX-loaded mixed micelles derived from diblock 
copolymers with 10K PEG or assembled from copolymers of 5K PEG with acid and 
urea groups randomly appended to hydrophobic polycarbonate block (1b). The mixed 
micelles system whereby acid and urea groups are on separate unimers proved to be a 
superior drug carrier than micelles derived from copolymer chains bearing both 
randomly arranged acid and urea groups. Although both 5K and 10K PEG mixed 
micelles preferentially accumulated in the tumour, the former was significantly more 
intense. DOX-loaded 5K PEG mixed micelles exerted stronger antitumour activity 
without inducing significant cardiotoxicity or body weight loss as compared to DOX-
loaded 10K PEG mixed micelles. Hence, 5K PEG mixed micelles can be a promising 
carrier for targeted delivery of anticancer drugs with amine functional group.  
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Chapter 6 Evaluation of galactose-functionalized polycarbonate 




As outlined in Chapters 3 to 5, we have demonstrated the potential of the acid 
and urea-functionalized polycarbonate systems for drug delivery due to their 
favourable physicochemical properties (i.e. nanosize, narrow size distribution, high 
drug loading capacity and excellent kinetic stability). The desirable particle size of 
below 200 nm and enhanced kinetic stability of these micellar nanostructures make 
them attractive for passive accumulation in the tumour by virtue of EPR effect. This 
was corroborated by the tumour-targeting ability of the mixed micelles in the 4T1 
mouse breast cancer model discussed in Chapter 5. Fenestrae in liver sinusoidal 
endothelial cells located in the intertwining capillaries branching from both hepatic 
artery and portal vein would also favour the extravasation of particles of 40 – 150 nm 
to reach hepatocytes of liver [205]. This presents the possibility of nanoparticles to 
accumulate passively in the liver for treatment of liver diseases such as liver cancer 
and hepatitis. Beyond passive accumulation, the presence of receptors on the 
hepatocytes can also be exploited for active targeting of the nanostructures to enhance 
their cellular uptake by hepatocytes via receptor-mediated endocytosis. Liver-specific 
drug delivery systems are desirable for the treatments of liver diseases as they can 
increase efficacy of treatment while reducing side-effects to other organs. 
The asialoglycoprotein receptor (ASGP-R), which is abundantly found on 
mammalian hepatocytes, presents a means for the development of liver-specific drug-
delivery systems [206]. It is a well-studied lectin that recognizes a broad range of 
molecules including its natural ligand, asialofetuin, as well as sugar residues such as 
D-galactose, D-lactose and D-mannose [207]. Proteins or nanoparticles with exposed 
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ASGP-R ligands would be internalized by hepatocytes through endocytosis pathway 
[207]. Research on drug or gene delivery carriers labeled with ASGP-R specific 
ligands has been ongoing since 1980s towards the development of liver-specific 
delivery systems [208]. For example, asialofetuin was conjugated to antiviral agents 
for the treatment of hepatocytes infected with Ectromelia virus [209]. Wu and Wu 
first exploited the use of ASGP-R ligand, asialoorosomucoid, conjugated to poly-L-
lysine as a gene vector for hepatocytes-targeted gene transfection [210]. Following 
this, there have been other hepatocytes-specific gene or drug delivery studies using 
galactose moieties such as the use of galactose-conjugated PEG-b-poly(γ-benzyl L-
glutamate) to deliver paclitaxel more efficiently to HepG2 cells than an ASGP-R 
negative cell line [211]. Hepatocyte-targeted in vivo gene expression was also realized 
by Shimada’s [212] and Hashida’s [213, 214] groups by showing enhanced reporter 
gene expression in the liver as compared to other organs in healthy mice with use of 
galactosylated synthetic polypeptides or cationic poly(L-ornithine) polymer 
respectively. Notably, ASGP-Rs were not found in all clinical samples of 
hepatocellular carcinomas (HCCs) although ASGP-R was maintained on the plasma 
membranes of all the neoplastic cells forming ASGP-R positive HCC samples [215]. 
Although ASGP-R may be expressed in lower levels in HCC than normal hepatocytes, 
the existence of ASGP-R in majority of HCCs warrants its exploitation for HCC 
chemotherapy using ASGP-R ligands. Yang et al. demonstrated that stable galactose-
labeled cross-linked micelles loaded with paclitaxel inhibited the growth of 
subcutaneous SMMC-7721 tumour in nude mice more effectively than paclitaxel-
loaded non-galactose cross-linked micelles or paclitaxel-loaded galactose non-cross-
linked micelles [216].  
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The expression of another galactose-binding lectin protein, galectin-3, has 
been identified to be up-regulated in a number of HCCs [217, 218], specifically in the 
blood vessel endothelial cells of HCC from an orthotopic HCC rat model and human 
clinical samples [219]. Galectin-3 is usually not expressed in healthy liver sinusoidal 
endothelial cells, making the protein one of HCC markers. The protein is found in the 
extracellular milieu of endothelial cells making it accessible for galactose to bind. 
Thus, it is postulated that galactose-decorated nanoparticles may deliver anticancer 
drugs effectively to HCC by receptors (ASGP-R and galectin-3) mediated endocytosis.  
Sorafenib is the only anticancer drug approved by United States Food and Drug 
Administration (FDA) for treatment of advanced HCC [220]. Sorafenib is a multi-
kinase inhibitor which blocks the RAF/MEK/ERK pathway to induce both HCC cell 
apoptosis and suppress angiogenesis [221]. However, the safety profile of sorafenib is 
low with 39% and 6% of sorafenib-treated patients experiencing grade 3 and grade 4 
adverse reactions respectively [222]. Active targeting of sorafenib to the HCC could 
mitigate the adverse side effects.  
Herein, biodegradable galactose-functionalized polycarbonate block 
copolymers with well-defined molecular structures were designed and synthesized via 
metal-free organocatalytic ring-opening polymerization (ROP) of galactose-
functionalized cyclic carbonate monomer and short PEG-functionalized carbonate 
monomer utilizing 4-methylbenzyl alcohol (4-MBA) as the initiator. This was 
followed by the sequential polymerization of the cyclic carbonate monomer 
containing urea groups. The urea groups in the copolymers were designed to interact 
with the urea group in sorafenib through hydrogen bonding for effective drug loading 
(Scheme 6.1). In this chapter, various molecular structures of galactose-functionalized 
polycarbonate copolymers were explored by varying the number of galactose and urea 
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units and appending another PEG-functionalized polycarbonate block. The 
physicochemical properties of the micelles assembled upon sorafenib loading were 
characterized with the best candidate appraised in an orthotopic HCC rat model for 
HCC-targeted drug delivery in comparison to micelles derived from a copolymer 
without galactose moieties, namely PEG5K-PUC from Chapter 5. 
 
Scheme 6.1: Poly(galactose carbonate)-b-poly(urea carbonate) copolymers were postulated to 
sequester sorafenib through hydrogen bonding between sorafenib (sites indicated by the 
yellow circles) and urea groups in the micellar core. 
 
 
6.2 Materials and Methods 
6.2.1 Materials 
McA-RH7777-luc2 cells which are McA-RH7777 cells (ATCC, U.S.A.) 
transfected with luc2 gene was provided by A/P Ruowen Ge, Department of 
Biological Science, National University of Singapore. Sorafenib free base and 
sorafenib tosylate were obtained from LC Laboratories, U.S.A. Cremophor EL, 
galectin-3 and Tween20 were obtained from Sigma Aldrich. Bovine serum albumin 




 flat-bottom 96 well plates were acquired from Thermo Fisher Scientific, 
U.S.A. 
 
6.2.2 Synthesis and characterization of galactose-functionalized polycarbonate 
copolymers  
Aliphatic polycarbonate copolymers bearing pendent galactose moieties and 
urea groups described in this chapter were synthesized by Dr Chuan Yang (Institute of 
Bioengineering and Nanotechnology, A*STAR). Polymerization proceeds via metal-
free organocatalytic ring-opening polymerization (ROP) of galactose-, short PEG- and 
urea-functionalized cyclic carbonates in the presence of 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) and N-(3,5-trifluoromethyl)phenyl-N’-cyclohexylthiourea (TU) thiourea 
co-catalysts, using 4-MBA as the initiator. Details in the synthesis of galactose and 
urea-functionalized monomers and their subsequent polymerization and molecular 
characterization are given in Appendix D. The CMC values of the galactose-
functionalized polycarbonate copolymers were determined in DI water, employing 
pyrene as a probe as detailed in the previous chapters. 
 
6.2.3 Preparation of sorafenib-loaded micelles and measurement of sorafenib 
loading  
Sorafenib encapsulation into polymeric micelles was carried out through a 
sonication/membrane dialysis method as described in the previous chapters with a few 
modifications. Briefly, 1 mg of sorafenib and 10mg of copolymer were solubilized in 
2 mL of dimethyl sulfoxide (DMSO) and vortexed, and added dropwise to 10 mL of 
DI water while being sonicated at 130 W for 2 min by a probe-based sonicator (Vibra 
Cell VCX 130). The resulting mixture was dialyzed against 1000 mL of DI water for 
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48 hours in a dialysis bag with molecular weight cut-off of 1000 Da (Spectra/Por 7, 
Spectrum Laboratories Inc.), with the water changed at 3, 6 and 24 h. The solution 
inside the dialysis bag was collected at 48 h for particle size analysis while the 
remaining was lyophilized. Each experiment was performed in triplicates. Sorafenib 
loading level was acquired using a high-performance liquid chromatography (HPLC, 
Waters 996 Photodiode Array Detector and Waters XBridge C8 46 × 150 mm column) 
according to the previously reported protocol [223]. Briefly, lyophilized sorafenib-
loaded micelles (1 mg) were dissolved in 1.5 mL of the mobile phase 
(acetonitrile/methanol/1% acetic acid at a volume ratio of 35:38:27). The elution was 
isocratic and the rate was set at 1 mL/min with the sorafenib detection wavelength set 
at 254 nm. The column and sample temperatures were maintained at 37 and 25 °C, 
respectively. A calibration line of sorafenib was formulated in the range of 5 to 50 
mg/L, and the r
2
 value of peak area intensity plotted linearly against sorafenib 
concentration was at least 0.9. The sorafenib loading level was determined based on 
the following formula: 
%100
micelles loaded-sorafenib of mass
micellesin  sorafenib of mass
%)wt(level loading Actual   
 
6.2.4 Characterization of sorafenib-loaded micelles 
Particle size was acquired from freshly prepared drug-loaded micelles (~ 0.6 
mg/mL) using dynamic light scattering with further details stated in Chapter 3. 
Stability of the drug-loaded micelles (~ 1 mg/mL) in the presence of serum was 
recorded by DLS similarly described in Chapter 4. Kinetic stability of the drug-loaded 
micelles in DI water was examined using sodium dodecyl sulfate (SDS) as a 
destabilizing agent using the protocols described in Section 5.2.8.  
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6.2.5 Solid phase binding study 
To assess whether the galactose moieties were accessible to galectin-3, solid 
phase binding study of the galactose-functionalized micelles and the micelles without 
galactose was performed using a reported protocol with modifications [224]. BSA or 
galectin-3 sample (in PBS containing 0.05% Tween 20, 100 µg/mL, 100 µL) was 
added to a Nunc® MaxiSorp
TM
 plate and incubated overnight at 4 °C. The plate was 
washed with PBS/0.05% Tween20 three times and blocked with 1% BSA (200 
µL/well) at room temperature for 2 h. After removing the blocking agent, the 
galactose-decorated micelles and the micelles without galactose, which were loaded 
with DiR were added into the galectin-3 or BSA-coated wells (0.0304 mg/mL DiR 
equivalent, 100 µL) and equilibrated for 2 h at room temperature. The plate was then 
washed with PBS/0.05% Tween20 three times and the fluorescent signal was 
measured with excitation at 725 nm and emission at 770 nm using Tecan Infinite 
M1000 Reader. 
 
6.2.6 Preliminary evaluation of in vivo therapeutic efficacy 
Adult male Buffalo rats weighing 200 – 300 g were purchased from Charles 
River laboratories, U.S.A. The animal protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC), SingHealth, Singapore. Rats were given 
free access to standard rodent diet and water ad libitum. A rodent surgical orthotopic 
HCC model was utilized for this antitumour efficacy study. Male Buffalo rats were 
anesthetized with intraperitoneal (i.p.) injection of ketamine (50 mg/kg) and diazepam 
(5 mg/kg). A small laporatomy was made and 10
7
 cells/ml of McA-RH7777-luc2 cells 
(100 µL) was injected into the subcapsular space of the left liver lobe. The abdomen 
was sutured and closed with 3/0 vincryl. The rats were divided randomly into four 
 119 
groups: saline control (n = 3), free sorafenib (n = 5), sorafenib-loaded 5b micelles (n 
= 6) and blank 5b micelles (n = 3) formulations. Three days post-inoculation, the 
animals were injected intravenously via tail vein at a dose of 10 mg/kg (sorafenib free 
base equivalent) scheduled for twice a week for eight treatments with free sorafenib, 
sorafenib-loaded 5b and its equivalent blank micelle solution. Drug-loaded and blank 
micelles were dissolved in saline (2 mL) while sorafenib tosylate containing 
equivalent amount of sorafenib was dissolved in DMSO (30 mg/mL) and diluted with 
Cremophor EL/ethanol/water (1:1:6, v/v/v) mixture. To monitor tumour growth, 
bioluminescent imaging was performed by prior i.p. injection of D-luciferin into each 
rat (150 mg/kg). The rats were imaged 7 min post-administration of luciferin to ensure 
consistency in readings obtained. The excitation filter was set to ‘Block’ while the 
emission filter was set to ‘Open’. Anesthetized rats were placed in supine position on 
the heated plate (37 ºC) for image taking. To quantify the signal obtained, a region of 
interest (ROI) was drawn over the signal using Living Image software with the 
bioluminescent counts giving semi-quantitative luciferase-expressing HCC cell 
number, recorded. Body weights of the rats were also recorded throughout the study. 
At Day 30 post-implantation of HCC cell line, all rats were euthanized by CO2 
inhalation. HCC tumours were harvested, separated from healthy liver tissues and 
weighed (n = 3 – 6 per treatment group).  
 
6.2.7 Biodistribution of micelles with and without galactose moieties 
Biodistribution of micelles with and without galactose moieties was 
investigated through non-invasive bioimaging. A near-infrared fluorophore, DiR, was 
loaded into the micelles according to the protocol described in Section 5.2.4. A rodent 
surgical orthotopic HCC model, which was described in Section 6.2.6, was utilized 
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for this biodistribution study. The rats were then injected via tail-vein with 1 mL of 
DiR-loaded micelles (0.0304 mg/mL DiR equivalent) four weeks post-tumour 
inoculation. Whole-body fluorescence images were taken at time points ranging from 
30 min to 48 h post-administration using Xenogen IVIS 100 (Caliper Life Sciences, 
U.S.A.) with excitation and emission set at 710 nm and 820 nm respectively. D-
luciferin was injected intraperitoneally into each rat using a 23-gauge needle at a dose 
of 150 mg/kg body weight for bioluminescence imaging to view the liver tumour. 
Rats underwent 3.5 % isoflurane gas anesthesia, after which bioluminescence images 
were acquired using IVIS with the emission filter set as open. Anesthetized rats were 
placed in a supine position on the heated plate (37 ºC) for taking fluorescence and 
bioluminescence images. The tumours and organs were removed from rats sacrificed 
by CO2 inhalation at 48 h post-administration of DiR, and subsequently imaged.  
 
6.2.8 Statistical analysis 
All data were presented as mean ± SD. Statistical analysis was accomplished 
using unpaired Student’s t-test and the data were considered significant if 0.01 < *p≤ 
0.05 and very significant if 0.001 < **p≤ 0.01 or extremely significant if ***p< 0.001. 
 
6.3 Results and Discussion 
6.3.1 Polymer synthesis and characterization 
Amphiphilic block copolymers with galactose moieties were synthesized 
through ROP of functional cyclic carbonates derived from 2,2-bis(methylol)propionic 
acid, employing 4-MBA as the initiator and TU and DBU as the co-catalysts (Scheme 
6.2). Two types of diblock copolymers having poly(carbonate-urea) (PUC) as the 
hydrophobic block were synthesized: 1) poly(carbonate-galactose) as the hydrophilic 
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block with varying hydrophilic and hydrophobic block lengths (P(MTC-Gal)-PUC) 
(4a, 4b, 4c, 4d); 2) poly(carbonate-galactose)-b-poly(carbonate-PEG) (P(MTC-Gal)-
P(MTC-PEG)) as the hydrophilic block with varying poly(carbonate-galactose) chain 
length (P(MTC-Gal)-P(MTC-PEG)-PUC) (5a, 5b) (Scheme 6.2). The copolymers 
were synthesized through the sequential polymerization of MTC-galactose and MTC-
urea for 4a-d and MTC-galactose, MTC-PEG and MTC-urea for 5a and b. Galactose 
moieties were capped with isopropylidene protecting groups (ipGal) during the 
polymerization, and removed by acidic hydrolysis to provide the final polymers. 
These polymers formed micelles with multiple galactose moieties in the corona to 
enhance selectivity and affinity to the galactose-binding lectins in the HCC. Urea 
groups on the other hand would drive the self-assembly of the polymers into micelles 
and interact with the anti-HCC drug sorafenib through hydrogen bonding and 
hydrophobic interactions. PEG5K-PUC without galactose from Chapter 5 was chosen 
to compare with 5b. The structures and repeating units of the monomers for different 
blocks were confirmed by 
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Scheme 6.2: Synthesis procedures and structures of galactose- and urea-functionalized 
polycarbonates copolymers. 
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6.3.2 Particle size, size distribution and drug loading capacity of drug-loaded 
micelles 
Table 6.1: Properties of galactose and/or urea-functionalized polycarbonate micelles. 












P(MTC-Urea)4  177.8 
 
344 ± 37 0.50 ± 0.01 2.0 ± 0.3 
4b 
4-MBA-P(MTC-Gal)15-
P(MTC-Urea)4  46.8 188 ± 3 0.18 ± 0.02 2.9 ± 0.5 
4c 
4-MBA-P(MTC-Gal)47-
P(MTC-Urea)18  112.2 233 ± 15 0.37 ± 0.04 7.8 ± 0.4 
4d 
4-MBA-P(MTC-Gal)15-








Urea)14  5.0 94 ± 2 0.15 ± 0.02 7.3 ± 0.1 
PEG5K-
PUC PEG113-P(MTC-Urea)9 15.8 116 ± 9 0.21 ± 0.05 4.2 ± 0.7 
a
 Sorafenib-loaded 
The number of galactose and urea groups appended onto the polycarbonate 
backbone was varied in copolymers 4a, 4b, 4c and 4d to understand its effect on self-
assembly and drug loading (Scheme 6.2, Table 6.1). Sorafenib is almost insoluble in 
water, giving low relative bioavailability (38-49%) [225, 226] which warrants the 
need to solubilize the drug with nanomedicine formulations. Sorafenib was enveloped 
in the micellar core due to hydrogen bonding and hydrophobic interactions between 
the drug and urea groups in the copolymers. An increased length of P(MTC-Gal) 
block led to sorafenib-loaded micelles with smaller size and narrow size distribution 
(4a vs. 4b micelles loaded with sorafenib; particle size, PDI: 188, 0.18 and 344 nm, 
0.50, respectively, Table 6.1). The number of galactose moieties however did not 
influence the drug loading level with the loading levels remaining comparable 
between 4a and 4b as well as 4c and 4d micelles (Table 6.1). Narrow size distribution 
was also observed for sorafenib-loaded 4d micelles in contrast to 4c. Notably, 
reducing the repeating units of MTC-Gal resulted in a lower CMC value which is 
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desirable when micelles are exposed to infinite dilution upon in vivo administration 
(177.8 vs. 46.8 mg/L and 112.2 vs. 22.4 mg/L, Table 6.1). Decreasing the repeating 
units of MTC-Gal probably ensued in increased hydrophobicity of the copolymers, 
rendering them easier to self-assemble in aqueous medium. 
Comparing copolymers 4a and 4c upon sorafenib encapsulation, increasing the 
number of urea groups at 47 repeating units of MTC-Gal resulted in smaller particle 
size from 344 to 233 nm and lower PDI. However, increasing urea content at lower 
repeating units of MTC-Gal (4b vs. 4d) ensued in larger particle size with narrow PDI 
upon sorafenib loading. Increasing the urea content similarly increased the drug 
loading level as well due to enhanced drug-copolymer hydrogen bonding (7.8 vs. 2.0 
and 9.6 vs. 2.9 wt%, Table 6.1). A decrease in CMC value was observed when PUC 
block length was increased (177.8 vs. 112.2 mg/L and 46.8 vs. 22.4 mg/L, Table 6.1). 
These results collectively show that the number of galactose moieties and urea groups 
interplay to modulate the hydrophobic/hydrophilic balance of the copolymers to 
determine the particle size of drug-loaded micelles and self-assembly of the 
nanostructures. A compromise between the number of galactose and urea groups has 
to be achieved to obtain the optimum hydrophobic/hydrophilic balance giving low 
CMC value and small particle size. 
Although the design of the block copolymers 4c and 4d allowed for successful 
encapsulation of sorafenib with drug loading levels of 7.8% - 9.6%, particle size and 
size distribution were not ideal. Therefore, P(MTC-PEG) block was added between 
P(MTC-Gal) and PUC with the aim of modulating particle size of drug-loaded 
micelles (5a and 5b).  Evidently, the addition of the MTC-PEG block lowered the 
CMC values (5a vs. 4a, 5b vs. 4d in Table 6.1). The presence of the P(MTC-PEG) 
block also resulted in narrow size distribution and significantly smaller particle size 
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with the sizes of drug-loaded micelles below 150 nm. As the copolymers for this 
study consisted of one polycarbonate backbone with different functional groups 
appended in block distribution, the assembled core-shell structure of the polymers 
would be affected by the relative hydrophilicity of the different functional groups. 
The higher hydrophilicity of pendent PEG groups as compared to the galactose groups 
probably led to better-defined core-shell structure due to easier self-assembly of the 
PEG-containing polymers in aqueous medium. The drug loading level increased 
greatly with the presence of MTC-PEG block in 5a compared to 4a (6.5 vs. 2.0 wt%) 
although pendent PEG groups was not so influential in 5b as the loading level was 
comparable to that of 4d (Table 6.1). Among the various copolymers, the copolymer 
5b emerged as the best candidate for preparing sorafenib-loaded galactose-decorated 
micellar nanoparticles due to the relatively high drug loading level, the smallest 
particle size and lowest CMC value, which are desirable for drug delivery. When 
PEG5K-PUC was loaded with sorafenib, the resulting particle size was 116 nm, 
which is below 150 nm, making the drug-loaded PEG5K-PUC favourable for passive 
accumulation in the HCC tissues based on the EPR effect. The loading level of 
PEG5K-PUC decreased slightly to 4.2 wt% probably due to the marginally lower urea 
content. Thus PEG5K-PUC micelles were accessed for tumour-targeting ability in 
comparison to 5b micelles, which were designed for galactose receptors-mediated 
active targeting, in an orthotopic HCC rat model. 
 
6.3.3 Stability of sorafenib-loaded micelles 
Adsorption of serum proteins on micellar surface can elicit rapid particle 
uptake by mononuclear phagocyte system (MPS) which is undesirable for in vivo 
applications [34]. The particle size of sorafenib-loaded PEG5K-PUC and 5b micelles 
remained comparable for 48 h while exposed to 10% FBS medium (Figure 6.1A), 
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making these micelles suitable for in vivo evaluation. The kinetic stabilities of 
sorafenib-loaded 5b and PEG5K-PUC micelles were next investigated by monitoring 
the scattered light intensity after the addition of destabilizing agent, SDS. The relative 
drop in the scattered light intensity represents the extent of micelles disassembly. As 
seen in Figure 6.1B, sorafenib-loaded PEG5K-PUC micelles were significantly more 
stable than sorafenib-loaded 5b micelles. The difference in the kinetic stabilities 
between these two micellar systems probably lied in the different 
hydrophobicity/hydrophilicity of the copolymers. The copolymer 5b has a higher 
content of PEG components and additional galactose moieties as compared to 
PEG5K-PUC, which might lead to higher overall hydrophilicity of 5b and thus lower 
kinetic stability. This phenomenon was also observed in our previous study described 
in Chapter 5 where the increase in PEG length of the polymer lowered the kinetic 



















































































Figure 6.1: Micelle stability. (A) Size of sorafenib-loaded micelles in DI water containing 
10% FBS over time. (B) Scattered light intensity measured at 90° of sorafenib-loaded 
PEG5K-PUC and 5b micelles against time after addition of SDS. Relative intensity (%) is 
represented as the percentage of the scattered light intensity at time x in relative to the 
scattered light intensity at time 0. 




6.3.4 Galectin-3 binding study 
To investigate whether the galactose moieties on 5b micelles exist in the 
corona of the micelles, the ability of 5b micelles to bind galectin-3 was investigated in 
comparison with PEG5K-PUC micelles. BSA and galectin-3 were coated onto a 
NUNC MaxiSorp plate after, which they were washed and treated with DiR dye-
labeled 5b or PEG5K-PUC micelles. 5b micelles preferentially bound to galectin-3 in 
comparison to PEG5K-PUC as the fluorescence of 5b micelles bound to the galectin-
3 coated plate was about 5-fold higher than that of PEG5K-PUC micelles (Figure 6.2). 
When the plate was coated with BSA instead, the fluorescence of 5b and PEG5K-
PUC micelles bound to the BSA-coated plate was similarly low, indicating no 
preferential binding of either micelle to BSA. These results collectively suggest that 
the galactose moieties existed in the corona of micelles, which were accessible to 






























































































Figure 6.2: Fluorescence intensity of DiR-loaded 5b and PEG5K-PUC micelles applied to 




6.3.5 Evaluation of antitumour effect of drug-loaded micelles in orthotopic HCC rat 
model 
Preliminary in vivo antitumour studies of sorafenib-loaded 5b micelles were 
performed in an orthotopic HCC rat model. McA-RH7777-luc2 HCC tumour was 
induced in the liver tissue. The bioluminescent signal from the tumour was monitored 
over time, and utilized to monitor the tumour size via non-invasive bioimaging. A 
region of interest (ROI) was drawn around the bioluminescent signal with the 
quantification given in luminescent counts. The rats were divided into 4 groups: 
saline-treated and blank 5b micelles-treated groups (3 rats each), free sorafenib-
treated group (5 rats) and sorafenib-loaded 5b micelles-treated group (6 rats). As 
shown in Figure 6.3A, the rate of increase in the bioluminescent signal was 
comparable for all groups from Day 2 to Day 27 post-implantation of HCC cells. 
After that, the signals from saline- and blank 5b micelles-treated rats increased at a 
faster rate than the rats treated with both free sorafenib- and sorafenib-loaded 5b 
micelles formulations. This implied that the blank 5b micelles had no antitumour 
effect. However, there was no significant difference in the bioluminescent signals 
between free sorafenib and sorafenib-loaded 5b micelles-treated groups (p > 0.1 at 
Day 29 post-implantation, Figure 6.3A), indicating that the antitumour efficacies 
exerted by free sorafenib- and sorafenib-loaded 5b micelles formulations were similar. 
Bioluminescence signals emanating from the HCC tumour is only semi-quantitative 
of the HCC size in the rats, warranting the need to obtain tumour weights from all rats 
at the end of the antitumour efficacy study for a more quantitative analysis. The body 
weights of rats in the control and treated groups were monitored for general toxicity 
effects from the different formulations. The body weights of all of the rats increased 
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over time presumably due to ageing until the end of the study with no significant 





















































































































































Figure 6.3: Antitumour efficacies of sorafenib and sorafenib-loaded 5b micelles in orthotopic 
HCC rat model. Evolution of (A) bioluminescent signals from HCC tumour and (B) body 
weight over 29 days for rats administered with PBS (n = 3), free sorafenib (n = 5), sorafenib-
loaded 5b micelles (n = 6) and respective blank micelles (n = 3). Rats were administered with 
10 mg/kg sorafenib equivalent and equivalent weight of 5b blank micelles at days 3, 6, 9, 13, 
16, 20, 23, 27 post-inoculation of McA-RH7777-luc2 HCC cell line. Percentage of body 
weight was calculated by dividing weight at a given time point over the initial value at day 2 
post-implantation of HCC cells and multiplied by 100%. (C) Tumour weights after tissue 
harvest at day 30 post-implantation of HCC cells, 0.01<*p ≤ 0.05. 
 
At Day 30 post-implantation of HCC cells, all of the rats were sacrificed with 
the tumour and liver tissues harvested. HCC tumour tissues were excised from liver 
tissues for tumour weight measurements. From Figure 6.3C, it was observed that the 
tumour weights of rats treated with both formulations of sorafenib were significantly 
lower than that of rats treated with saline or blank 5b micelles due to the anticancer 
therapeutic effect of sorafenib (0.01<*p ≤ 0.05). However, there was no significant 
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difference between the tumour weights of sorafenib- and sorafenib-loaded 5b micelle-
treated rats or between saline- and blank 5b micelle-treated rats, corroborating that 
blank 5b micelles had no antitumour effect. 
While it was previously postulated that the presence of the lectin proteins 
(galectin-3 and ASGP-R) in the HCC tumour may promote tumour-targeting of the 
galactose-functionalized micelles, the results obtained from the antitumour efficacy 
studies oppose this hypothesis as free sorafenib and sorafenib-loaded 5b micelles 
formulations exerted the same therapeutic effect. To determine the distribution of 
sorafenib in the tissues, harvested tumour and liver tissues were also homogenized 
and tested for its sorafenib content by Dr Yanjun Hong (Department of Pharmacy, 
Faculty of Science, NUS). As shown in Figure A5.1 in Appendix E, rats treated with 
sorafenib-loaded 5b micelles exhibited significantly higher sorafenib content in the 
liver tissue than that of rats treated with free sorafenib. However, sorafenib content in 
the tumour tissues of rats treated with both formulations of sorafenib were similar, 
explaining their comparable antitumour efficacy. This suggests that galactose-
moieties on 5b micelles rendered its preferential accumulation in liver tissues over the 
HCC tumour. This finding warrants the need to study the biodistribution of the 5b 
micelles in the HCC rat model in comparison to PEG5K-PUC micelles without 
galactose. 
 
6.3.6 In vivo biodistribution of micelles in orthotopic HCC rat model 
In order to further assess the tumour-targeting ability of 5b micelles in the 
animal model, dual-colour in vivo imaging of the rats injected intravenously with 
DiR-loaded 5b and PEG5K-PUC micelles was conducted. PEG5K-PUC micelles 
without galactose moieties were used as the control. The distribution of DiR-labeled 
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micelles in the orthotopic HCC rat model was monitored over 48 h by IVIS imaging 
with the rats placed in a supine position. In vivo imaging of the bioluminescent signals 
from the luciferase-expressing HCC tumour was done concurrently.  
 
Figure 6.4: In vivo imaging of Buffalo rats with orthotopic HCC at various time points after 
tail-vein injection of DiR-loaded 5b and PEG5K-PUC micelles. Fluorescence images indicate 
biodistribution of DiR-loaded micelles while bioluminescence images indicate location of 
HCC tumour. An overlay of fluorescence (blue) and bioluminescence (red) images at each 
time point were also shown. n = 3 per treatment group, representative images were shown. 
 
DiR signals in rats injected with 5b micelles were concentrated in the middle 
of the body compared to the surrounding area at 30 min post-injection, prevailing for 
48 h (Figure 6.4). The close proximity of the DiR signals to the luminescence signals 
of the HCC tumour suggests that the micelles could have accumulated in the liver 
tissue as fast as 30 min post-administration. Rats administered with PEG5K-PUC 
micelles on the other hand did not exhibit strong DiR signals in the middle of the 
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the middle of the body. To confirm the location of tissue accumulation of 5b and 
PEG5K-PUC micelles, an overlay of the bioluminescence and fluorescence images at 
each time point was also depicted (Figure 6.4). There was no overlap of the DiR 
signals with the luminescent signals of the HCC tumour for rats injected with 5b 
micelles, indicating that the 5b micelles most likely preferentially homed to the liver 
after 30 mins post-administration (Figure 6.4). In contrast, no specific accumulation in 
the tumour was seen up to 5h post-administration of PEG5K-PUC micelles. However 
the fluorescent and bioluminescent signals overlapped at 24 h post-administration 
onwards, signifying that PEG5K-PUC micelles amassed in the HCC tumour. 
The only tissue exhibiting luminescence was the HCC tumour, indicating that 
no metastasis had occurred in the timeframe of this study (Figure 6.5A). Ex vivo 
fluorescence imaging of major tissues of the rats demonstrated that DiR-labeled 5b 
micelles generally existed in the liver with notably weak signals present in the tumour, 
spleen and lungs (Figure 6.5A). Strong fluorescent signals from DiR-labeled PEG5K-
PUC micelles contrarily were seen in the tumour tissues with signals present in other 
tissues. Negligible fluorescence in the heart was observed from both micelle 
formulations. Quantitative analysis of the fluorescent signals in the tissues (Figure 
6.5B) revealed a significant difference between the fluorescent signals in the liver and 
tumour of rats treated with 5b micelles. On the other hand, fluorescent signals were 
more pronounced in the tumour compared to the liver for rats treated with PEG5K-
PUC, suggesting preferential accumulation in the tumour as compared to other tissues. 
Significant difference in the fluorescence between DiR-loaded 5b and PEG5K-PUC 
micelles in liver or tumour was also observed. To further study the tissue penetration 
of the micelles in the liver and tumour tissues, the cross-sections of corresponding 
tissues were similarly imaged (Figure 6.5C) as localization of the micelles could 
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merely exist on the tissue surface [227]. High DiR signals were observed in the cross-
sections of liver tissues while low to none DiR signals could be discerned in the cross-
sections of tumour tissues of 5b-treated rats, indicating deep penetration of 5b 
micelles in the liver tissues. Rats treated with dye-labeled PEG5K-PUC micelles on 
the other hand displayed DiR signals in the cross-sections of both liver and tumour 














































































































































































































































































































































































































































Figure 6.5: Ex vivo organ imaging of DiR-encapsulated 5b and PEG5K-PUC micelles at 48 h 
post-injection. (A) Tissue distribution of DiR-loaded micelles in healthy liver, spleen, tumour, 
heart, lungs and kidneys, n = 3 per treatment group. Representative images were shown. (B) 
Quantification of radiant efficiency around the region of interest in liver and tumour tissues of 
rats treated with DiR-loaded 5b and PEG5K-PUC micelles (mean ± SD, n = 3, 0.001<**p≤ 
0.01, ***p<0.001).  (C)  Tissue distribution of DiR-loaded micelles in the cross-sections of 
liver and tumour tissues to indicate penetration of micelles. 
 133 
Looking at these results collectively, 5b micelles were primarily taken up by 
liver tissues, showing high penetration within liver tissues themselves. The presence 
of the ASGP-R on the healthy hepatocytes elicits hepatic targeting of the galactose-
modified 5b micelles and presumably endocytosis-mediated uptake of the micelles, 
resulting in deep penetration of the micelles within the liver tissue. While liver 
targeting of nanoparticles is possible via action of the MPS, this course of targeting is 
probably improbable in our 5b micelle system as there was very low DiR signals in 
other MPS-rich tissues, specifically the spleen and kidneys of 5b-treated rats. 
Although there was presence of ASGP-R and galectin-3 in HCC tumour tissues [215, 
219], the large numbers of freely accessible ASGP-R on hepatocytes sinusoidal cell 
membrane [215, 228, 229] compared to that in HCC tumours probably rendered the 
5b micelles to be more selective for liver tissues as fast as 30 mins post-
administration. Furthermore, Seymour et al. has demonstrated that the majority of 
DOX-N-(2-hydroxypropyl)methacrylamide or HPMA conjugate copolymers 
accumulated in the healthy liver compared to areas of hepatic tumour in patients with 
liver cancer. This was attributed to the low ASGP-R expression in the HCC samples 
and agrees with our observation [230]. These biodistribution results corroborated the 
analysis of sorafenib content in the tumour and liver tissues at the end of the 
antitumour study (Figure A5.1). This suggests that 5b micelles would be unsuitable to 
deliver drugs for HCC tumour targeting. However, galactose-functionalized 
polycarbonate micelles can be considered to deliver other therapeutics for the 
treatment of liver diseases whereby the ASGP-R is still preserved (e.g. virus 
infection).  
PEG5K-PUC micelles on the contrary displayed preferential accumulation in 
the HCC tumour tissue after 24 h via EPR effect. The small size of the PEG5K-PUC 
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micelle enabled it to traverse the leaky vasculature of the tumour and passively 
accumulate in the HCC tumour. The presence of the fluorescent signals in the spleen 
insinuates the uptake of a part of PEG5K-PUC micelles by Kupffer cells, a 
phenomenon reported by others [231]. However, the DiR signals in the tumour tissues 
were higher indicating that tumour uptake was more favourable. Tumour 
accumulation and penetration could be possibly enhanced if the study was continued 
beyond 48 h. PEG5K-PUC micelles with no galactose moieties proved to be a better 
candidate for targeting liver cancer. It remains to be seen whether sorafenib-loaded 
PEG5K-PUC micelles were able to exhibit antitumour effect against the HCC. 
 
6.4 Conclusion 
Diblock and triblock galactose-functionalized polycarbonate-based 
copolymers with varying repeating units of galactose- and urea-functionalized 
carbonate monomers were successfully synthesized. The galactose-functionalized 
copolymers were able to encapsulate sorafenib due to copolymer-drug hydrogen 
bonding and hydrophobic interactions, yielding nanosized micelles with narrow size 
distribution. A compromise between the numbers of galactose- and urea-
functionalized carbonate repeating units has to be achieved to modulate particle size 
while the addition of PEG-functionalized polycarbonate block in triblock copolymers 
yielded desirable particle size and drug loading level. 5b with the optimized number 
of galactose and urea groups formed micelles below 100 nm upon sorafenib loading 
with 7.3 wt% loading level and were confirmed to have exposed galactose groups on 
its surface. Sorafenib-loaded 5b micelles exhibited comparable antitumour activity as 
free sorafenib in an orthotopic HCC rat model due to its accumulation in the liver 
tissue, as demonstrated by live bioimaging studies. Hepatic targeting of 5b micelles 
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was facilitated by presence of ASGP-R in large numbers in the hepatocytes. This 
characteristic of 5b could be exploited for delivery of other therapeutic agents for 
liver infection diseases for example. In comparison, PEG5K-PUC micelles which do 
not contain surface galactose groups were shown to preferentially accumulate in the 
tumour implying its promising ability to deliver anticancer drugs passively to the 
HCC for enhanced antitumour effect. This chapter shows the successful incorporation 
of targeting ligands to the polycarbonate chain for hepatic targeting.  
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Chapter 7 Conclusion and Future Perspectives 
 
7.1 Conclusion 
The common thread linking the different aims in this thesis was the overall 
goal of designing and evaluating biodegradable polycarbonates-based copolymers 
yielded by organocatalytic ring-opening polymerization (ROP) of functional cyclic 
carbonate monomers as suitable drug carriers in the form of micellar nanoparticles. 
The hypothesis stating that amphiphilic functionalized polycarbonate copolymers 
synthesized from organocatalytic ROP possess well-controlled molecular weights and 
low polydispersity and are non-toxic and competent in delivering anticancer drugs, 
was studied.   
In Aim (1), a proof-of-principle was granted that amphiphilic triblock 
copolymers of PEG, acid-functionalized polycarbonate and ethyl-functionalized 
polycarbonate were able to encapsulate amine-containing DOX into micelles. When 
acid groups were placed as the terminal end of the hydrophobic block, the desirable 
particle size was achieved upon loading of DOX and the drug loading levels were 
above the benchmark of 20 wt% previously reported by other research groups [52], 
contributed by the strong ionic interactions between acid groups and amine group in 
DOX. However, DOX-loaded micelles derived from acid-functionalized 
polycarbonates exhibited low kinetic stability due to its assembly merely driven by 
hydrophobic interactions.   
As described in Aim (2), acid-functionalized polycarbonate copolymers were 
blended with urea-functionalized polycarbonate copolymers to form mixed micelles 
with the objective to improve on the kinetic stability of the micelles. The mixed 
micelles exhibited enhanced kinetic stability due to the specific hydrogen bonding 
formed between urea and acid groups, while yielding nanoscopic particle size below 
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200 nm, narrow size distribution and drug loading levels above 30 wt% upon DOX 
loading. Varying the number of urea units or relative acid/urea content did not 
influence the size and loading level of DOX-loaded mixed micelles significantly. 
However, mixed micelles containing acid to urea content in 1:1 molar ratio was found 
to be the best candidate as a drug delivery vehicle as the DOX-loaded mixed micelles 
induced cytotoxicity to HepG2 cells at an IC50 value similar to that of free DOX. The 
mixed micelles without DOX exhibited low toxicities to HepG2 cells.  
In Aim (3), the simplification of mixed micelles fabrication was attempted by 
incorporating both acid and urea groups into polycarbonate block. Chapter 4 describes 
the study of the effects of distribution and number of both functional groups within 
the polycarbonate block in PEG-polycarbonate diblock copolymers. It was validated 
that the distribution of the functional groups within the polycarbonate block indeed 
influenced the self-assembly of the micelles and that the randomly distributed acid 
and urea groups in the polycarbonate chain exhibited the more desirable 
physicochemical properties. The DOX-loaded micelles made from the copolymer 
bearing randomly arranged 10 acid-carbonate and urea-carbonate repeating units each 
were found to be the best candidate as a drug carrier due to their small particle size, 
high drug loading level, non-adsorption of serum proteins, ability to re-disperse after 
freeze-drying and cytotoxic effect to HepG2 cells upon DOX loading. In addition, the 
blank micelles without DOX were non-cytoxic.  
The study of how kinetic stability of the micelles influences in vivo 
applications was carried out in Aim (4). As two different acid- and urea- 
functionalized polycarbonate systems were made as DOX carriers, an evaluation was 
carried out to compare these two systems. Mixed micelles self-assembled from 
individual copolymers bearing 9 units of acid-carbonate and urea-carbonate on 
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separate chains were fabricated with PEG chains of 5 kDa and 10 kDa. DOX-loaded 
PEG5K mixed micelles exhibited superior kinetic stability as compared to that of the 
DOX-loaded micelles made from the copolymer bearing randomly arranged 9 acid-
carbonate and urea-carbonate repeating units each, demonstrating the importance of 
the arrangements of acid and urea groups in keeping the micellar structures intact. 
Longer PEG length would result in more hydrophilic copolymers and lower kinetic 
stability of resulting micelles. PEG5K mixed micelles exhibiting better kinetic 
stability were shown to accumulate in tumours faster to a greater degree and exhibited 
better antitumour effect in a 4T1 mouse breast cancer model in comparison to that of 
PEG10K mixed micelles. PEG5K mixed micelles are a promising carrier for delivery 
of anticancer drugs with amine functional group.   
In Aim (5), galactose-functionalized polycarbonate micelles were designed for 
lectin-mediated targeting in an orthotopic hepatocellular carcinoma (HCC) rat model 
due to the presence of asialoglycoprotein receptor (ASGP-R) and galectin-3 in the 
HCC. It was demonstrated that the presence of PEG groups modulated the particle 
size of the micelles upon loading of sorafenib. The copolymer 5b with good 
hydrophobicity/hydrophilicity balance was found to form micelles at low 
concentrations with sizes smaller than 100 nm and excellent loading capacity for 
sorafenib. Galactose moieties in the corona of 5b micelles were accessible for protein 
binding, and the micelles preferentially accumulated in the healthy liver tissues of the 
rats as compared to other tissues including the HCC tumour tissues as fast as 30 mins 
post-injection while PEG5K-PUC micelles with no galactose moieties accumulated in 
the HCC tumour after 24 h post-administration by virtue of the EPR effect. Hepatic 
targeting of 5b micelles was probably due to the abundance of ASGP-R on the liver 
hepatocytes when compared to the lectin proteins in the HCC. Receptor-mediated 
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uptake of 5b micelles by the healthy liver can be exploited for targeted delivery of 
therapeutics for other liver diseases (e.g. virus infections). The hepatic targeting of 5b 
verifies that the polycarbonate system functionalized with targeting ligands is able to 
target specific tissue of choice.  
In overall, this thesis has shown evidence supporting the hypothesis that the 
micelles made from the designed amphiphilic polycarbonates with well-defined 
molecular weight and functionalities have desirable properties, including nanosize, 
narrow size distribution, high drug loading capacity and excellent stability, for the 
delivery of anticancer drugs. Polycarbonates as a class of biomaterials have exhibited 
its versatility in incorporating a myriad of functional groups (acid, urea, ethyl ester, 
galactose and PEG) to allow for reversible non-covalent interactions within the 
micellar core and between the micellar core and the anticancer drugs, and to offer 
targeting ability. The non-covalent interactions enhance drug loading capacity, 
thermodynamic and kinetic stabilities of micelles, and promote the formation of 
nanosized micelles. Successful delivery of anticancer drugs using micelles formed 
from amphiphilic polycarbonate copolymers with optimal compositions has been 
demonstrated both in vitro and in vivo.  
  
7.2 Future Perspectives 
While the findings in this thesis have upheld the hypothesis stated, further 
investigations are still warranted to uncover more possibilities of using polycarbonate 
micelles as a drug delivery carrier. The enhancement of thermodynamic and kinetic 
stabilities as well as drug loading via non-covalent interactions has been demonstrated 
using the functional polycarbonate micelles. The polycarbonate micelles formed with 
higher kinetic stability has exerted greater in vivo antitumour efficacy. To realize the 
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full potential of clinically using these polycarbonate-based polymeric micelle 
formulations, a full toxicological evaluation is needed. Nanoparticle formulations of 
drugs tend to reduce the toxicity of the encapsulated drug such as in the case 
demonstrated in Chapter 5 whereby DOX-loaded mixed micelle formulation exerted 
low cardiotoxicity in mice in comparison to the free DOX formulation. However, 
particular stress on the toxicity of the blank micelles should be placed to investigate 
discrete toxicities between drug-loaded and blank micelles formulations. The first step 
in such evaluation is acute toxicity tests to investigate the dose-dependent acute 
toxicity and animal mortality in animal models after administration of the 
polycarbonate systems. Different groups of mice could be injected with different 
doses of the polycarbonate copolymers, after which they are observed for any 
abnormal changes in physiology, behavior, appetite, bowel movements and mortality. 
The acute median lethal dose or LD50 could be acquired from this particular study. 
Immunotoxicity studies should also be conducted to identify potential 
immunogenicity issues arising from using such nanomedicine formulations. 
Preclinical antitumour efficacy studies should also be evaluated in large animals to 
gather supporting data on nanomedicine safety and efficacy, and to establish 
appropriate dosing parameters before going to clinical trials.  
Other tangential studies relating to the reports in this thesis can also be done in 
the future. Since PEG5K-PAC/PEG5K-PUC mixed micelles was presented as a 
promising carrier for the delivery of anticancer drugs with amine functional group, the 
mixed micelles could be loaded with other amine-containing drugs that were 
previously not formulated in nanoparticles (topotecan, sunitinib, tamoxifen etc) and 
tested in an extensive variety of human cell lines and disease-specific animal models 
to prove the broad applications of our polycarbonate system due to the variety of 
 141 
functional groups appended onto the copolymers designed. Orthotopic animal models 
would be preferred if resources allow as they impart complexity to classical models to 
mirror human tumoural development. Secondly, although 5b micelles were found to 
be inappropriate in targeting HCC tissue, it still exhibited ASGP-R-mediated hepatic 
targeting that could be exploited. Natural hepatitis B virus (HBV) particles in the 
bloodstream was found to infect the liver due to receptor-mediated uptake by the 
binding of HBV particles to ASGP-R [232]. This characteristic interaction with HBV 
particles constitutes ASGP-R as a promising target for therapeutic intervention. Proof-
of-concept of using sugar-functionalized colloidal systems to deliver antiviral drugs to 
the liver for HBV treatment has been provided by others [233]. Similarly, to exploit 
the broad appeal of our polycarbonate system, the effectiveness of galactose-
functionalized polycarbonate copolymers as drug carriers for this application can be 
evaluated. Thirdly, our finding that the PEG5K-PUC micelles accumulated in the 
orthotopic HCC tissue is promising to warrant sorafenib-loaded urea-functionalized 
polycarbonate formulation to be evaluated for its antitumour efficacy in the same 
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Appendix A: Synthesis and characterization of copolymers bearing urea groups 
and benzyl protecting carboxylic acid group 
 
Materials: Reagents were available commercially from Aldrich and used as received 
unless otherwise noted. 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 98%) was stirred 
over CaH2, vacuum distilled twice, then stored in glove box. Monomethoxy 
poly(ethylene glycol) (Mn 2400 g/mol, PDI 1.04) was purchased from polymer source 
Inc., Canada, which was  azeotropically distilled from toluene and dried in vacuo 
prior to use. Dry THF were obtained by using a solvents drying system from 
Innovative. Amberlyst-15, the ion exchange resin, was rinsed with the reaction 
solvent prior to use. 
 
Copolymer characterization: 
Gel permeation chromatograph (GPC): GPC analysis for block copolymers was 
carried out with a Waters HPLC system equipped with a 2690D separation module 
with two Styragel HR1 and HR4E (THF) 5 mm columns (size: 300 × 7.8 mm) in 
series and a Waters 410 differential refractometer detector. The mobile phase used 
was THF with a flow rate of 1 mL/min. Number-average molecular weights as well as 
polydispersity indices were calculated from a calibration curve using a series of 
polystyrene standards with molecular weight ranging from 1,350 to 151,700. 
 
1
H NMR spectroscopy: 
1
H NMR spectra were recorded on a Bruker Advance 400 
NMR spectrometer at 400 MHz at room temperature. The 
1
H NMR measurements 
were carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 
30° pulse width, 5208-Hz spectral width, and 32 K data points. Chemical shifts were 











































































Scheme A1.1: Synthesis procedures of (A) MTC-OBn, (B) MTC-OEt, and (C) MTC-OU.  
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Synthesis of 5-Methyl-5-benzyloxycarbonyl-1,3-dioxan-2-one (MTC-OBn):  
(i) A mixture of 2,2-bis(methylol)propionic acid (bis-MPA; 18.0 g, 0.134 mol), 
KOH (85% assay; 8.9 g, 0.135 mol), and DMF (100 mL) was heated to 100 °C for 1 h 
(the reaction mixture became a homogenous solution after 0.5 h reaction). Benzyl 
bromide (27.6 g, 0.162 mol) was added to the warm solution under stirring, and the 
reaction was continued at 100 °C for 16 h. The reaction mixture was cooled down and 
the solvent was removed under vacuum. Ethyl acetate (120 mL), hexanes (120 mL), 
and water (80 mL) were added to the residue. The organic layer was retained, washed 
with water (80 mL), dried over MgSO4 and evaporated. The resulting solid was 
recrystallized from toluene (30 mL) to give pure benzyl 2,2-bis(methylol)propionate 
(19.5 g, 65%). 
1
H NMR (400 MHz, CDCl3, 22 °C): δ 7.38 (m, 5H, PhH), 5.19 (s, 2H, 
-OCH2Ph), 3.94 (d, 2H, -CH2OH), 3.73 (d, 2H, -CH2OH), 1.12 (s, 3H, -CH3). 
(ii) Benzyl 2,2-bis(methylol)propionate (11.2 g, 0.05 mol) was dissolved in 
CH2Cl2 (150 mL) and pyridine (25 mL, 0.3 mol) and the solution was chilled to 
−75 °C with dry ice/acetone under N2 atmosphere. A solution of triphosgene (7.5 g, 
25 mmol) in CH2Cl2 (150 mL) was added dropwise over 1 h, and then the reaction 
mixture was allowed to warm to room temperature for 2 h. The reaction was 
quenched by addition of saturated aqueous NH4Cl (75 mL), after which the organic 
layer was washed with 1 M aqueous HCl (3  100 mL), saturated aqueous NaHCO3 (1 
 100 mL), dried over MgSO4, filtered and evaporated. The resulting solid was 
recrystallized from ethyl acetate (15 mL) to give MTC-OBn as a white solid (10.7 g, 
86%). 
1
H NMR (400 MHz, CDCl3, 22 °C): δ 7.37 (m, 5H, PhH), 5.20 (s, 2H, -
OCH2Ph), 4.69 (d, 2H, -CH2OCOO), 4.23 (d, 2H, -CH2OCOO), 1.31 (s, 3H, -CH3). 
 
Synthesis of 5-methyl-5-ethyloxycarbonyl-1,3-dioxan-2-one (MTC-OEt):  
  (i) bis-MPA (22.1 g, 0.165 mol) was added in ethanol (150 mL) with 
Amberlyst-15 (6.8 g) and refluxed overnight. The resins were then filtered out and the 
filtrate was evaporated. CH2Cl2 (200 mL) was added to the resulting viscous liquid to 
filtrate the unreacted reagent and by-product. After the solution was dried over 
MgSO4 and evaporated, ethyl 2,2-bis(methylol)propionate was obtained as a clear and 
colorless liquid (24.3 g, 91%).
1
H NMR (400 MHz, CDCl3, 22 °C): δ 4.09 (q, 2H, -
OCH2CH3), 3.74 (d, 2H, -CH2OH), 3.57 (d, 2H, -CH2OH), 1.18 (t, 3H, -OCH2CH3), 
0.98 (s, 3H, -CH3). 
(ii) A solution of triphosgene (11.7 g, 0.039 mol) in CH2Cl2 (150 mL) was 
added dropwise to a CH2Cl2 solution (150 mL) of ethyl 2,2-bis(methylol)propionate 
(12.6 g, 0.078 mol) and pyridine (39 mL, 0.47 mol) over 30 min at -75 °C with dry 
ice/acetone under N2 atmosphere. The reaction mixture was kept stirring for another 2 
h under chilled condition and then allowed to heat to room temperature. The reaction 
was quenched by addition of saturated aqueous NH4Cl (75 mL), after which the 
organic layer was washed with 1 M aqueous HCl (3  100 mL), saturated aqueous 
NaHCO3 (1  100 mL), dried over MgSO4, filtered and evaporated. The residue was 
recrystallized from ethyl acetate to give MTC-OEt as white crystals (8.0 g, 55%). 
1
H 
NMR (400 MHz, CDCl3, 22 °C): δ 4.67 (d, 2H, -CH2OCOO), 4.25 (q, 2H, -
OCH2CH3), 4.19 (d, 2H, -CH2OCOO), 1.30 (s, 3H, -CH3), 1.27 (t, 3H, -OCH2CH3). 
 
Synthesis of phenylureaethyl cyclic carbonate (MTC-urea, MTC-OU):  
(i) Ethanolamine (5.0 g, 48.5 mmol, 1eq) was placed in a dry 100 mL round 
bottom flask equipped with a stir bar, and dry THF (30 mL) was added. The resulting 
solution was chilled to 0 °C via ice bath. Phenylisocyanate (5.19 g, 4.74 mL, 43.6 
mmol, 0.9eq) and 30 mL of dry THF was added dropwise into the mixture through a 
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dropping funnel over 30 min. The resulting mixture was left to warm to ambient 
temperature and allowed to stand under stirring for an additional 16 h. Rotational 
evaporation was used to remove THF. The resulting crude product was recrystallized 
from ethyl acetate before being stirred rigorously for an additional 4 h. The 
recrystallized solids were isolated by filtration and further washed with ethyl acetate 
and dried until a constant weight was reached, giving a yield of 7.0 g (~80%). 
1
H-
NMR (400 MHz, DMSO-d6, 22 °C): δ 8.19 (s, 1H, -NHPh), 7.39 (d, 2H, PhH), 7.21 (t, 
2H, PhH), 6.88 (s, 1H, PhH), 6.10 (t, 1H, -CH2NHCO-), 4.40 (t, 1H, -OH), 3.40 (q, 
2H, -CH2OH), 3.05 (q, 2H, -CH2NHCO-), 2.43 (m, 4H, -CH2CH2CH2-), 2.32 (m, 2H, 
-CH2CH2CH2).  
(ii) Initially, MTC-COOH (4.3 g, 26.8 mmol) was converted to MTC-Cl by 
standard using oxalylchloride. The resulting intermediate was dissolved in 50 mL of 
dry methylene chloride and placed in an additional funnel. Phenylureapentanol (5.55 
g, 25 mmol), pyridine (1.97 g, 2.02 mL, 25 mmol) and dry methylene chloride (150 
mL) were then added in a dry 500 mL round bottom flask equipped with a stir bar. 
The additional funnel was attached to the flask under nitrogen with the flask cooled to 
0 °C using an ice bath. The MTC-Cl solution was added dropwise into the flask over 
30 min and left under stirring for an additional 30 min. The solution was then warmed 
to ambient temperature and allowed to stand under stirring for an additional 16 h. 
Purification of the crude product obtained was done by column chromatography using 
silica gel. Methylene chloride was utilized as an eluent to begin with before the 
polarity of the eluent was slowly increased to the final concentration of 5%(v) 
methanol. The product fractions were acquired, and the solvent was removed by 
rotational evaporation. The product was dried under vacuum prior to reaching a 
constant weight, giving 8.0g (~80%) of an off-white/yellowish oil which crystallized 
upon standing. 
1
H-NMR (400 MHz, DMSO-d6, 22 °C) δ 8.39 (s, 1H, -NHPh), 7.40 (d, 
2H, PhH), 7.20 (t, 2H, PhH), 6.88 (t, 1H, PhH), 6.10 (t, 1H, -CH2NHCO-), 4.57 (d, 
2H, -COOCH2CH2-), 4.39 (d, 2H, -CH2OCOO-), 4.16, (d, 2H, -CH2OCOO-), 3.10 (q, 
2H, -CH2NHCO-), 1.62 (m, 2H, -COOCH2CH2-), 1.45 (m, 2H, -CH2CH2NHCO-), 
1.35 (m, 2H, -CH2CH2CH2-), 1.18 (s, 3H, -CH3).   
 
Synthesis of acid-functionalized block copolymers: 
Block copolymers with benzyl protecting carboxylic acid group: The details of the 
procedure for ROP of the mixture of MTC-OBn and MTC-OEt (molar ratio 1:1) with 
MPEG are given as a typical example. A solution of MTC-OBn (0.3 g, 1.2 mmol) in 
CH2Cl2
 
(0.75 mL) was mixed with the solution of MTC-OEt (0.226 g, 1.2 mmol) in 
CH2Cl2 (0.75 mL), then the mixture was transferred to the solution of MPEG (0.144 g, 
0.06 mmol) and DBU (9.2 mg, 0.06 mmol) in CH2Cl2 (0.75 mL) under stirring. After 
reacted for 4 h, benzoic acid (5-10 mg) was added to quench the polymerization. The 
reaction mixture was then precipitated into diethyl ether (40 mL) and the precipitate 
was centrifuged and dried in vacuo. Finally, the crude product was purified by column 
chromatography on a Sephadex LH-20 column with THF as eluent, to give PEG-
P[(MTC-OEt)x-random-(MTC-OBn)y] as colorless viscous liquid (0.56 g, 84%). 
  For block copolymer PEG-P(MTC-OBn)-P(MTC-OEt), firstly, a solution of 
MTC-OBn (0.3 g, 1.2 mmol) in CH2Cl2
 
(0.75 mL) was added to the solution of 
MPEG (0.144 g, 0.06 mmol) and DBU (9.2 mg, 0.06 mmol) in CH2Cl2 (0.75 mL) 
under stirring. After reacted for 2 h, a solution of MTC-OEt (0.226 g, 1.2 mmol) in 
CH2Cl2
 
(0.75 mL) was added. The reaction was continued for another 2 h before 
benzoic acid was added. Block copolymer PEG-P(MTC-OEt)-P(MTC-OBn) was 
synthesized with a similar procedure where MTC-OEt was reacted with MPEG first, 
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followed by MTC-OBn. The yields and analytical data for all five block copolymers 
are given as followed. 
  PEG-P(MTC-OBn): Yield, 82%. 
1
H NMR (400 MHz, CDCl3, 22 C): δ 7.29 (m, 
180H, PhH), 5.12 (s, 72H, -OCH2Ph), 4.27 (m, 139H, -CH2OCOO), 3.63 (m, 217H, H 
of MPEG), 1.22 (s, 108H, -CH3). 
  PEG-P(MTC-OBn)-P(MTC-OEt): Yield, 86%. 
1
H NMR (400 MHz, CDCl3, 22 
C): δ 7.29 (m, 100H, PhH), 5.12 (s, 40H, -OCH2Ph), 4.27 (m, 190H, -CH2OCOO and 
-OCH2CH3), 3.63 (m, 219H, H of MPEG), 1.23 (m, 174H, -CH3 and -OCH2CH3). 
  PEG-P(MTC-OEt)-P(MTC-OBn): Yield, 84%. 
1
H NMR (400 MHz, CDCl3, 22 
C): δ 7.28 (m, 95H, PhH), 5.11 (s, 35H, -OCH2Ph), 4.21 (m, 182H, -CH2OCOO and 
-OCH2CH3), 3.64 (m, 214H, H of MPEG), 1.21 (m, 165H, -CH3 and -OCH2CH3). 
  PEG-P[(MTC-OEt)-random-(MTC-OBn)]: Yield, 84%. 
1
H NMR (400 MHz, 
CDCl3, 22 C): δ 7.31 (m, 85H, PhH), 5.14 (s, 34H, -OCH2Ph), 4.27 (m, 167H, -
CH2OCOO and -OCH2CH3), 3.65 (m, 218H, H of MPEG), 1.22 (s, 153H, -CH3 and -
OCH2CH3). 
  PEG-P(MTC-OEt): Yield, 85%. 
1
H NMR (400 MHz, CDCl3, 22 C): δ 4.20 (m, 
206H, -CH2OCOO and -OCH2CH3), 3.65 (m, 214H, H of MPEG), 1.25 (s, 210H, -
CH3 and -OCH2CH3). 
 
Deprotection of benzyl groups: A mixture of the above polymers (0.5 g), THF (7.5 
mL), methanol (7.5 mL), and Pd-C (10% w/w, 0.2 g) was swirled under H2 (7 atm) 
overnight. After evacuation of the H2 atmosphere, the mixture was filtered through 
THF-wetted Celite. Additional THF (15 mL) and methanol (15 mL) were used to 
ensure complete transfer. The collected washings were evaporated, and the residue 
was purified by column chromatography on a Sephadex LH-20 column with THF as 
eluent, to give the final acid-functionalized polymers listed in Table 1 as colorless 
semi-solid. The yield was more than 90%, and 
1
H NMR spectra showed that the 
protected groups were removed after hydrogenation. 
 
Synthesis of urea-functionalized block copolymer (PEG-PUC): In a glove box 
thiourea catalyst (32 mg, 80 μmol), sparteine (19 mg, 80 μmol), and  
monomethylether PEG (Mn 5,000 g/mol from Fluka, 1.0 g, 0.2 mmol) was charged in 
a dry 20mL glass vial equipped with a stir bar. A small volume of methylene chloride 
was added and the formed solution kept under stirring for 10 min. Phenylureapentyl-
MTC (0.58 g, 1.6 mmol) was added with additional methylene chloride (for a total 
concentration of 1 M to monomer) and the resulting solution kept under stirring for 16 
h. Benzoic acid (15 mg, 120 μmol) was added to quench the catalyst and the crude 
polymer precipitated in 500 mL of cold diethylether. The non-solvent was gently 
allowed to warm to ambient temperature after which the supernatant was decanted. 
The off-white solids were collected and dried under vacuum until a constant weight 
was reached. Yield 1.2 g (75%). GPC: PDI 1.04. 
1
H-NMR (400 MHz, DMSO-d6, 22 
C) δ: 8.37 (s, 7H, PhNH-), 7.38 (d, 14H, PhH), 7.17 (t, 14H, PhH), 6.84 (t, 7H, PhH), 
6.09 (s, 7H, -CH2NH-), 3.87-4.29 (m, 42H, -CH2OCOO- and -COOCH2CH2-), 3.20-
3.70 (m, 466H, H of MPEG and -CH2NHCO-), 1.55 (s, br, 14H, -COOCH2CH2-), 






Appendix B: Synthesis and characterization of urea-functionalized copolymers 
with benzyl protecting carboxylic acid group 
 
Materials: All reagents were purchased from Sigma-Aldrich. MPEG (Mn 5,000 g/mol, 
PDI 1.04) obtained from Polymer Source Inc. (Canada) was azeotropically distilled 
from toluene and dried in vacuum. Sparteine was stirred over CaH2, distilled in 
vacuum twice, and stored in glove box. N-(3,5-trifluoromethyl)phenyl-N’-
cyclohexylthiourea (TU) was prepared according to the protocol in [178]. TU was 
dissolved in dry THF, stirred with CaH2, filtered, and dried in vacuo. 
 
Synthesis of acid- and urea-functionalized copolymers acid: 
Urea-functionalized block copolymers with benzyl protecting carboxylic acid group: 
The synthetic procedures for preparation of the acid- (MTC-OBn) and urea-
functionalized (MTC-urea) carbonate monomers can be found in Appendix A. The 
detailed method for ROP of MTC-OBn and MTC-urea with MPEG (1, molar ratio 
20:20:1) is given as a typical example. In a glove box, MPEG (0.2 g, 0.04 mmol) in 
CH2Cl2 (0.75 mL) was mixed with TU (22.2 mg, 0.06 mmol) in CH2Cl2 (0.75 mL), 
followed by the addition of sparteine (13.8  µL, 0.06 mmol) and the mixture stirred 
for 10 min. A solution of MTC-OBn (0.2 g, 0.8 mmol) and MTC-urea (0.26 g, 0.8 
mmol) in CH2Cl2 (1.5 mL) was then introduced and reacted for 16 h, followed by 
quenching of the reaction with benzoic acid (15-20 mg). The reaction mixture was 
purified by column chromatography on a Sephadex LH-20 column with THF as the 
eluent to yield PEG-P[(MTC-OBn)19-(MTC-urea)19] (1d) as an off-white solid (0.54 g, 
82%).  For synthesis of triblock copolymer PEG-P(MTC-urea)-P(MTC-OBn) (2), a 
solution of MTC-urea (0.29 g, 0.09 mmol) in CH2Cl2 (1.5 mL) was added to a 
mixture of MPEG (0.3 g, 0.06 mmol), TU (33.3 mg, (0.09 mmol) and sparteine (20.7 
µL, 0.09 mmol) in CH2Cl2 (0.75 mL) under stirring. After 20 h, MTC-OBn (0.23 g, 
0.09 mmol) in CH2Cl2 (0.75 mL) was added. Polymerization proceeded for another 16 
h, after which benzoic acid was added to quench the reaction. Triblock copolymer 
PEG-P(MTC-OBn)-P(MTC-urea) (3) was synthesized with a similar procedure 
whereby MTC-OBn was reacted with MPEG first, followed by MTC-urea. The yields 
for the block copolymers were ≥ 80%.  
 
Deprotection of benzyl groups: 
A combination of the above polymers (0.5 g), THF (7.5 mL), methanol (7.5 mL), and 
Pd-C (10% w/w, 0.2 g) was swirled under H2 (7 atm) overnight and filtered through 
THF-wetted Celite with washings of THF (15 mL) and methanol (15 mL) after 
evacuation of the H2 atmosphere. The collected washings were evaporated, and the 
residue dialyzed against DMSO in a dialysis bag with 1,000 Da MWCO (Spectra/Por 
7, Spectrum Laboratories Inc.) for 48 h, followed by another dialysis against DI water 
for two days before being freeze-dried in vacuo. A white solid was obtained (yield > 
90 %). 1a copolymer was purified by column chromatography on a Sephadex LH-20 
column with THF as eluent, instead of dialysis.  
 
1
H-NMR analysis of acid/urea-functionalized polycarbonate block copolymers: 
1a: Yield, 88%. 
1
H-NMR (400 MHz, DMSO-d6, 22 C): δ 8.54 (s, 5H, PhNH- 
of MTC-urea),  7.38 (m, 35H, PhH of MTC-urea and PhH of MTC-OBn), 7.15 (m, 
10H, PhH of MTC-urea), 6.87 (t, 5H, PhH of MTC-urea), 6.27 (s, 5H, -CH2NH- of 
MTC-urea), 5.07 (s, 10H, PhCH2- of MTC-OBn), 4.04-4.23 (d, br, 50H, -CH2OCOO- 
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and -COOCH2CH2-), 3.48 (s, 455H, H of MPEG), 3.27 (s, 10H, -CH2NHCO- of 
MTC-urea), 1.09 (s, 30H, -CH3). 
1b: Yield, 83%. 
1
H-NMR (400 MHz, DMSO-d6, 22 C): δ 8.57 (s, 8H, PhNH- 
of MTC-urea),  7.31 (m, 56H, PhH of MTC-urea and PhH of MTC-OBn), 7.18 (m, 
16H, PhH of MTC-urea), 6.86 (t, 8H, PhH of MTC-urea), 6.24 (s, 8H, -CH2NH- of 
MTC-urea), 5.09 (s, 16H, PhCH2- of MTC-OBn), 4.06-4.21 (d, br, 80H, -CH2OCOO- 
and -COOCH2CH2-), 3.59 (s, 455H, H of MPEG), 3.31 (s, 16H, -CH2NHCO- of 
MTC-urea), 1.12 (s, 48H, -CH3). 
1c: Yield, 82%. 
1
H-NMR (400 MHz, DMSO-d6, 22 C): δ 8.59 (s, 13H, 
PhNH- of MTC-urea),  7.41 (m, 91H, PhH of MTC-urea and PhH of MTC-OBn), 
7.17 (m, 26H, PhH of MTC-urea), 6.87 (t, 13H, PhH of MTC-urea), 6.25 (s, 13H, -
CH2NH- of MTC-urea), 5.09 (s, 26H, PhCH2- of MTC-OBn), 4.04-4.26 (d, br, 130H, 
-CH2OCOO- and -COOCH2CH2-), 3.44 (s, 455H, H of MPEG), 3.31 (s, 26H, -
CH2NHCO- of MTC-urea), 1.13 (s, 78H, -CH3). 
1d: Yield, 82%. 
1
H-NMR (400 MHz, DMSO-d6, 22 C): δ 8.57 (s, 19H, 
PhNH- of MTC-urea),  7.38 (m, 133H, PhH of MTC-urea and and PhH of MTC-OBn), 
7.16 (m, 38H, PhH of MTC-urea), 6.86 (t, 19H, PhH of MTC-urea), 6.24 (s, 19H, -
CH2NH- of MTC-urea), 5.09 (s, 38H, PhCH2- of MTC-OBn), 4.07-4.29 (d, br, 190H, 
-CH2OCOO- and -COOCH2CH2-), 3.50 (s, 455H, H of MPEG), 3.30 (s, 38H, -
CH2NHCO- of MTC-urea), 1.14 (s, 114H, -CH3). 
2: Yield, 80%. 
1
H-NMR (400 MHz, DMSO-d6, 22 C): δ 8.60 (s, 12H, PhNH- 
of MTC-urea),  7.32 (m, 79H, PhH of MTC-urea and PhH of MTC-OBn), 7.17 (m, 
24H, PhH of MTC-urea), 6.88 (t, 12H, PhH of MTC-urea), 6.27 (s, 12H, -CH2NH- of 
MTC-urea), 5.09 (s, 22H, PhCH2- of MTC-OBn), 4.05-4.21 (d, 116H, -CH2OCOO- 
and -COOCH2CH2-), 3.55 (s, 455H, H of MPEG), 3.30 (s, 24H, -CH2NHCO- of 
MTC-urea), 1.15 (s, 69H, -CH3). 
3: Yield, 81%. 
1
H-NMR (400 MHz, DMSO-d6, 22 C): δ 8.56 (s, 12H, PhNH- 
of MTC-urea),  7.35 (m, 99H, PhH of MTC-urea and PhH of MTC-OBn), 7.17 (m, 
24H, PhH of MTC-urea), 6.86 (t, 12H, PhH of MTC-urea), 6.22 (s, 12H, -CH2NH- of 
MTC-urea), 5.09 (s, 30H, PhCH2- of MTC-OBn), 4.06-4.22 (d, 132H, -CH2OCOO- 
and -COOCH2CH2-), 3.51 (s, 455H, H of MPEG), 3.29 (s, 24H, -CH2NHCO- of 
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Figure A2.1: 1H NMR spectra of 1d (A) before and (B) after benzyl deprotection, in DMSO-
d6. 
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Appendix C: Synthesis and characterization of urea-functionalized (PEG-PUC) 
and benzyl-protected acid-functionalized (PEG-P(MTC-OBn)) copolymers 
 
Materials: All reagents were obtained from Sigma-Aldrich and utilized as received 
unless otherwise indicated. Monomethoxy PEG with Mn 5,000 g/mol (PDI 1.04) and 
Mn 10,000 g/mol (PDI 1.06) obtained from Polymer Source Inc. (Canada) was 
azeotropically distilled from toluene and dried in vacuum before usage. Sparteine was 
stirred over CaH2, distilled in vacuum twice, and then stored in glove box. N-(3,5-
trifluoromethyl)phenyl-N’-cyclohexylthiourea (TU) was prepared according to our 
previous protocol [178]. TU was dissolved in dry THF, stirred with CaH2, filtered, 
and dried in vacuo. 
 
Copolymer characterization: 
The protocols for GPC and 
1
H NMR analysis for block copolymers synthesized were 
previously described in Appendix A.  
 
The synthesis procedures for preparation of the benzyl-protected acid- (MTC-
OBn) and urea-functionalized (MTC-urea) carbonate monomers were described 
previously in Appendix A. The details of the procedure for organocatalytic ROP of 
MTC-OBn (or MTC-urea) with 5K PEG are given below as typical examples.  
 
Synthesis of block copolymer PEG-P(MTC-OBn)): In a glove box, PEG (0.4 g, 0.08 
mmol, Mn 5,000 g/mol, PDI 1.04) in CH2Cl2 (0.75 mL) was mixed with MTC-OBn 
(0.2 g, 0.8 mmol) and DBU (12 mg, 0.08 mmol) in CH2Cl2 (0.75 mL) and the mixture 
stirred for 2 h followed by quenching the reaction with benzoic acid (15-20 mg). The 
reaction mixture was precipitated into diethyl ether (40 mL) with the precipitates 
collected after centrifugation and dried in vacuo. The precipitates were then purified 
by column chromatography on a Sephadex LH-20 column with THF as the eluent to 
give 5K PEG-P(MTC-OBn)9 as an off-white solid (0.53 g, 88%).  
 
Deprotection of benzyl groups in PEG-P(MTC-OBn) 
A mixture of PEG-P(MTC-OBn) (0.5 g), THF (7.5 mL), methanol (7.5 mL), and Pd-
C (10% w/w, 0.2 g) was swirled under H2 (7 atm) overnight and filtered through 
Celite wetted with THF after evacuation of the H2 atmosphere. Additional washings 
with THF (15 mL) and methanol (15 mL) were carried out to ensure total transfer. 
Washings were collected, and the solvents were evaporated. The residue was dialyzed 
against DMSO using a dialysis membrane with molecular weight cut-off (MWCO) of 
1,000 Da (Spectra/Por 7, Spectrum Laboratories Inc.) for 48 h, and then against de-
ionized (DI) water for an additional two days before being freeze-dried in vacuo. 
Eventually, PEG-PAC was obtained as a white solid (yield: > 90 %). 
 
Synthesis of urea-functionalized block copolymer (PEG-PUC): A solution of 
thiourea catalyst (TU) (33.3 mg, 0.09 μmol), sparteine (20.3 mg, 90 μmol) and 5K 
PEG (0.3 g, 0.06 mmol) in CH2Cl2 was stirred for 10 min.  MTC-urea (0.29 g, 0.9 
mmol) in CH2Cl2 (1.5 mL) was added to the mixture and stirred for 16 h. Benzoic 
acid (15mg) was added to end the reaction and the crude polymer precipitated in 40 
mL cold diethyl ether with the precipitates collected after centrifugation and dried in 
vacuo. The precipitates were purified by column chromatography on a Sephadex LH-
20 column with THF as the eluent to give 5K PEG-P(MTC-urea)9 (i.e. 5K PEG-PUC) 
as an off-white solid (0.50 g, 85%). 
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1
H-NMR analysis of acid- or/urea-functionalized polycarbonate block copolymers: 
 5K PEG-(MTC-OBn)9: Yield, 88%; PDI 1.08. 
1
H-NMR (400 MHz, CDCl3, 
22 C): δ 7.28 (m, 45H, PhH), 5.11 (s, 18H, PhCH2-), 4.25 (t, 36H, -CH2OCOO-), 
3.71 (s, 455H, H of MPEG5K), 1.20 (s, 27H, -CH3).  
10K PEG-(MTC-OBn)9: Yield, 82%; PDI 1.13. 
1
H-NMR (400 MHz, CDCl3, 
22 C): δ 7.31 (m, 45H, PhH), 5.13 (s, 18H, PhCH2-), 4.24 (t, 36H, -CH2OCOO-), 
3.70 (s, 909H, H of MPEG10K), 1.24 (s, 27H, -CH3). 
5K PEG-P(MTC-urea)9: Yield, 85%; PDI 1.10.
 1
H-NMR (400 MHz, DMSO-
d6, 22 C): δ 8.60 (s, br, 9H, PhNH-),  7.36 (s, 18H, PhH), 7.17 (s, 18H, PhH), 6.85 (s, 
9H, PhH), 6.27 (s, br, 9H, -CH2NH-), 4.14 (d, 54H, -CH2OCOO- and -COOCH2CH2-), 
3.55 (s, 455H, H of MPEG), 3.31 (s, 18H, -CH2NHCO-), 1.13 (s, 27H, -CH3). 
10K PEG-P(MTC-urea)9: Yield, 80%; PDI 1.11. 
1
H-NMR (400 MHz, 
DMSO-d6, 22 C): δ 8.54 (s, 9H, PhNH-),  7.36 (s, 18H, PhH), 7.18 (s, 18H, PhH), 
6.87 (s, 9H, PhH), 6.22 (s, 9H, -CH2NH-), 4.14 (d, 54H, -CH2OCOO- and -







































































H NMR spectra of (A) PEG5K-(MTC-OBn)9 in CDCl3, (B) PEG5K-PAC, and 
(C) PEG5K-PUC. 
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Appendix D: Synthesis and characterization of galactose-functionalized 
polycarbonate block copolymers 
 
Materials: Reagents were commercially available from Sigma-Aldrich and used 
without any other purification unless otherwise noted. 5-Methyl-5-carboxyl-1,3-
dioxan-2-one (MTC-OH) and 2-(3-phenylureido)ethyl 5-methyl-2-oxo-1,3-dioxane-5-
carboxylate (MTC-Urea) were synthesized as previously reported [91, 178]. TU was 
prepared as previously reported [178] and freeze-dried before transferred to glovebox. 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU; 98%) was stirred over CaH2, vacuum 
distilled twice, then transferred to glovebox. 
 
Copolymer characterization: 
The protocols for GPC and 
1
H NMR analysis for block copolymers synthesized were 
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Scheme A4.1: Synthesis procedures of galactose-functionalized polycarbonate copolymer 5. 
 
Synthesis of 1,2;3,4-Di-O-isopropylidene-3-O-MCDO-D-galactopyranose (MTC-
ipGal): The monomer MTC-ipGal were prepared according to the protocol reported 
in the previous work [105]. Briefly, a solution of oxalyl chloride (2.48 mL, 19.0 
mmol) in 50 mL of dry THF was dropwise added into a solution of MTC-OH (2.75 g, 
17.2 mmol) in 50 mL of dry THF, followed by adding a catalytic amount of 
anhydrous DMF (3 drops) over 30 min under N2 atmosphere. The reaction solution 
was stirred for 1 h, bubbled with N2 flow to remove volatiles, and evaporated under 
vacuum. The solid residue (intermediate product MTC-Cl) was then dissolved in 50 
mL of dry DCM, and a mixture of 1,2;3,4-Di-O-isopropylidene-D-galactopyranose 
(ipGal, 4.13 g, 15.8 mmol) and triethylamine (2.8 mL, 20.6 mmol) in 50 mL of dry 
DCM was dropped stepwise into the solution over 30 min at room temperature. 
Subsequently, the reaction mixture was heated to 40 °C and reacted for 48 h. After 
cooling down to room temperature, the reaction solution was concentrated and 100 
mL THF was added to precipitate triethylamine salt. After evaporating the filtrate, the 
crude product was passed through a silica gel column by gradient eluting of ethyl 
acetate and hexane (20/80 to 50/50) to provide the product as a sticky colorless oil 
that slowly solidified to give a white solid (5.85 g, 85%). 
1
H NMR (400 MHz in 
CDCl3):  5.54 (d, 1H, H-a), 4.73 (dd, 2H, H-c), 4.64 (d, 1H, H-b), 4.44 (d, 1H, H-f), 
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4.35 (m, 2H, H-d and H-e), 4.22 (m, 3H, H-c and H-g), 4.04 (m,  1H, H-g), 1.32-1.49 
(5 s, 15H, H-h and H-i). 
 
Synthesis of MTC-PEG: Monomethoxy poly(ethylene glycol) (MPEG, 4.5 g, Mn = 
750, PDI 1.03, 6 mmol) was charged in a 250 mL three-neck RBF and heated to 82 C 
in vacuo with stirring overnight. After being cooled down to room temperature, a 
solution of MTC-OH (1.44 g, 9 mmol) in dry THF (50 mL) was added to the RBF 
under N2 atmosphere, followed by gently adding a solution of DCC (2.48 g, 12 
mmol) in dry THF (50 mL) and stirred for 48 hours. Then, the reaction solution was 
filtered and concentrated to dryness, Finally, the resulting crude product was purified 
by column chromatography on a Sephadex LH-20 column with THF as eluent, giving 
pure MTC-PEG as a white viscous solid (4.6 g, 83%). 
1
H NMR (400 MHz, CDCl3, 
22 °C): δ 4.45 (dd, 4H, -CH2OCOO-), 4.35 (d, 2H, -COOCH2-MPEG), 3.65 (s, 68H, 
H of MPEG), 1.34 (s, 3H, -CH3). 
 
Synthesis of 4-MBA-P(MTC-ipGal)-P(MTC-PEG)-P(MTC-Urea): The polymer was 
prepared from a series of two ring opening polymerizations (ROP) using methyl 
benzyl alcohol as an initiator. The details of the procedure for preparation of 3b are 
given below as a typical example of 4-MBA-P(MTC-ipGal)-P(MTC-PEG)-P(MTC-
Urea). Briefly, in a glovebox, 4-methylbenzyl alcohol (4-MBA, 3.74 mg, 0.03 mmol) 
and TU (11.1 mg, 0.03 mmol) were added to the solution of MTC-ipGal (0.242 g, 0.6 
mmol) in 1 mL of DCM, followed by adding DBU (4.5 mL, 0.03 mmol) to initiate the 
polymerization. After it reacted for 1 hr, a solution of MTC-PEG (0.279 g, 0.3 mmol) 
in 1 mL of DCM was added to the reaction solution and stirred for one more hour. 
Then, a solution of MTC-urea (0.232 g, 0.72 mmol) in 2 mL of DCM reaction 
mixture was added to the reaction solution and stirred for another 2 hrs before benzoic 
acid (about 5-10 mg) was added to quench the polymerization. Finally, the reaction 
mixture was purified by column chromatography on a Sephadex LH-20 column with 
THF as eluent, giving 4-MBA-P(MTC-ipGal)-P(MTC-PEG)-P(MTC-Urea) (3b) as a 
white viscous solid (0.66 g, 88%). PDI: 1.35. 
1
H NMR (400 MHz, CDCl3, 22 °C): δ 
8.56 (s, 15H, -NHCONHPh of MTC-Urea), 7.37 (d, 30H, PhH), 7.19 (s, 30H, PhH), 
6.86 (s, 15H, PhH), 6.24 (s, 15H, -NHCONHPh of MTC-Urea), 5.41 (s, 19H, H of H-
a of MTC-ipGal), 4.61 (m, 19H, H of H-b of MTC-ipGal), 4.21 (m, 263H, -
CH2OCOO-,-COOCH2-, and H of H-(d to g) of MTC-ipGal), 3.43 (s, 544H, H of 
MPEG), 2.24 (s, 3H, -CH3Ph of 4-MBA), 1.01-1.39 (m, 354H, -CH3).  
3a. Yield, 81%. PDI: 1.30. 
1
H NMR (400 MHz, CDCl3, 22 °C): δ 8.59 (s, 12H, -
NHCONHPh of MTC-Urea), 7.37 (d, 24H, PhH), 7.19 (s, 24H, PhH), 6.86 (s, 12H, 
PhH), 6.25 (d, 12H, -NHCONHPh of MTC-Urea), 5.41 (s, 46H, H of H-a of MTC-
ipGal), 4.59 (m, 46H, H of H-b of MTC-ipGal), 4.23 (m, 502H, -CH2OCOO-,-
COOCH2-, and H of H-(d to g) of MTC-ipGal), 3.42 (s, 687H, H of MPEG), 2.27 (s, 
3H, -CH3Ph of 4-MBA), 1.06-1.38 (m, 756H, -CH3). 
 
Synthesis of 4-MBA-P(MTC-Gal)-P(MTC-PEG)-P(MTC-Urea)(5b): The above 
protected polymer was dissolved in 8 ml of formic acid and followed by addition of 2 
ml of DI water before stirred for 48 hours. Then, dialysis against ACN using 1000 
MWCO membrane was performed during 48 hours changing solvent every 6 hours. 
Finally, the solution in the bag was transferred in a vial and freeze-dried to give 4b as 
a white powder  in good yields (90%). 
1
H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.57 
(s, 15H, -NHCONHPh of MTC-Urea), 7.37 (d, 30H, PhH), 7.19 (s, 30H, PhH), 6.87 
(s, 15H, PhH), 6.25 (s, 15H, -NHCONHPh of MTC-Urea), 4.23 (m, 263H, -
 166 
CH2OCOO-,-COOCH2-, and H of H-(d to g) of MTC-ipGal), 3.43 (s, 544H, H of 
MPEG), 2.24 (s, 3H, -CH3Ph of 4-MBA), 1.17 (m, 126H, -CH3). 
5a. Yield, 84%.
 1
H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.57 (s, 12H, -
NHCONHPh of MTC-Urea), 7.36 (d, 24H, PhH), 7.20 (s, 24H, PhH), 6.86 (s, 12H, 
PhH), 6.20 (s, 12H, -NHCONHPh of MTC-Urea), 4.24 (m, 502H, -CH2OCOO-,-
COOCH2-, and H of H-(d to g) of MTC-ipGal), 3.48 (s, 680H, H of MPEG), 2.27 (s, 
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H NMR spectra of (A) 4-MBA-P(MTC-ipGal)-P(MTC-PEG)-P(MTC-Urea) 
5’b  and (B) its deprotected product 5b in DMSO-d6. 
 
Synthesis of 4-MBA-P(MTC-Gal)-P(MTC-Urea)(4): For the synthesis of control 
polymer without MTC-PEG, the protocol is quite similar to the synthesis protocol of 
4-MBA-P(MTC-Gal)-P(MTC-PEG)-P(MTC-Urea), except that there is no addition of 
MTC-PEG in the polymerization.  
4a, Yield, 81%. 
1
H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.60 (s, 4H, -
NHCONHPh of MTC-Urea), 7.38 (d, 8H, PhH), 7.19 (m, 8H, PhH), 6.86 (s, 4H, PhH), 
6.29 (s, 4H, -NHCONHPh of MTC-Urea), 4.23 (d, 439H, -CH2OCOO-, -COOCH2- 
and H of H-(d to g) of MTC-ipGal), 2.28 (s, 3H, -CH3Ph of 4-MBA), 1.16 (m, 153H, 
-CH3). 
4b, Yield, 85%. 
1
H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.57 (d, 4H, -
NHCONHPh of MTC-Urea), 7.38 (d, 8H, PhH), 7.19 (d, 8H, PhH), 6.87 (s, 4H, PhH), 
6.26 (s, 4H, -NHCONHPh of MTC-Urea), 4.24 (d, 151H, -CH2OCOO-, -COOCH2- 
and H of H-(d to g) of MTC-ipGal), 2.30 (s, 3H, -CH3Ph of 4-MBA), 1.18 (m, 63H, -
CH3). 
4c, Yield, 82%. 
1
H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.56 (d, 18H, -
NHCONHPh of MTC-Urea), 7.38 (d, 36H, PhH), 7.20 (d, 36H, PhH), 6.87 (s, 18H, 
PhH), 6.24 (s, 18H, -NHCONHPh of MTC-Urea), 4.23 (m, 495H, -CH2OCOO-, -
COOCH2- and H of H-(d to g) of MTC-ipGal), 2.28 (s, 3H, -CH3Ph of 4-MBA), 1.17 
(m, 195H, -CH3). 
4d, Yield, 88%. 
1
H NMR (400 MHz, DMSO-d6, 22 °C): δ 8.58 (d, 14H, -
NHCONHPh of MTC-Urea), 7.35 (d, 28H, PhH), 7.24 (d, 28H, PhH), 6.85 (s, 14H, 
PhH), 6.27 (s, 14H, -NHCONHPh of MTC-Urea), 4.21 (d, 191H, -CH2OCOO-, -
COOCH2- and H of H-(d to g) of MTC-ipGal), 2.28 (s, 3H, -CH3Ph of 4-MBA), 1.15 
(m, 87H, -CH3). 
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Appendix E: Analysis of sorafenib concentration in tissues 
 
LC-MS/MS analysis of sorafenib concentration in tissues: The LC-MS/MS analysis 
was conducted by Dr Yanjun Hong (from Assoc. Prof. Chan Chun Yong Eric, 
Department of Pharmacy, National University of Singapore). Each snap-frozen 
healthy liver and tumour sample was weighed and homogenized in saline (100 
mg/mL) using 4 mm stainless steel beads at 25 Hz for 5 min. Acetonitrile was added 
to the liver homogenates and spiked with internal standard, tolnaftate (3ng/ml). The 
mixture was then vortexed and centrifuged at 12,000 rpm for 10 min at 4 °C. The 
resulting supernatant was collected into vials and loaded into the AB Sciex 5500 
QTRAP® LC-MS/MS system. The mobile phase was made up of solvent A (Water + 
0.1% Formic acid) and B (ACN + 0.1% Formic acid). For sample analysis, the 
chromatographic analysis was conducted under gradient elution as follows: solvent B: 
50% (0–1.6 min), from 50% to 95% (1.6–1.99 min), 95% (1.99–2 min), from 95% to 
50% (2–2.5 min), and 50% (2.5–12.00 min). The separation was performed at a flow 
rate of 0.6 mL/min. The temperature of column was maintained at 45 °C. The results 
of the sorafenib concentration in the liver and tumour tissues at the end of the anti-














































Figure A5.1: Concentration of sorafenib (free base) in liver tumour compared to healthy liver 
at the end of the anti-tumour study. 
 
 
